var title_f34_35_35376="Posterior vaginal wall prolapse 4";
var content_f34_35_35376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A longitudinal central defect is seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35376=[""].join("\n");
var outline_f34_35_35376=null;
var title_f34_35_35377="Disseminated superficial actinic porokeratosis - legs";
var content_f34_35_35377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disseminated superficial actinic porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous macules with peripheral keratotic rims are present on the lower legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35377=[""].join("\n");
var outline_f34_35_35377=null;
var title_f34_35_35378="Division of the right gastric and gastroepiploic vessels";
var content_f34_35_35378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Division of the right gastric and gastroepiploic vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The right gastric and gastroepiploic vessels are double ligated in sequence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35378=[""].join("\n");
var outline_f34_35_35378=null;
var title_f34_35_35379="Food allergy treatment and avoidance";
var content_f34_35_35379=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/35/35379/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35379/contributors\" id=\"au917\">",
"       Scott H Sicherer, MD, FAAAAI",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/35/35379/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35379/contributors\" id=\"se5673\">",
"       Robert A Wood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/35/35379/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35379/contributors\" id=\"de2295\">",
"       Elizabeth TePas, MD, MS",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/35/35379?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      FOOD ALLERGY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     People with food allergies can have serious or even life-threatening reactions after consuming certain foods. The most important strategy in the management of food allergies is to avoid eating these foods.",
"    </p>",
"    <p>",
"     However, it is not always easy to know if packaged foods or meals at restaurants contain allergens, so it is also important to know how to treat an allergic reaction.",
"    </p>",
"    <p>",
"     This topic will discuss tips for living with food allergies, non-food sources of food allergens, and the importance of having a food allergy emergency action plan. The symptoms and diagnosis of food allergies are discussed in a separate topic. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"      \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some children with food allergies have difficulty getting the proper amount and type of foods in their diet. This issue is discussed in detail in a separate article. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7993?source=see_link\">",
"      \"Nutritional issues in food allergy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      GENERAL FOOD ALLERGY CONSIDERATIONS",
"     </span>",
"    </p>",
"    <p>",
"     People with food allergies are typically told to completely avoid the offending food. However, it is often difficult to do this in real life. As a result, anyone with food allergies must be prepared to treat an unexpected allergic reaction at any time and in any setting.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      How careful do I need to be?",
"     </span>",
"     &nbsp;&mdash;&nbsp;In general, people with food allergies must strictly avoid eating or drinking anything that contains even a minuscule amount of a food allergen. It is usually not possible to know what amount of the allergen will trigger an allergic reaction. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"      \"Management of food allergy: Avoidance\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Eating, touching, and inhaling allergens",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with food allergies react after eating a food. Other types of exposure, such as touching or inhaling the food, may lead to localized reactions (eg, hives) in children. However, this type of exposure is unlikely to cause severe reactions in most people with food allergies.",
"    </p>",
"    <p>",
"     Smelling foods is also unlikely to cause a severe reaction. As an example, the smell of peanut butter is related to volatile organic compounds (VOCs), substances that evaporate easily. The smell of peanut butter is not related to particles of peanut butter in the air, so it is not likely to trigger an allergic reaction.",
"    </p>",
"    <p>",
"     However, inhaling tiny food particles (as a result of steaming, boiling, frying, grating, shedding, or grinding) can potentially trigger an allergic reaction in highly sensitive people. Thus, people who are very sensitive should avoid situations in which aerosolized food could be inhaled. Although peanut protein does not easily become airborne from peanut butter, it may from peanut flour or \"dusty\" roasted peanuts. Similarly, touching an allergenic food and then touching the eyes, nose, or mouth can cause an allergic reaction.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      LIVING WITH FOOD ALLERGIES",
"     </span>",
"    </p>",
"    <p>",
"     Adults and parents of children with food allergies must learn to carefully read food labels, prepare meals at home, and talk to others about their condition. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3705?source=see_link\">",
"      \"Food allergy in schools and camps\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Food labeling",
"     </span>",
"     &nbsp;&mdash;&nbsp;Laws regarding food labeling vary by country. People with food allergies must consider not only a food's ingredients, but also any potential cross-contact (also called cross-contamination) that can occur as the food is prepared. It's also important to know that ingredients may change over time and labels should be read each time you purchase a product.",
"    </p>",
"    <p>",
"     In the United States, the Food Allergen Labeling and Consumer Protection Act mandates that nutritional labels on food packages clearly identify eight specified food allergy sources (milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, and soy), although other foods may still appear under multiple names. Additionally, for tree nuts, crustacean shellfish and fish, the specific type (eg, walnut or cashew, shrimp or lobster, tuna or salmon, etc), must be labeled.",
"    </p>",
"    <p>",
"     This law applies to all packaged foods manufactured in the United States and also to foods that are imported for sale in the US. However, the law does not apply to packaged fresh meat, poultry, or egg products. Updates to this law are available online from the Center for Food Safety and Applied Nutrition, a branch of the Food and Drug Administration (",
"     <a class=\"external\" href=\"file://www.fda.gov/Food/default.htm\">",
"      www.fda.gov/Food/default.htm",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Potential allergens other than the eight listed above may still be listed on food labels with unclear names (eg, garlic or sesame may be listed as a spice, natural flavor, or even an artificial flavor). If the label is unclear, call the manufacturer to clarify the ingredients.",
"    </p>",
"    <p>",
"     In addition, it's important to understand that \"substitute\" foods, which are used to remove fats or other components of a food, may not remove the allergenic proteins. As an example, some egg substitutes (which are lower in cholesterol) still contain egg white proteins.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Advisory labeling",
"     </span>",
"     &nbsp;&mdash;&nbsp;A manufacturer may use certain phrases when a particular allergen is not an intended ingredient, but the ingredient may come in contact with the food during the manufacturing process. As an example, a blueberry muffin may not contain nuts, but may be made in a bakery where banana nut muffins are made. Manufacturers may use phrases such as: \"may contain,\" \"processed in a facility with,\" \"manufactured on shared equipment with,\" and others. There are no laws regarding when this type of label should be used.",
"    </p>",
"    <p>",
"     Although manufacturers use a variety of label terms in their voluntary advisory warnings, these do not necessarily reflect the level of risk. As an example, a muffin that says that it \"may contain nuts\" is no more or less likely to contain nuts than a muffin that says \"processed in a facility with nuts\".",
"    </p>",
"    <p>",
"     Advisory labeling may help to reduce the risk of an allergic reaction, but may also significantly reduce the food choices available to people with food allergies. Most allergists recommend avoiding foods that have an advisory label because it is impossible to know the actual risk. Serious allergic reactions have occurred as a result of cross-contact.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Alcoholic beverages",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alcoholic beverages may contain allergens, including unexpected ones, such as eggs, tree nuts, and seafood. Labeling laws do not currently apply to these beverages. People with food allergies are advised to call the manufacturer if there are questions about the ingredients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Preparing meals at home",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some families avoid bringing food allergens into the home if one person is allergic. Other families keep the food in the house but are careful to avoid cross-contact.",
"    </p>",
"    <p>",
"     Avoiding cross-contact requires thoroughly cleaning utensils, cookware, glassware, storage containers, and other food preparation materials used with a food allergen before the item is used to prepare or serve \"safe\" meals. (See",
"     <a class=\"local\" href=\"#H10\">",
"      'Cleaning'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     All members of the family, including children, must be careful if allergenic foods are brought into the house. As an example, if a child uses a knife to prepare a peanut butter and jelly sandwich,",
"     <span class=\"nowrap\">",
"      he/she",
"     </span>",
"     could introduce peanut allergen into otherwise safe jelly and subsequently cause a reaction in a peanut-allergic sibling who eats the jelly.",
"    </p>",
"    <p>",
"     Other tips for preparing meals at home include preparing the safe meal first, keeping food containers covered to prevent spills, and designating specific containers of food for the allergic person only.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Cleaning",
"     </span>",
"     &nbsp;&mdash;&nbsp;Washing food storage containers and dishes in a dishwasher or hand washing with hot water and liquid dish soap is generally adequate to remove food allergens.",
"    </p>",
"    <p>",
"     Tabletops and other surfaces may be cleaned with a household cleaner or commercial wipe. Bar or liquid soap, but not alcohol-based antibacterial hand gel, can remove peanut allergen from adults' hands [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/35/35379/abstract/1\">",
"      1",
"     </a>",
"     ]. Studies of other food allergens have not been performed, although these cleaning methods are probably adequate.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Restaurant meals",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dining out can be challenging for people with food allergies. The following tips can help to ensure that the risk of contact with a food allergen is minimized (",
"     <a class=\"graphic graphic_table graphicRef75693 \" href=\"mobipreview.htm?10/27/10684\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Nuts are sometimes served on airplanes, increasing the risk of an allergic reaction. If you are traveling with a young child, clean the tray tables and inspect the seating area for peanuts or other foods that your child might find and eat. Some airlines provide additional accommodations when requested in advance (eg, a flight where peanuts are not served).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      FOOD ALLERGENS IN NON-FOOD ITEMS",
"     </span>",
"    </p>",
"    <p>",
"     Non-food items, such as medications, cosmetics, vaccines, and craft supplies may contain food ingredients. Labeling laws do not apply to these products. If there are questions about a product's ingredients, it is often helpful to call the manufacturer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Vaccines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gelatin, egg, and chicken products may be used in the production of certain vaccines. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=see_link\">",
"      \"Allergic reactions to vaccines\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gelatin &mdash; Gelatin is included in measles, mumps, rubella (MMR), varicella, diphtheria, tetanus, acellular pertussis (DTaP), and Japanese encephalitis vaccines.",
"      </li>",
"      <li>",
"       Egg &mdash; Egg protein is present in yellow fever vaccine and some influenza vaccines. People with egg allergies can be given the egg-based inactivated influenza vaccine safely; you should consult with your allergy specialist for guidance. (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link\">",
"        \"Influenza vaccination in individuals with egg allergy\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Chicken &mdash; Chicken proteins may be present in the yellow fever vaccine.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Medications and asthma inhalers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nonprescription and prescription medications (in tablet, capsule, and inhaler form) can contain food allergens.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lactose &mdash; Lactose is a sugar derived from milk. Although lactose used in medications is unlikely to contain milk proteins, some experts recommend that highly allergic patients avoid using products that contain lactose (eg, use metered dose inhalers rather than dry powder inhalers that contain lactose).",
"      </li>",
"      <li>",
"       Soy lecithin &mdash; Soy lecithin is the fatty derivative of soy, and it contains trace amounts of soy proteins. Certain asthma inhalers contain small amounts of soy lecithin, which could potentially cause an allergic reaction in a person who was highly allergic to soybeans or peanuts. You should discuss the risks and benefits of these inhalers with your healthcare provider.",
"      </li>",
"      <li>",
"       Casein &mdash; Casein is a cow's milk protein that has been used as an anti-stick agent on latex gloves.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Cosmetics and crafts",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cosmetics may contain a variety of food-derived ingredients, including milk, nut oils, wheat, and soy. Craft items, such as modeling dough may contain wheat. Egg white is sometimes used to smooth finger-paints. If there is a question about a product's ingredients, call the manufacturer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      PERSONAL CONTACT AND FOOD ALLERGIES",
"     </span>",
"    </p>",
"    <p>",
"     Saliva and other bodily fluids can potentially expose an allergic person to food allergens. Kissing or sharing straws, glasses, or utensils are the most likely ways that saliva may be spread from one person to another. Based upon a study of peanut butter, waiting several hours after eating an allergenic food and then eating a nonallergenic food(s) seems to reduce the level of allergen in the saliva and is suggested.",
"    </p>",
"    <p>",
"     It is theoretically possible to have a food allergy reaction after other forms of contact, such as sexual intercourse or a blood transfusion. However, this type of reaction is uncommon. The partner of a person with a food allergy can consider not eating large amounts of the allergen before sex to further reduce this risk.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      FOOD ALLERGY TREATMENT PLAN",
"     </span>",
"    </p>",
"    <p>",
"     Because it is not always possible to avoid food allergens, it is important to develop a plan for dealing with this type of emergency before it happens. Serious allergic reactions are often unexpected, develop suddenly, and require immediate treatment. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"      \"Food-induced anaphylaxis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The best treatment for an anaphylactic reaction is epinephrine, which is available for self-injection. The use of epinephrine autoinjectors is discussed in detail in a separate topic. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=see_link\">",
"      \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H253622\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/27/35250?source=see_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42370?source=see_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/35/17971?source=see_link\">",
"      Patient information: Peanut allergy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H253636\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=see_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40681?source=see_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=see_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=see_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37430?source=see_link\">",
"      Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3705?source=see_link\">",
"      Food allergy in schools and camps",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44057?source=see_link\">",
"      Future therapies for food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=see_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20119?source=see_link\">",
"      Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38776?source=see_link\">",
"      Respiratory manifestations of food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16346?source=see_link\">",
"      Seafood allergies: Fish and shellfish",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17304?source=see_link\">",
"      The impact of breastfeeding on the development of allergic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=see_link\">",
"      Unique aspects of anaphylaxis in infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7993?source=see_link\">",
"      Nutritional issues in food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Consortium of Food Allergy Research (Food Allergy Education Program)",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cofargroup.org/\">",
"        www.cofargroup.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Medline Plus",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/foodallergy.html\">",
"        www.nlm.nih.gov/medlineplus/foodallergy.html",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       National Institute of Allergy and Infectious Disease",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niaid.nih.gov/Pages/default.aspx\">",
"        www.niaid.nih.gov/Pages/default.aspx",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Allergy Asthma and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aaaai.org/patients.stm\">",
"        www.aaaai.org/patients.stm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Food Allergy Research and Education",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.foodallergy.org/\">",
"        www.foodallergy.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Allergy, Asthma, and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.acaai.org/\">",
"        www.acaai.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/35/35379/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/35/35379?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35379/abstract/1\">",
"      Perry TT, Conover-Walker MK, Pom&eacute;s A, et al. Distribution of peanut allergen in the environment. J Allergy Clin Immunol 2004; 113:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35379/abstract/2\">",
"      Simonte SJ, Ma S, Mofidi S, Sicherer SH. Relevance of casual contact with peanut butter in children with peanut allergy. J Allergy Clin Immunol 2003; 112:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35379/abstract/3\">",
"      Lack G. Clinical practice. Food allergy. N Engl J Med 2008; 359:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35379/abstract/4\">",
"      Simons E, Weiss CC, Furlong TJ, Sicherer SH. Impact of ingredient labeling practices on food allergic consumers. Ann Allergy Asthma Immunol 2005; 95:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35379/abstract/5\">",
"      Maloney JM, Chapman MD, Sicherer SH. Peanut allergen exposure through saliva: assessment and interventions to reduce exposure. J Allergy Clin Immunol 2006; 118:719.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f34_35_35379=[""].join("\n");
var outline_f34_35_35379=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           FOOD ALLERGY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           GENERAL FOOD ALLERGY CONSIDERATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           LIVING WITH FOOD ALLERGIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           FOOD ALLERGENS IN NON-FOOD ITEMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           PERSONAL CONTACT AND FOOD ALLERGIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           FOOD ALLERGY TREATMENT PLAN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/27/10684\" title=\"table 1\">",
"           Dining out allergy tips PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f34_35_35380="Glucarpidase: Pediatric drug information";
var content_f34_35_35380=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glucarpidase: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"    see \"Glucarpidase: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/43/8883?source=see_link\">",
"    see \"Glucarpidase: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14266243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Voraxaze&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F14315381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Enzyme",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F14315388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"      see \"Glucarpidase: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Methotrexate toxicity:",
"     </b>",
"     I.V.: 50 units/kg as a single dose (Buchen, 2005; Widemann, 1997; Widemann, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intrathecal methotrexate overdose:",
"     </b>",
"     Limited data available: Children &ge;5 years, Adolescents, and Adults: Intrathecal: 2000 units as soon as possible after accidental exposure (O&rsquo;Marcaigh, 1996; Widemann, 2004); further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: No dosage adjustment provided in the manufacturer&rsquo;s labeling; has not been studied",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13743258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Voraxaze&reg;: 1000 units [contains lactose 10 mg/vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13743098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Voraxaze&reg; is distributed through ASD Healthcare; procurement information is available (24 hours a day; 365 days a year) at 1-855-7-VORAXAZE (1-855-786-7292). Voraxaze&reg; is also commercially available in the U.S. through certain pharmacy wholesalers on a drop-ship basis; orders will only be processed during business hours for overnight delivery. For additional information, refer to  file://www.btgplc.com/products/specialty-pharmaceuticals/voraxaze.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14315389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Reconstitute each vial (1000 units/vial) with 1 mL NS; mix gently by rolling or tilting vial; do not shake. Prior to administration, flush I.V. line; infuse glucarpidase over 5 minutes; flush I.V. line after administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intrathecal: Reconstitute 2000 units with 12 mL preservative-free NS (Widemann, 2004); typically administered over 5 minutes via lumbar route, ventriculostomy, Ommaya reservoir, or lumbar and ventriculostomy (O'Marcaigh, 1996; Widemann, 2004); others reports of lower doses (1000 units) have been administered through ventricular or lumbar catheter over 5 minutes (O'Marcaigh, 1996)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13743116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F14315385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Reconstituted solutions should be used immediately or may be stored for up to 4 hours under refrigeration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14315382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of toxic plasma methotrexate concentrations (&gt;1 micromole/L) in patients with delayed clearance due to renal impairment (FDA approved in ages &ge;1 month and adults); has also been used as a rescue agent to reduce methotrexate toxicity in patients with accidental intrathecal methotrexate overdose",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to the risk of subtherapeutic methotrexate exposure, glucarpidase is",
"     <b>",
"      not",
"     </b>",
"     indicated when methotrexate clearance is within expected range (plasma methotrexate concentration &le;2 standard deviations of mean methotrexate excretion curve specific for dose administered)",
"     <b>",
"      or",
"     </b>",
"     with normal renal function or mild renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8092329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Flushing, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea/vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Antiglucarpidase antibody development",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Allergic reaction, blurred vision, diarrhea, head pressure, hypersensitivity, hypertension, rash, shaking, throat irritation/tightness, tremor, warmth",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14315383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glucarpidase or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14790048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use should be accompanied with concomitant leucovorin therapy, adequate hydration, and urinary alkalinization. Use caution with leucovorin administration times; leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; do not administer leucovorin calcium within 2 hours before or after a glucarpidase dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In children, upon resolution of renal dysfunction following glucarpidase therapy, rechallenge with high-dose methotrexate therapy has been successfully completed; monitor renal function and serum methotrexate concentrations closely in these patients (Christensen, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Intrathecal glucarpidase use for an intrathecal methotrexate overdose should be used in conjunction with immediate lumbar drainage (Widemann, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14315384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity reactions which may be serious have been reported rarely (&lt;1 %). Methotrexate concentrations determined by immunoassays are unreliable when samples are collected within 48 hours of glucarpidase administration; DAMPA, an inactive methotrexate metabolite with a half-life of 9 hours, may interfere with immunoassay and result in the overestimation of the methotrexate serum concentration (when collected within 48 hours of glucarpidase administration). The only reliable method of measuring methotrexate serum concentrations during this time period is the chromatographic method.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14395087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14395085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: Glucarpidase may decrease serum concentrations of the active metabolite(s) of Leucovorin Calcium-Levoleucovorin. Specifically, 6S-5-methyltetrahydrofolateconcentrations may be reduced. Glucarpidase may decrease the serum concentration of Leucovorin Calcium-Levoleucovorin.  Management: Avoid leucovorin administration within 2 hours of glucarpidase dosing.  Continue to administer the pre-glucarpidase leucovorin dose for at least the first 48 hours after glucarpidase administration, and dose based on methotrexate concentration thereafter.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13743100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13743101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. If administered to a pregnant woman, the risk to the fetus is unknown; use only if clearly needed. In general, medications used as antidotes should take into consideration the health and prognosis of the mother.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14315390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum methotrexate concentrations using chromatographic method if &lt;48 hours from glucarpidase administration (DAMPA interferes with immunoassay results until &gt;48 hours). CBC with differential, bilirubin, ALT, AST, serum creatinine; evaluate for signs/symptoms of methotrexate toxicity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14315386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recombinant enzyme which rapidly hydrolyzes the carboxyl-terminal glutamate residue from extracellular methotrexate into inactive metabolites (DAMPA and glutamate), resulting in a rapid reduction of methotrexate concentrations independent of renal function",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F14790049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Methotrexate toxicity: I.V.: Within 15 minutes a &ge;97% reduction of methotrexate serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Methotrexate toxicity: Up to 8 days a &gt;95% of methotrexate serum concentration reduction maintained",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14315387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : I.V.:  3.6 L; distribution restricted to plasma volume",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: I.V.: Normal renal function: 6-9 hours; impaired renal function (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): 8-10 hours (Phillips, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F14315391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/43/8883?source=see_link\">",
"      see \"Glucarpidase: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause flushing, low blood pressure, headache, nausea, vomiting, and paresthesias; notify prescriber for any immediate signs of an allergic reaction (wheezing; chest tightness; fever; itching; cough; difficulty breathing; swelling of face, lips, tongue, or throat).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14790083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leucovorin calcium administration should be continued after glucarpidase; the same dose as was given prior to glucarpidase should be continued for the first 48 hours after glucarpidase; after 48 hours, leucovorin doses should be based on methotrexate concentrations. A single methotrexate concentration should not determine when leucovorin should be discontinued; continue leucovorin until the methotrexate concentration remains below the threshold for leucovorin treatment for &ge;3 days.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Buchen S, Ngampolo D, Melton RG, et al, &ldquo;Carboxypeptidase G2 Rescue in Patients With Methotrexate Intoxication and Renal Failure,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2005, 92(3):480-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/35/35380/abstract-text/15668713/pubmed\" id=\"15668713\" target=\"_blank\">",
"        15668713",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Christensen AM, Pauley JL, Molinelli AR, et al, &ldquo;Resumption of High-Dose Methotrexate After Acute Kidney Injury and Glucarpidase Use in Pediatric Oncology Patients,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/35/35380/abstract-text/22252903/pubmed\" id=\"22252903\" target=\"_blank\">",
"        22252903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Marcaigh AS, Johnson CM, Smithson WA, et al, \"Successful Treatment of Intrathecal Methotrexate Overdose by Using Ventriculolumbar Perfusion and Intrathecal Instillation of Carboxypeptidase G2,\"",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1996, 71(2):161-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/35/35380/abstract-text/8577190/pubmed\" id=\"8577190\" target=\"_blank\">",
"        8577190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips M, Smith W, Balan G, et al, &ldquo;Pharmacokinetics of Glucarpidase in Subjects With Normal and Impaired Renal Function,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2008, 48(3):279-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/35/35380/abstract-text/18192538/pubmed\" id=\"18192538\" target=\"_blank\">",
"        18192538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widemann BC, Balis FM, Kim A, et al, &ldquo;Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(25):3979-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/35/35380/abstract-text/20679598/pubmed\" id=\"20679598\" target=\"_blank\">",
"        20679598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widemann BC, Balis FM, Murphy RF, et al, &ldquo;Carboxypeptidase-G2, Thymidine, and Leucovorin Rescue in Cancer Patients With Methotrexate-Induced Renal Dysfunction,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(5):2125-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/35/35380/abstract-text/9164227/pubmed\" id=\"9164227\" target=\"_blank\">",
"        9164227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widemann BC, Balis FM, Shalabi A, et al, &ldquo;Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2004, 96(20):1557-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/35/35380/abstract-text/15494606/pubmed\" id=\"15494606\" target=\"_blank\">",
"        15494606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86261 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35380=[""].join("\n");
var outline_f34_35_35380=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14266243\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315381\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315388\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13743258\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13743098\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233912\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315389\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13743116\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315385\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315382\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8092329\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315383\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790048\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315384\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14395087\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14395085\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13743100\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13743101\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315390\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315386\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790049\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315387\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315391\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790083\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86261\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86261|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=related_link\">",
"      Glucarpidase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/43/8883?source=related_link\">",
"      Glucarpidase: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_35_35381="HRCT ground glass in scleroderma";
var content_f34_35_35381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F70357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F70357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Interstitial lung disease in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan through the lung bases in a patient with scleroderma shows bibasilar interstitial lung disease with ground glass changes in the right lower lobe. Note also the patulous esophagus (dashed arrow) and bilateral pleural effusions (black arrows). The heart is also enlarged.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35381=[""].join("\n");
var outline_f34_35_35381=null;
var title_f34_35_35382="Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)";
var content_f34_35_35382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/35/35382/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35382/contributors\">",
"     John Varga, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/35/35382/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35382/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35382/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/35/35382/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35382/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/35/35382/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary disease complications occur in over 80 percent of patients with systemic sclerosis (SSc). Pulmonary involvement is second in frequency only to esophageal involvement as a visceral complication and has surpassed renal involvement as the most common cause of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35382/abstract/1\">",
"     1",
"    </a>",
"    ]. Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the most frequent major types of lung involvement. Affected patients have a poorer prognosis than those with SSc who are free of pulmonary involvement.",
"   </p>",
"   <p>",
"    Evidence of both types of SSc-associated lung disease (ILD or PAH) is frequently detected in patients with no cardiopulmonary symptoms using a combination of noninvasive tests for screening and invasive studies for confirmation. The ability to detect ILD and PAH at early presymptomatic stages, coupled with the availability of pharmacologic interventions that may slow the progression of these complications of SSc, provide a rationale for extensive initial evaluation and regular monitoring of patients for the presence of pulmonary involvement.",
"   </p>",
"   <p>",
"    The evaluation and diagnosis of SSc-associated lung disease will be reviewed here. The clinical manifestations, therapy, and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26329?source=see_link\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/19/7482?source=see_link\">",
"     \"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6935?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFLUENCE OF SSC SUBSETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major subsets of SSc are commonly recognized. Skin involvement proximal to the forearm is characteristic of the diffuse cutaneous SSc subset, while sclerodermatous changes confined to the fingers, distal portion of the extremities, and to the face are characteristic of limited cutaneous SSc (lcSSc). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=see_link\">",
"     \"Classification of scleroderma disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with dcSSc are at an increased risk of developing ILD early in the course of their disease; however, clinically significant ILD may also occur in patients with lcSSc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35382/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The presence of nucleolar autoantibodies such as",
"    <span class=\"nowrap\">",
"     Th/To,",
"    </span>",
"    and less commonly anti-Scl-70 autoantibodies, in patients with lcSSc are associated with increased risk of ILD. Patients with lcSSc often develop PAH late in the course of the disease with or without associated ILD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF PULMONARY INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two principal forms of SSc lung involvement, which may occur separately or together:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interstitial lung disease &ndash; The interstitial lung diseases (ILDs) are a heterogeneous group of disorders caused by a wide variety of occupational and environmental exposures and connective tissue diseases, including SSc. The clinical and pathologic features of SSc-associated ILD are typically those of nonspecific interstitial pneumonia (NSIP) or less commonly, usual interstitial pneumonia (UIP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35382/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]. The clinical features and pathologic findings of NSIP and UIP are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link\">",
"       \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary vascular disease &ndash; Pulmonary arterial hypertension (PAH) is the most common manifestation of pulmonary vascular disease in SSc. Pathologically, SSc-associated PAH is indistinguishable from idiopathic PAH. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common pulmonary complications of SSc include: pleural disease, aspiration pneumonia, bronchiectasis, spontaneous pneumothorax, drug-associated pneumonitis, and lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26329?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\", section on 'Types of pulmonary involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION FOR LUNG DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with SSc should be screened for ILD and PAH at presentation and periodically thereafter, because of the frequent occurrence of these lung diseases and their high morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35382/abstract/5\">",
"     5",
"    </a>",
"    ]. The history and physical exam should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inquiring about pulmonary symptoms such as cough, dyspnea on exertion, exertional presyncope, syncope, or chest pain.",
"     </li>",
"     <li>",
"      Seeking physical signs of ILD and PAH, including crackles (rales), an increased A wave in the jugular venous pulse, increased pulmonic component of the second heart sound or a right ventricular S4, a right ventricular heave, a pulmonary arterial \"tap\", a murmur suggestive of tricuspid regurgitation, and peripheral edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically screen patients with SSc as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We typically obtain a high resolution computed tomography (HRCT) scan of the chest rather than a conventional chest radiograph due to the greater sensitivity of the HRCT. However, for patients who have already had a chest radiograph performed, the films are inspected for hazy or reticular opacities in the lower lobes, enlarged pulmonary arteries",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      right ventricular prominence. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link\">",
"       \"High resolution computed tomography of the lungs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link&amp;anchor=H2#H2\">",
"       \"High resolution computed tomography of the lungs\", section on 'Clinical application of HRCT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A HRCT scan of the chest is examined for the presence and distribution of ground glass or reticular opacities, \"honeycombing\", bronchiectasis, emphysematous blebs, or bullae. The prognostic utility of screening patients with SSc for ILD was illustrated in a prospective study of 215 patients; progressively more extensive interstitial disease on HRCT was highly predictive of mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35382/abstract/6\">",
"       6",
"      </a>",
"      ]. A more widespread distribution of reticular opacities appears to correlate with greater responsiveness to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35382/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link&amp;anchor=H4#H4\">",
"       \"High resolution computed tomography of the lungs\", section on 'HRCT patterns'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/19/7482?source=see_link\">",
"       \"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary function testing (PFT) is performed to assess for the presence or absence of a restrictive ventilatory defect or a decrease in the single breath diffusion capacity for carbon monoxide (DLCO) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35382/abstract/8\">",
"       8",
"      </a>",
"      ]. The combination of reduced lung volumes and reduced DLCO suggests ILD; a significant decrease in DLCO (less than 65 percent of predicted) in the absence of significant lung volume abnormalities or a decrease in DLCO &ge;20 percent in a year suggest PAH, particularly in patients with long standing lcSSc. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link\">",
"       \"Overview of pulmonary function testing in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with dyspnea on exertion, desaturation during ambulatory oximetry,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a reduced DLCO, pulmonary arterial pressures are estimated utilizing Doppler echocardiography. Screening echocardiography is not routinely performed in the absence of symptoms, an abnormal DLCO, or HRCT findings suggestive of PAH or heart failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6935?source=see_link&amp;anchor=H5#H5\">",
"       \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\", section on 'Screening'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The echocardiographic findings of pulmonary hypertension are summarized in the figures (",
"      <a class=\"graphic graphic_figure graphicRef77640 \" href=\"mobipreview.htm?39/52/40782\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef63058 \" href=\"mobipreview.htm?5/12/5313\">",
"       figure 2",
"      </a>",
"      ). When PAH is suggested by Doppler echocardiography, right heart catheterization is necessary for confirmation and to exclude occult left ventricular dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=see_link\">",
"       \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6935?source=see_link\">",
"       \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Analysis of the studies described above allows patients with SSc-associated ILD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PAH to be distinguished from patients without pulmonary complications. Those with normal studies at the initial evaluation are reevaluated periodically. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Reevaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis of ILD",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the presence of ILD is suggested by the initial evaluation (eg, respiratory symptoms, PFTs, HRCT), additional testing is required to distinguish progressive ILD that may be amenable to treatment from similar radiographic changes or abnormalities in pulmonary function testing that result from infection, recurrent aspiration due to gastroesophageal reflux or esophageal dysmotility, thromboembolism, superimposed left heart failure, or the presence of irreversible pulmonary fibrosis. Further testing may involve bronchoalveolar lavage (BAL), or in some cases, thoracoscopically guided or open lung biopsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active interstitial pneumonitis &ndash; Cellular infiltration of the interstitium and alveolar filling is suggested by the presence of \"ground-glass\" opacification on HRCT (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70357 \" href=\"mobipreview.htm?34/35/35381\">",
"       image 1",
"      </a>",
"      ). However, ground glass opacities can also be seen with pulmonary edema, as well as early fibrosis and infection. In some instances, careful follow up with serial imaging studies and PFTs is required to determine if the lung involvement is progressive. Worsening radiographic appearance and deteriorating pulmonary function tests (such as a decline &ge;10 percent in FVC in a year) are supportive of active ILD. Bronchoscopy with BAL is usually performed when the HRCT findings are atypical for SSc-associated ILD or when granulomatous or opportunistic infection is suspected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=see_link\">",
"       \"Basic principles and technique of bronchoalveolar lavage\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=see_link\">",
"       \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Some patients with SSc-associated ILD have elevated numbers of granulocytes in their BAL fluid, particularly neutrophils and eosinophils [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35382/abstract/9\">",
"       9",
"      </a>",
"      ]. Excess lymphocytes and an increase in mast cells also may be seen. Initial studies suggested that granulocytosis in the BAL indicated active alveolitis and in some studies, patients with active alveolitis appeared more likely to respond to immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35382/abstract/9\">",
"       9",
"      </a>",
"      ]. However, subsequent studies indicate that while BAL granulocytosis is associated with the severity of ILD, and thus increased mortality, it does not predict disease progression or response to therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35382/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26329?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\", section on 'Bronchoalveolar lavage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary fibrosis &ndash; Parenchymal fibrosis is suggested by the presence of prominent reticular opacifications and honeycombing on HRCT and the relative absence of ground glass opacities (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72569 \" href=\"mobipreview.htm?38/6/39008\">",
"       image 2",
"      </a>",
"      ). Lung biopsy is rarely needed for the evaluation of SSc-associated ILD, unless HRCT findings suggest an alternate diagnosis, such as possible infection or malignancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link&amp;anchor=H5#H5\">",
"       \"High resolution computed tomography of the lungs\", section on 'Reticular pattern'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26329?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\", section on 'Lung biopsy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link\">",
"       \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis of PAH",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the presence of PAH is suggested by symptoms (eg, exertional dyspnea, chest pain, near syncope, or syncope), a low diffusing capacity with relatively normal lung volumes, or elevated pulmonary artery pressures on Doppler echocardiography, we proceed to right-heart catheterization to verify the presence of pulmonary hypertension and to exclude left heart failure and pericardial disease. Because Doppler echocardiography may be associated with false positive and false negative test results, right-heart catheterization remains the diagnostic gold standard for PAH. At the time of right heart catheterization, severity of pulmonary hypertension and, in some cases, acute responsiveness to vasodilators, are measured to guide treatment choices. The evaluation and management of SSc-associated PAH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6935?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of brain natriuretic peptide (BNP) or amino-terminal-proBNP (NT-proBNP) in the serum are promising noninvasive approaches that may be able to identify patients at higher risk for having or developing PAH. There may eventually be a role for these blood tests in the identification and monitoring of PAH and its response to therapy, especially in patients with coexisting ILD. However, further study of the sensitivity and specificity of these tests is needed before they are used in the routine evaluation of patients with suspected PAH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26329?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\", section on 'Investigational assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     REEVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dcSSc are at an increased risk for development of ILD, particularly during the first three to five years of illness. In contrast, patients with lcSSc have a lower risk for early ILD but are more likely to develop PAH late in the course of the disease. We typically follow patients with SSc at three to six month intervals to assess changes in symptoms or physical examination.",
"   </p>",
"   <p>",
"    For patients who have no evidence of ILD or PAH on initial evaluation, we suggest annual screening studies (ie, HRCT and PFTs with DLCO). Earlier reevaluation is performed, if new symptoms develop prior to the appointed time.",
"   </p>",
"   <p>",
"    Worsening dyspnea or cough in a patient with SSc should arouse suspicion for aspiration due to gastroesophageal reflux",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    esophageal dysmotility. Additional considerations may include infection, thromboembolism, or superimposed left heart failure. Patients receiving a combination of glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    are also at risk for opportunistic infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring for involvement of other organs by SSc is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=see_link\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary involvement occurs in most patients with systemic sclerosis (SSc). Interstitial lung disease (ILD) or pulmonary arterial hypertension (PAH) may occur independently or may coexist. Early pulmonary involvement in SSc is often asymptomatic. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Types of pulmonary involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two major subsets of SSc are commonly recognized. Skin involvement proximal to the forearm is characteristic of the diffuse cutaneous SSc subset, while sclerodermatous changes confined to the fingers, distal portion of the extremities, and to the face are characteristic of limited cutaneous SSc. Patients with diffuse cutaneous SSc tend to have an increased risk of developing ILD, while patients with limited cutaneous SSc tend to develop PAH late in the course of the disease with or without associated ILD. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Influence of SSc subsets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In view of the potentially ominous prognosis of these pulmonary complications and the availability of treatment, we suggest that all SSc patients undergo extensive evaluation at presentation to detect ILD",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PAH. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial evaluation for lung disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation for SSc lung disease includes a medical history with careful attention to exertional dyspnea, exercise intolerance, and other respiratory symptoms, physical examination, pulmonary function testing (including spirometry, lung volumes, and diffusing capacity [DLCO]),and high resolution computed tomography (HRCT). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial evaluation for lung disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SSc-associated ILD is largely based on the HRCT finding of ground glass and reticular opacities in a basilar and subpleural distribution. Ground glass opacities on HRCT may reflect active alveolitis. However, pulmonary edema, fibrosis, and infection may have a similar appearance. The main role for bronchoalveolar lavage (BAL) is to help in excluding an infection. Lung biopsy is occasionally necessary when the HRCT findings are atypical or when opportunistic infection is suspected. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis of ILD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=see_link\">",
"       \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PAH is suggested by exertional dyspnea and a DLCO that is decreased out of proportion to the spirometry and lung volumes or by a fall in DLCO &ge;20 percent in one year, especially in patients with long-standing limited cutaneous scleroderma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Influence of SSc subsets'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis of PAH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the results of Doppler echocardiography suggest the presence of PAH, or when patients have suggestive symptoms but inconclusive noninvasive studies, right-heart catheterization is indicated to measure pulmonary artery pressures and rule out heart failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6935?source=see_link\">",
"       \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Further study of the sensitivity and specificity of measurements of serum BNP and NT-proBNP (when used to identify patients with SSc who are at particularly high risk of having or developing PAH) is needed before a recommendation to use or not use them in clinical practice can be made. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis of PAH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SSc who have no evidence of ILD or PAH at the time of initial evaluation are reevaluated clinically at three to six month intervals; screening studies (eg, HRCT, PFTs with DLCO) are repeated annually in the absence of new symptoms. These studies are repeated earlier if new respiratory symptoms develop prior to the appointed time. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Reevaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/1\">",
"      Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/2\">",
"      Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 2008; 134:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/3\">",
"      Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 2010; 35:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/4\">",
"      Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/5\">",
"      Hesselstrand R, Ekman R, Eskilsson J, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005; 44:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/6\">",
"      Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/7\">",
"      Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011; 63:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/8\">",
"      Behr J, Furst DE. Pulmonary function tests. Rheumatology (Oxford) 2008; 47 Suppl 5:v65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/9\">",
"      Harrison NK, Glanville AR, Strickland B, et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med 1989; 83:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/10\">",
"      Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35382/abstract/11\">",
"      Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4377 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35382=[""].join("\n");
var outline_f34_35_35382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFLUENCE OF SSC SUBSETS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF PULMONARY INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL EVALUATION FOR LUNG DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis of ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis of PAH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REEVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4377\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4377|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/35/35381\" title=\"diagnostic image 1\">",
"      HRCT ground glass in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/6/39008\" title=\"diagnostic image 2\">",
"      HRCT reticular pattern in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4377|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/52/40782\" title=\"figure 1\">",
"      Schematic of echo findings in PH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/12/5313\" title=\"figure 2\">",
"      Doppler estimation of RA RV gradient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=related_link\">",
"      Classification of scleroderma disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26329?source=related_link\">",
"      Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/19/7482?source=related_link\">",
"      Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6935?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_35_35383="Estradiol (systemic): Pediatric drug information";
var content_f34_35_35383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Estradiol (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?14/25/14746?source=see_link\">",
"    see \"Estradiol (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/58/38824?source=see_link\">",
"    see \"Estradiol (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8018272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8018338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alora&reg;;",
"     </li>",
"     <li>",
"      Climara&reg;;",
"     </li>",
"     <li>",
"      Delestrogen&reg;;",
"     </li>",
"     <li>",
"      Depo&reg;-Estradiol;",
"     </li>",
"     <li>",
"      Divigel&reg;;",
"     </li>",
"     <li>",
"      Elestrin&reg;;",
"     </li>",
"     <li>",
"      Estrace&reg;;",
"     </li>",
"     <li>",
"      Estrasorb&reg;;",
"     </li>",
"     <li>",
"      EstroGel&reg;;",
"     </li>",
"     <li>",
"      Evamist&reg;;",
"     </li>",
"     <li>",
"      Femring&reg;;",
"     </li>",
"     <li>",
"      Femtrace&reg;;",
"     </li>",
"     <li>",
"      Menostar&reg;;",
"     </li>",
"     <li>",
"      Minivelle&trade;;",
"     </li>",
"     <li>",
"      Vivelle-Dot&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8018339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Climara&reg;;",
"     </li>",
"     <li>",
"      Depo&reg;-Estradiol;",
"     </li>",
"     <li>",
"      Estraderm&reg;;",
"     </li>",
"     <li>",
"      Estradot&reg;;",
"     </li>",
"     <li>",
"      EstroGel&reg;;",
"     </li>",
"     <li>",
"      Menostar&reg;;",
"     </li>",
"     <li>",
"      Oesclim&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Estradiol Derm 100;",
"     </li>",
"     <li>",
"      Sandoz-Estradiol Derm 50;",
"     </li>",
"     <li>",
"      Sandoz-Estradiol Derm 75",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10824233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Estrogen Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10824256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/25/14746?source=see_link\">",
"      see \"Estradiol (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Use lowest effective dose for shortest duration possible that is consistent with an individual's treatment goals and risks; all dosage needs to be adjusted based upon the patient's response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Female hypogonadism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cypionate: 1.5-2 mg given once each month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Valerate: 10-20 mg given once each month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 0.5-2 mg/day in a cyclic regimen (3 weeks on drug, 1 week off)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Once-weekly patch (Climara&reg;): Initial: 0.025 mg/day patch applied once weekly (titrate dosage to response)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Twice-weekly patch: Alora&reg;, Estraderm&reg;: Initial: 0.05 mg patch; Vivelle Dot&reg;: Initial: 0.0375 mg patch; titrate dosage to response; apply patch twice weekly in a cyclic regimen (3 weeks on drug, 1 week off) in patients with intact uterus and continuously in patients without a uterus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vaginal ring: Moderate to severe vasomotor symptoms associated with menopause; vulvar/vaginal atrophy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Femring&trade;: 0.05 mg intravaginally; following insertion, ring should remain in place for 3 months; dose may be increased to 0.1 mg if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical emulsion: Moderate to severe vasomotor symptoms associated with menopause: 3.48 g (contents of 2 pouches) applied once daily in the morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical gel: Moderate to severe vasomotor symptoms associated with menopause or vulvar and vaginal atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Divigel&reg;: 0.25-1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Elestrin&reg;: 0.87 g applied once daily at the same time each day; adjust dose based on patient response. Dosing range: 0.87-1.7 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     EstroGel&reg;: 1.25 g applied once daily at the same time each day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical spray: Evamist&trade;: Initial: One spray (1.53 mg) per day. Adjust dose based on patient response. Dosing range: 1-3 sprays per day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8018425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion, topical, as hemihydrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estrasorb&reg;: 2.5 mg/g (56s) [contains ethanol, soybean oil; each pouch contains estradiol hemihydrate 4.35 mg; contents of two pouches delivers estradiol 0.05 mg/day]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Divigel&reg;: 0.1% (30s) [contains ethanol; delivers estradiol 0.25 mg/0.25 g packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Divigel&reg;: 0.1% (30s) [contains ethanol; delivers estradiol 0.5 mg/0.5 g packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Divigel&reg;: 0.1% (30s) [contains ethanol; delivers estradiol 1 mg/1 g packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elestrin&reg;: 0.06% (35 g [DSC]) [contains ethanol; delivers estradiol 0.52 mg/0.87 g; 30 actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elestrin&reg;: 0.06% (70 g) [contains ethanol; delivers estradiol 0.52 mg/0.87 g; 60 actuations; packaged as 2x35 g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EstroGel&reg;: 0.06% (50 g) [contains ethanol; delivers estradiol 0.75 mg/1.25 g; 32 actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil, as cypionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo&reg;-Estradiol: 5 mg/mL (5 mL) [contains chlorobutanol, cottonseed oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil, as valerate: 10 mg/mL (5 mL); 20 mg/mL (5 mL); 40 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delestrogen&reg;: 10 mg/mL (5 mL) [contains chlorobutanol, sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delestrogen&reg;: 20 mg/mL (5 mL); 40 mg/mL (5 mL) [contains benzyl alcohol, benzyl benzoate, castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal [once-weekly patch]: 0.025 mg/24 hours (4s); 0.0375 mg/24 hours (4s); 0.05 mg/24 hours (4s); 0.06 mg/24 hours (4s); 0.075 mg/24 hours (4s); 0.1 mg/24 hours (4s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.025 mg/24 hours (4s) [6.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 2 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.0375 mg/24 hours (4s) [9.375 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 2.85 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.05 mg/24 hours (4s) [12.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 3.8 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.06 mg/24 hours (4s) [15 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 4.55 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.075 mg/24 hours (4s) [18.75 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 5.7 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.1 mg/24 hours (4s) [25 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 7.6 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menostar&reg;: 0.014 mg/24 hours (4s) [3.25 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal [twice-weekly patch]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alora&reg;: 0.025 mg/24 hours (8s) [9 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 0.77 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alora&reg;: 0.05 mg/24 hours (8s) [18 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 1.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alora&reg;: 0.075 mg/24 hours (8s) [27 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 2.3 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alora&reg;: 0.1 mg/24 hours (8s) [36 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 3.1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minivelle&trade;: 0.037 mg/24 hours (8s) [2.48 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total estradiol 0.62 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minivelle&trade;: 0.05 mg/24 hours (8s) [3.3 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total estradiol 0.83 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minivelle&trade;: 0.075 mg/24 hours (8s) [4.95 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total estradiol 1.24 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minivelle&trade;: 0.1 mg/24 hours (8s) [6.6 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total estradiol 1.65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivelle-Dot&reg;: 0.025 mg/24 hours (24s) [2.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 0.39 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivelle-Dot&reg;: 0.0375 mg/24 hours (24s) [3.75 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 0.585 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivelle-Dot&reg;: 0.05 mg/24 hours (24s) [5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 0.78 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivelle-Dot&reg;: 0.075 mg/24 hours (24s) [7.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 1.17 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivelle-Dot&reg;: 0.1 mg/24 hours (24s) [10 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 1.56 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ring, vaginal, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femring&reg;: 0.05 mg/24 hours (1s) [total estradiol 12.4 mg; releases 0.05 mg/24 hours over 3 months]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femring&reg;: 0.1 mg/24 hours (1s) [total estradiol 24.8 mg; releases 0.1 mg/24 hours over 3 months]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Evamist&reg;: 1.53 mg/spray (8.1 mL) [contains ethanol; delivers 75 sprays after priming]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [micronized]: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estrace&reg;: 0.5 mg, 1 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estrace&reg;: 2 mg [scored; contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femtrace&reg;: 0.45 mg [DSC], 0.9 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8018341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Oral tablet, patch, valerate oil for injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10824257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with food or after a meal to reduce GI upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Injection for I.M. use only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal: Apply to clean, dry area; do not apply to breasts; do not apply to waistline (may loosen patch); rotate application sites",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10824238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypoestrogenism (due to hypogonadism, castration, or primary ovarian failure), moderate to severe vasomotor symptoms of menopause, and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; palliative treatment of breast cancer in select patients; palliative treatment of androgen-dependent prostate cancer; prevention of osteoporosis in postmenopausal women; FDA approved in adults",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8018336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alora&reg; may be confused with Aldara&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Elestrin&reg; may be confused with alosetron",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [oral and transdermal patch]; Strength of recommendation - strong [oral and transdermal patch]).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vivelle: Brand name for estradiol [U.S. and multiple international markets, but also the brand name for ethinyl estradiol and norgestimate [Austria]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8018353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some adverse reactions observed with estrogen and/or progestin combination therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, DVT, edema, hypertension, MI, stroke, syncope, TIA, vasodilation,  venous thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dementia, dizziness, epilepsy exacerbation, headache, insomnia, irritability, mental depression, migraine, mood disturbances, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, chloasma, dermatitis, erythema multiforme, erythema nodosum, hemorrhagic eruption, hirsutism, loss of scalp hair, melasma, rash, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast cancer, breast enlargement, breast pain, breast tenderness, carbohydrate intolerance, fibrocystic breast changes, fluid retention, galactorrhea, hot flashes, hypocalcemia, libido changes, nipple discharge, nipple pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, abdominal pain, bloating, cholecystitis, cholelithiasis, constipation, diarrhea, dyspepsia, flatulence, gallbladder disease, gastritis, nausea, pancreatitis, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Alterations in frequency and flow of bleeding patterns, breakthrough bleeding, cervical ectropion changes, cervical secretion changes, cystitis, dysmenorrhea, endometrial cancer, endometrial hyperplasia, genital eruption, menorrhagia, metrorrhagia, ovarian cancer, ovarian cyst, Pap smear suspicious, spotting, uterine leiomyomata size increased, leukorrhea, uterine cancer, uterine enlargement, uterine pain, urinary incontinence, urogenital pruritus, vaginal candidiasis, vaginal discharge, vaginal moniliasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Aggravation of porphyria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatic hemangioma enlargement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel, spray: Application site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patches: Erythema, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, chorea, leg cramps, myalgia, muscle cramps, skeletal pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blindness, contact lens intolerance, corneal curvature steepening, retinal vascular thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, pulmonary thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid/anaphylactic reactions, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Vaginal ring: Bowel obstruction, ring adherence to vaginal wall, toxic shock syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10824239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to estradiol or any component; history of or current DVT or PE; recent (eg, within past year) or current arterial thromboembolic disease (eg, MI, stroke); undiagnosed vaginal bleeding; pregnancy; known, suspected, or history of breast cancer (except in select patients being treated for metastatic disease); estrogen-dependent neoplasia; liver disease or dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10824246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with asthma, epilepsy, migraines, diabetes, hypothyroidism, hypocalcemia, hypercalcemia, endometriosis, porphyria, SLE, hepatic hemangioma, history of cholestatic jaundice due to past estrogen use or pregnancy, or cardiac, liver, or renal dysfunction. Estrogens may cause premature closure of the epiphyses in young individuals (with large and repeated doses over an extended period of time); may cause premature breast development in prepubertal girls or gynecomastia in boys; may include vaginal bleeding or vaginal cornification in girls; may increase risk of ovarian cancer; may increase blood pressure; may cause fluid retention; may greatly increase triglycerides and lead to pancreatitis and other problems in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10824243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens have been reported to increase the risk of endometrial carcinoma",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding; the addition of a progestin has been shown to decrease the risk of estrogen-induced endometrial hyperplasia, a condition thought to be a precursor to endometrial cancer. Do not use estrogens (with or without progestins) for the prevention of cardiovascular disease",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; a significantly increased risk of MI, stroke, PE, DVT, and invasive breast cancer was reported in postmenopausal women receiving conjugated equine estrogens combined with medroxyprogesterone acetate (Rossouw, 2002); use of conjugated estrogens alone significantly increased the risk of stroke in postmenopausal women, but did not affect the risk of coronary heart disease (Women's Health Initiative Steering Committee, 2004); due to these risks, use estrogens (with or without progestins) at the lowest effective doses and for the shortest duration possible that is consistent with an individual's treatment goals and risks",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; periodic risk:benefit assessments should be conducted; discontinue estrogens immediately if MI, stroke, PE, or DVT occur; in order to minimize the risk of thromboembolism in patients receiving estrogens, other risk factors for venous thromboembolism (eg, obesity, SLE, personal or family history of venous thromboembolism) and arterial vascular disease (eg, diabetes mellitus, hypertension, tobacco use, obesity, hypercholesterolemia) should be appropriately managed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Since estrogens may increase the risk of venous thromboembolism, discontinue therapy, if possible, at least 4-6 weeks before surgery that is associated with an increased risk of thromboembolism, or during times of prolonged immobilization. Estrogens may increase the risk of breast cancer, gallbladder disease, hypercalcemia, and retinal vascular thrombosis (discontinue estrogen therapy in patients with sudden partial or complete loss of vision, sudden onset of diplopia, proptosis, or migraine, or if eye exam reveals retinal vascular lesions or papilledema). The combined use of conjugated equine estrogens and medroxyprogesterone acetate was reported to significantly increase the risk of probable dementia in postmenopausal women",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; it is currently not known if these findings apply to younger women or to patients receiving estrogen alone.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Transdermal patch may contain conducting metal (eg, aluminum) which may cause a burn to the skin during an MRI scan; remove and dispose of patch prior to MRI. Apply new patch after scan is completed. Due to the potential for altered electrical conductivity, remove transdermal patch before cardioversion or defibrillation. Injection may contain benzyl alcohol and oral tablet may contain tartrazine, both of which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; avoid use of estradiol products containing benzyl alcohol in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Estradiol may be absorbed by others upon physical contact with topical emulsion application site. Topical gel is alcohol based and is flammable; patients should avoid fire, flame, or smoking until the gel has dried (gel dries in 2-5 minutes after application); photosensitivity after gel application and effects of concurrent application of sunscreen with gel have not been evaluated; estradiol was",
"     <b>",
"      not",
"     </b>",
"     absorbed by others after physical contact with topical gel application site 1 hour after application.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8018356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C8 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8018357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10824252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Larger doses of vitamin C (eg, 1 g/day in adults) may increase the serum concentrations and adverse effects of estradiol; vitamin C supplements are not recommended, but this effect may be decreased if vitamin C supplement is given 2-3 hours after estrogen; dietary intake of folate and pyridoxine may need to be increased; grapefruit juice may possibly increase estrogen plasma concentrations and effects",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8018343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8018344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, the use of estrogen and progestin as in combination hormonal contraceptives has not been associated with teratogenic effects when inadvertently taken early in pregnancy. These products are contraindicated for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10824261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, weight, serum calcium, glucose, liver enzymes; bone maturation and epiphyseal effects in young patients in whom bone growth is not complete; breast exam, mammogram, Papanicolaou smear, signs for endometrial cancer in female patients with a uterus; bone density measurement if used for prevention of osteoporosis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10824253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synthesis of DNA, RNA, and various proteins in target tissues; reduces the release of gonadotropin-releasing hormone from the hypothalamus; reduces FSH and LH release from the pituitary",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10824254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Well-absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Widely distributes throughout the body; sex hormone target organs contain higher concentrations; distributes into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Primarily bound to sex hormone-binding globulin and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, via cytochrome P450 isoenzyme CYP3A4; estradiol is converted to estrone and estriol; estrone is also converted to estriol and is converted to estradiol (",
"     <b>",
"      Note:",
"     </b>",
"     A dynamic equilibrium of metabolic interconversions between estrogens exists in the circulation); estrogens also undergo hepatic sulfate and glucuronide conjugation and enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Excreted in the urine as estradiol, estrone, and estriol and glucuronide and sulfate conjugates",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10824324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/58/38824?source=see_link\">",
"      see \"Estradiol (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol, caffeine, and grapefruit juice; notify physician if sudden severe headache or vomiting, disturbance of vision or speech, numbness or weakness of extremity, sharp or crushing chest pain, calf pain, shortness of breath, severe abdominal pain or mass, mental depression, or unusual bleeding occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10824325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See package insert for doses related to postmenopausal symptoms, prevention of osteoporosis in postmenopausal women, and palliative treatment of breast cancer or androgen-dependent prostate cancer in adults.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, \"Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/35/35383/abstract-text/ 12117397 /pubmed\" id=\" 12117397 \" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Women's Health Initiative Steering Committee, \"Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/35/35383/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15980 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35383=[""].join("\n");
var outline_f34_35_35383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018272\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018338\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018339\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824233\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824256\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018425\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018341\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824257\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824238\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018336\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018353\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824239\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824246\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824243\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018356\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018357\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824252\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018343\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018344\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824261\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824253\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824254\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824324\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824325\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15980\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15980|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/25/14746?source=related_link\">",
"      Estradiol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/58/38824?source=related_link\">",
"      Estradiol (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/1/38935?source=related_link\">",
"      Estradiol (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/34/40485?source=related_link\">",
"      Estradiol (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_35_35384="Guttate psoriasis 2";
var content_f34_35_35384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64836%7EDERM%2F55141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64836%7EDERM%2F55141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Guttate psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFFAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDtoEZSMnPqac0O/D4RgDU7Q4+ZQQCOakhUBN3IU9q8W3Q9+/UiEaEEr908ECpPLRCOcse4qRYQB95h9P4qe0SL82CMCm0IiiiMp3MTwcc1YWNVJ4YnPWmLHgYTIZjnPUVN5DBtxJIx07U0D0GFAxwchTxipYFO5gB9e+acFI6ckDvR8wG8FgB37VS3J1JViCtuIAx61HK6xEk9W6DPSnxPvXCncR1xTkto2CM6bmXoab1Wg0ktytcopkiVk3A8Zx0+tWt/kJt2klj/AAjpTxGDyQ3XPTipIyFnAOW7gelCjYfNdDHt+r8gnFWY1KhdwySM4prTkyEIucc4qXyhKUd8hhzjNWrLYzd+oIm/AyUIPbk1OyMoJJ2o3AqJGXzCQvI6nsKnOcjHzqeo9KpK6JZAqNHuMxLDsAOlWYlYsDgqMY2/1qRFyTkc44OKQngFSdo4xVWsJu5DMCEY5z6AcVyOq2DJPK3leb5i4yf4T7V2M0gKgnHDcZqukatIuVLBxyM8VlVgp6HRQqunqZfhmN4IERhke54/Gtwb5lYptODnkfnSNFhoiiAY7DgAGraIvBPBXoB/Orpw5VYyq1OeXP3KmdjODhXxkk1zF3cXK3ZmR8pnGGbg468V10hE0rwkHcBwTXMXNjcEvFGgZcnDt1BPpWddO2hthmru5paTei7tkZSEbOCOtaCJIJwhKhQuSMc9aztJgSys1hlwNxxk9a03JEqFXAQdRjOa1he2pjVtzPlI548rIRtDnAU5z+NNRJV2jdk4+bHenwOJgWUgoG4YVL3UtkZ5wOtVbsZtlKNA8jSGMq+cYPGaVym8BmCN02nvUzt5k4QDBHBFV5RHkytkoDn6VNil5iLFgHO0EnPBqNwSudo+U9DRfytDEJYVb0IxSW0plhjlPyOeoqLq9iknbmFWLEu7q3pmh3UhsnjpUxijExkAO9h270wOjqyxneUOGH90/wCTTsLciADrzwfWqN9fx24Afd19K0AGRuo2YyAazNRtml3FRnNRNtL3TSko83vDoJIpY8xDjODx0qZoVXcWPTnPYVDpdo1rDsYct3PpVkgKF6kdKIarUU0k9CisOyd2ViY2HANDqeN+A46YNX3XI3K3AHPFVpSxcZQgHjNJqwk7mTqJZIXMfIGc+tZWj6jJPO0EiY2810jQL82M++fSoreyigcvHHgsefUVk4Sck7nRGpBQcWtSoVYE8ZOc05QxJbGPQetXZIRGzYHzeppqxdW43Y5ArTlOdyKLRAgD7ueSaryRKCGAyR0PrV1iAW3gjbzn1qHKyxhlGVPpUvUdjOmjbGQTnr/9ahYAAWZCGPpzmrLRhNxfIbPApGBJAOQCO5qStyqQNpI4+tVZEKwkLg5xgHtWk0QwRkAHjGetR+QpG3HzAc1NugtDGDF/M8xWBHTNRMDtXYqsSe5xgVNrDS28DlNvA49646XU7y1nheVgyucFcdKyc1HRm8aLmro6gxRbjgjd0pDaK6Epxml8hZ4A0a7iwySKlgttq4kUjjB5q0YSVjumyUC7dx6ZqNgyKyqMkcVPEy7AxyBjvUgjBfdjI7Gt9xLQqsjMgCnOO/vTzE4RdpyRxz3qfYm/AI+Xkk0bdrDBJH1osO7I4zhsBfmxg+lThGwu7jH8qEUZ4UH8elTlBjEmMVUUJldk3ocgkYxjGM1JHGCMDPAwF7CnMhLKckAc465qYRKVypxzTSFcrpEI87c8n0qymVPA+XHekhyoAY7snjtinxogwM43eveml2B+YxVYkYPynvmnLGUVsAkg5GO9Odoo1bPygcmiLa8qyqW6cDPH1pgVZ0lWMzRIfNHbNWLZnMIkm4bGWFPvZ/skRmOW5HA7VnW+vW09wsQwpboT61LlGLs2aRhOcbpbGuhAUEZO49BU0cYVh1wxPGabGMJleAfT1p6qBNndx+XNaowY+MBQxznuc9qjuJAiNgDaB0pDGu87s7eoApzxRxqzsAM9ec0xKxy2rzzS3BS3cjb8x9qZpWoT212ILhgyg/e9vWrt3p0u8zWLZLr6UlhoshlaWVt79AG4rj5Z810elzU+Sz2/E6SFhNHlZNyMAAR2qVFAwpLEqMEkcUkMaxwrGFA6HPSpAwWTaSNpGK7rdzym9dCAF0KuMFieT6Urpu2oynAOfrSX8Uj2jLBgOPQ0y33rDiTcZQACPrR1sV05hkiBrhEZNy8nOeBT0bYuWA3EEAe1TZBK4IAHGKgkh3JnqcnGONtT5oad9GK6YVUiUKCdxWhM+buZmwvAUU/Zlyx6hQoJqTADbQQe5Jp2JuQqBKoZSN+eeOAKcVDcA4I6ccE1BEqozIgZBk5JqXzEBYbseWPm9KVxtEdxD5km1Tx6ZyKa8YZP3ajjjkYBFW1G5AynAPJpGj3ocjCn1oaEpFYLsYYzg56dvaoWiSNJGVAATyR1JqzKpZAsRG7jkjioZY0cqenGGA70mi0yMRExrtw3YjPNQucyeUxGOpGORViUOFCwHBBAPuKcQpZiwBOPvdKloL2INoIwxJINLIBsIBHr0pEuIy3ytkd/anSFAC2DkjoDT0sGpSc7gjJhl3YJBpl9MkK5dsfWrKFF3Ko2gHgjpmsvXraW4UNGCWx+dZTbUW1ua04qU0nsSQzRyKQCQ31p1sNoIYncO5FYej291DOzXBZUAwc/pW902sScN1NTTm5q7RdaHI7J6DJ1OQSQQeCM0eWQRkAY6+pFTTgbAM49x61Csm5duRntV6JmNm0QTpG3zMPw/wAarxxx4Vc4PUAVduBtj5OAeme1Z83lNcANhZB93B5NRLfQtJj8K0hjxk0x4RuIxhsVIBvl5DAr3Pc0mSWcEfMDjNILPoVGj5yfmA6Y7Ux49ozyA3bNXEJYkN25+tKyhx0+UDg9aErhdmPd2azxlGGVPTNYjeGYZLpZ2ycDGDzXVTqxyFGM9c1CqGNQDz6gCocIt6mkKs4R91lK2hWOMxMmzHAPrUEkBLuP4MZyTzWsFy2G4J6fSoZIQSMgH6U2jK+pvhSgbeSVz6VaiRyOe4xTIikzlwcjoB1BqyM/Nx061qkEm9iu0eGzjI9aUqXyPmGTwancggAL8x98UgARQPvDv7U7CuxIYgF4H09qlaM/eLZAHamBh7Y9vSnbd3HVD3zTS0Fq3cb5eXDCpHLLgLz68cU9UUIdpPpinjH8fA7560WE3cqhGacEHA7ilkaRZU2gue/sKsghxnjb9OaekQROB7/NRYrmIXCyHY44PY1IsWw4VDjHTtSuMSgHBP8AD7USbllTrxxg96dhXKup2/2i0baT0PIrn9P0iRbuPcoVEbdv7112Rubn5awNb8TWWl3K28qlpDy3GAM1lVjC6nPQ6KNWdnCCudEirHGqE8HgHvUixRpGc8IOhJ61StryC7gjnU5x90ntmrELo8RVvmWt010OVxfUgvrxIIfMDdeAAOtYC6tcSiSTZlY+WGeo9hWrrcBeyPkgkDpWPBJAq4mVwyLtBxgsT1rnquXNa530IR5LpXZoWGqCRxhD5YxwT3NbsI2kysQM8eormdM09nI8tFEO4hTXWWduRGqSkMV9a1oOT3OfFKEX7o9IuScnnke1JD8jCMv83JyV608yFgQfkJGMClRSzDY2SnBJHWuheRx+o1dhjJUlgW5571G/3ZBnr3p0uwAQsCFl6bRQ6AqyYIwMA56UnsNdytaIIJhGuXB+Zm96sgZDsBjnv0IpVhVIkCHPTBPPFIp3sFDAoQRQlbQG76kZXcNr/dZsnmpJQQRsAIJ5z6U9CGKuDnt9TTQoCBZGGSeKBXIkLyRyK6bBnAIoEYRwpBZSOSelSSnC4AyOmAaST5Y8qwAHWlYdxsZywDfLgcD0pNmYnDEkN1pVAZiwbORxWTrN5PbRFUQqec85zUykoxuy4R55cqNAYCgRtiPrk0ojU528g/ez6+1Q2DGe2jDLlSMsKtZAzkfKOnNC1V0J6OzK6FGUDGSScnHpVDVFleFvKYjPQnsK1GJMQwmPYVBLHIyjZwD1FKcbqxdOVpXOMu4mhaORmdJMZypIz7kV09hmSCJ2GSV+lQnRlmlYSOck5NaMFuINqrkBeM1hRpyi22dFerGcUluROmX+Rec8g0kwZchFOf6VYcRxsWY4H1prqNhYfNnvXRY5LlUhSQp78ZxTXjIjAQAHPTsKm25yQeT0z1pMu0q7SCD+lS13Kv2KbRbVO3JPXr0NU0RY5SPvFjzWpPgKzAZbqQBUZVMAlWBbjpzUSjfYtSsUnicwlUYFwf4hxXKapa3yamjw7t+c5HQCu3JxIARwBkUx1Uu28HcOhrOpSU1a5rRrezu7GdblyMSKMYFPQbyd6gYPGOeKmAjVmUlt3cntmjY+PlZQB3qkrIh6kTRAE7ARkc5pFAUYCjaRip2TaehbimGNAC+eSfXpVEFJwo5wWxxg1AFJJxggcdOlXWUMxyeP0NRbVViFB55zioaK3KkytHt2Luz3znFQsj7mJPOOMVoSpleh46EVVEY3F1znpx0qWgQnhgTx4V95UAjDdq6KOYefsYfNj8KkggRchUKke3WntbLKSQpU4ABHWqhTcFZM0q1Yzk3aw0gltynIBGRUOpEx2hdQAe4q4sahefzJqtqKB7VvMPC89etXLZkQ1kjk0vbj7QGRpNpYjGOK6hZ4/IjErqhcDj/CuVtrqL7WpALKrYDBeM10D6d9tljmJ4UdPSuWi3Z21O3ERjdX0NSVA6YUnJHGKkVTtIfLfh1otYykYGDj1NS7CZAcgDpiuxLqee+wy1RRlVB565NWioA44B4z6VHkDJzg1LuBTA+bHXIqo7EN31AKoYgA8cVVWOdrsksDABx61bjjABzuB6YzTwrIfmOQelDVwUrbFYLgBsZA6n0NeI/EMXN/4lnMJcRKdoT6d694LDyyAAAex4rjdT0G0l1R5pUDMfmI6f8A6658VSc4pI7cDUjGTcl0MjwfczroYju2OWb5CT/DjrW7FJcJ57h9oQBlx0Ye1RGMErHCqoYxkbfSrH2dnh8swHg5zu/SsYp2t2OiXLe/c3tPmW5tgxIORz9KV7CB5VZVU4Oai0q2MFuQMeYea1DiErIw4xiu6K5ormPNnLlk+QrlRErOqEbOgFZaaqzXRDJ1445reKMZRhfkKnJP+FUG02J7hpgu05zyO9KcZO3KFOcNectwfvYlLMxOc5HFWd20hFAKEcnNRW6rHEY0BBUkn3qGWZIgJfN2rt5WttlcxtzOyLMyqUXDYOMA4qHYXURMSXYckcVBY6hFcPtiPCdj3qaRnjjYuc5OR6gUrp6oOWUfdZIzBUcphnRdoHXNGwuIyflPt2pF+VlOOW6k+lKyMwHz4AbP4UxbCKfM3oycK350gwDuKkNk9e9S71Bx0H6moJjuKkIflOM57UMNxs0W/eyOwJ6e1NUPGx80gp1x1zUhXdk5I2dDS7Eyp3fe+Y5pWGmMkZmCeSAFPTtxVe7jWXdwGkU9xwKshTgMy+WAc9c8UxWLtKAgWPoCe9JocXZ6DIoxBgJnnt2zU7QgICeMc8U2MIyjvjpUzbAQvOfQ9qaWgm9SHncFxlGHBP60YHBzkdKCFA+Vt/PHtTAFDtk9QOPSkFhpIdT5ZGRwSPrUmQQOmD7VE5XYxT5SevHWoYxJtLINpBxtPNJsrluSSJg7sjHdfUVj6xqa2UPyruc9FFaxCs7SYG7jOaytWsFun3qzK3sKzq83L7u5tR5eZKZV0vVzcXDRSKUdB0/nWsCJMnaA3tWXpukNFdGaVssy4IFbAUAYIHsSailzcvvFV+Tm9waO2VJ7fSmMCUG3rngCpWzhSWKgHJzTWTGdoAycnJrQxKd1C8uNp2MpzTiGZSOrfqankGMZOWx1FImzd1Lc/gaVtSrtogMJRchBk9u+aijRnjKOQGA5I4q2yCUKQzAKeRTVjbfhsHJ7GlYVyu+QOhfHSoo9rJnBVs9DxVuSMKrADODwMY5qNVD7WVdrAYINLqNbFTI2NwvHao5ACh25HtU8qEHbHjk4PtT2iKgED24NKzY9CmcDg4zUTLjlR171bmUIUznJOOlJtAJB64+lFhPTY3do27jksevPAp2CMgjOe/XFAj2uBycYqTaN2SOT6VtYjciRMnHf171WvLYTxSKCfmBXgVoIuF5BB7Gk2kjJVSD6UnFNWHGVnc46HQpxhNxWInJx3rpoIPJhESg/7xrQWPIJOB7CgjBIIx64qadFQ2NKuIlU0ZXCZO1ske1Pk4ICDnuTUwVQQRz6nPSk2jnpzz7YrRoxuVkUgjzTyeMCpUbLjcuMelOEe0MzEE/y9qwda1KeJAYEIPYkdazlNU1dmkIOq7I3ElRiFDD5eopbqYRRlmVn9hXIaJqN1NqEayHcrHkV2SAJtA5B9e1FKr7RXRVaj7GVmQuSYfOIYH0rl7qWS41CMghQrfLn+L2NdbOx3bfx5rmpbWW2LeUhKsSSfrUVk3bsa4ZpX7lPU5zbzwlYdu7qxODn0+ldBosjTWxaRcHtXM/Z7qbyo7rAVX+Vz1rr9JtBFCF+8BUULynfoa4rljTt1LFrB5cryHliatArh0KhmHOP5U11dVURths9/SpfdcFxwea7UraHmSd9QZZGCMvyY6jNNDs6sQh+Ukc01pBG5JYhcYA7UitIHJLARYBxRcSQy6neG3LqBuOATnp715zq+qv9u8uOXejMcgc45ru9XXz9Pk8kA7gcdq4fS9BnuLx5JVZADxnmuHFc8moxPUwKpxjKczotDiOwXO454Xae3tW+smIozKB5jHGByM1Ts7X7HFFGgLDuT1og+0byzY3FuF7AV0U1yKxy1Ze0bkXnfYwZiBk4H1pRjZsY8kc57iqjnzHKMuVQ569TVshl2gDLHgj0rRamDjYeVVBnA4HAqGaUgKNpLEdh0pXch3LDPy5wTUicklyMnn6CnuTtuAVgEHVj14xmmSOI3IKsSw6j+GgldxJzlzgf/qpzt+7bcvyngH2oH1GblZQMfIBkkmpkYNGpVMA4GfWo/KiACycK3AWpJJAkQ8tTjOOO1P1Fo9EMIyCvAB7jvWLrF3JbGJVKqzHGTxzUtjqIubloNjK2flPtmo9b077YuWc//XrCo3KF4HVSgqdS1QxYLm8SaUTORHGcs3b8Ksyawfs7PEpcj07e9UItNu4w0c0n7s5woP8AOmlkt45EPyN0PuK5FKS30O9whLZXJrDXxNOwnJySMV0tvL5yq2cA15lNI0l+yQLkbvvYwK7/AEtwLZMg5UDPpV4apJtpmeLoRilKKNIfMjIiqG7VFEHMKmToPfrUZvoomJZlwP5UlrI9xJI25GiI+UDtXSpJuyOHkaWpPn5gUXtjk9qRUEjCPlvfpipH4UkfKR0wahw5hw5/eDHSnYnQWWNTFu7jimqNxGR2zzTzllG4AAc9eKRYxkEgBB0xTFe2jCSLOAG5OM1AI9hCgKMdcVPsbPOcE9u1MIVZcqSwJwaTGhANwPU8YPvTAckgcHpkinqhySvA9MdaZKr44XPP5UhIjw4YjOBnvzShVzzyfUdqcCApCgZ6nNKULEYBHqRRYdypgM+cFcn17Uqg7SQMgc8UoGMqMn09RUqjax64PXikhy2IJAcDgHvg1WkVTjPJ7VdPzRkcEAdcVWiRQMMcnpjH60nuJbGwDz8rgqOKmhBVg+QR71TtLZrfcJiSCck9qtKypwAWPX3q4vuEl0RLIGJyhIHcEdTTICWDKwwM4Ge1Ir5wQv1z1qaNcl/lI59e9V1JeiEJZQSDk0i5YbdwBxxx0pSw3yDbgDqe2TTE2luuaOohwHGDwetNWTlQ5564pxGBkHrg9elRNGnnK7feHT0oKVibByMAY6E+lV57RLjDSpnAPy9qsA4Y/NweabGmwMCxPP40NJ6MSbWqIrHTIbYBo0GR/EatRoTgkdDwKeoVkwj8/XqaUZzzkj1pqKirIUpuT1B2Cvlx8x4x6VFOyY5AC+lRXas0qmNj8o5HtVfVEP2WQxcShePWlKTsyoRTa1My71Kx+1JHIQxUk5FdDZussMe0gA52mvKyiiWQncZS2Mc5zXoGgpMLeH5xtUfNXLhqznN3O/F4aNOCszWurgQYd+3FPXb5fmRjO79aQLHJGVkbcOc5qaNShboV/hFdqWtzzHaxEoBCxlflA3ZFMeRgQvAyO9SyN+7LMCCM8CoZAPOQ84PGMUmOL7lD7Vm9a3MTbFGQeetWEieN3bClW6Adqbc3MVvKvmMNx49MVMZg9uSrcEZyKhdmzWV7aLQZczAFWLBQoycelUIdUhmnMAJB9+/vU17GZreRI2OSvWuY03TLw6khmzsRs5rOpOcZJRWhvRpU5Qk5PVHYKGE+4bRHj8/elZ5GXKfMzNgn2rPuo2a9h2MdicFRV2P5kLjlweAeBWid9DCSS1HkK0ufvE4BAP6U/GGySDu7YpjNiT7uFA+b1poc7FGzg8decVV7EWuTAsrHgdcDHQChjuRgrHA6ZH9KaEBwFJG3360/a7ZAIVc/pTFohqOQeASAPvGlkYiNiSoY9uwFIXCqSfuD0FUtVvFtoC2OevNQ2oq7ZUIucrJDoYIIrkm3QCVuWbpVt0Ro0WQkknOa53RtW+1XrLwFBwO3PrXQRyFVbzPvfzqacoyV0aVoShKz3GPGAS2Pn7Y9MVhXelC9bzW69wfWtTULgwwPKu7jj6Cquj3EtwsgbkA9aiajKSgzSm5wi5pmVZ6KUv083BVf1Fa06GKyYQAbRnA6VoNGfMQkBR0J96aR5oljVF29DRGkoppBLESnJORwLzq9xK10Ty3GCQD+FXfCt7KzMjc9cA+nvV3UfDwaTMOOuce9XdO0tLNlYrkY6gVy06VSM7ndWr0pU9DVtyTjfg+9Ol+VSefenRcLuXpjGMUoIYYK5OPwr0Oh5LepGfnCjaMEYNIY8dSwUHkVIrIVBBC7fXioid0bBmyfWkCB13YIOzt14NVwjC5JGCu3oPrTyfLCI7FuRyamRlGGA4Y4BNTa5SdiLflHYK3HJx60jbmXgHnnPXNL5hAPAyeoHepEUDIY8H2p+Qm7alVy6MPkyenXgCnxDtntVnYAeQc4z9aijjEPRgOc80WaYc10RMFXlu3em/fB4DZ6GpJdsy7HA5/CmwxkYXGVXr7VNtQvoRGIjI28dhUEisCTt4OOauyBs8D6c1VlKEgMSpXse1DBGy0ZYMN5ye5pvl4B+Y9cg1NuPJIBA6npTd4fO3Aya10JVxgwqhh8x9qdE29Mggc09VUDPTPahUUAYAJ9+KEhXuMn3DC7dwbk5piI6McfMmOmalkkTfsyN45xUSyrGwGcsf1pPuNX2JNpxyOnWmueT0OD+VPUqQScDI4zUJZmYADCZ5HemwQqgpGZHyT060v3uh+8MZ6UYYuMdP5U98Z2j5mB6jtSC5T06yFnDIpk3OW3ZJ9atI4Jbc5UH1pzHGc42jgmoJ7y3hQGT5snIpaQRfvTfdl8IASQCe/HrTJ1EkeHAB7Y9aitrlZl+ViV9KmEiEli3Qdq0umtDKzT1MttDtxJ5pjBk7GrcSpGTAqkdzjjNWs+hPI6CmrtyMfMx5+lQoJaot1JS+J3HM+1kQqfmGMjt9akZkJC7juWmrhS245OMgA1EWKoW2fNjpnrVp2M7XJ7iVQOCRu4H1qAGUMquNw6k04APsLjkHIFKXw5RuCehobuFrKxzPiGykkZGj2bQSDuOOSetTacy21osUsmdgO5jWteRgoAFLZ7GsTXIXS3eRSQuACo/rXLOHs5OaO6nP2kVTkJeawUEf2aFnDsFIHatlcFYg52HGcetcv4dkUu5Ucg5x7d66eQKyiQAFhnAFOjJyXMTiIKD5EiNsGdd4285Uev1qWEuUyy8qxCgd6jMsi3AXAwe/pVj70flIxyRnP92tUYMYi8OHyy9WPrRbs4wHCA/wAhQh2gxeYSygbjjnFMjDOCxBwD+dPqIsRkMp5xu464pyFQdgJA7ZqHcDIikHPXHb86kfzOiMA2OeOlNMTQ4LkqpI+Xg471keJ4t9i3ljLdB69a1HVWVWJZVU53DvUXko0zMWLg4PPSpnHmVi6UuWSl2OI0Gzmj1EPImxD8rDHJrvlJEZwuTjjPUGoYIdrsX2dflCirEe9gxkwgzx64qKNL2asaYmv7aVyKSIzRnzcAcZ+lMjVIyqRL8o5OKnf50YAZBP4cUqpuBKgBdvXrWttTC+gh4wBzngk9KjZgsoQLjAyRjgipg2Ih19cYqOVm2+Yg+c46+lDEhjRgqwU4bp9KRo13BSQQDg4NO3ErlevcGo7mWO1jZm9s0npqVq3ZEm+MR5O0YNMSWNt3llc98Gse+v8AzbSR4kPqMCsvRrtzcMiE/OOTj7p96wlXtJI3jhm4OT3OtZc7gwBU9qghjkWVlJHlYyOelOhfaqq/zMeoqZ9sfJXJPXH6Vto9TDVaCMAOX6A8cdK5HWtYa3uAFLNF0x05rrJTujYjIJXA7g1594msZklJJBBJ46Vz4mTjG8TswUIylaZa03xJG90I5wwLHapJrr4ZFKK4BbPT3rym2RnlQj5MMMLjp7/WvTtHH+hRcj5h61nhakp3TNcdRjTs0W0lBYBgV3D16fjR8wBLYJ9qm24b5eQO1NlXc+ADnpXZY80rb9/QfUGnow7ZBxUu1cjaAp7HsacVwMcEmhIGzNuJmjZgFOR6981yV29wt7uRpN+77pNdzLEcgEcd++KpT28Ttu+UkjrjmsalNy6nTRqqHQ3wgCcDntUTIqnAHPfFCtuVT1XpSFvfkHpiulnJqImSfmJxnPHanOdoJ6HNI7Atxxxxihm3knv6daEHUjVFEzuF/eMOTTI9rTb2Xay9DUoA4PU/zpGjKuxUfMRg1JQOGDYznPFJHlWbJ4HWgrl9ucdximEERgMwY9flFAyUAMcq2B7dKFbZjagOe9UJI5vtSeWAIyCW96uBeg5HcZpKVxuNrEV2/lQSNIVyOcVyF3eS3DKy48sNsI9/XFdHrSGe1KITuH3j1rjlFwokgWIMxbIbpjFceIk726Ho4KC5ebqdZoUoFuVDcqSrA9jVsarDC5VznuDxgiudSKfTdLy+SWJY5POT71Hbxp+9afDRlQQSe57U1VlFKKQpUISbm3odNZakJyVEm4seARjFaEcvySK4IweDjrXBaHPs1Eqd2VY9+1d5AMoCoz9a3oVXNXZhi6KpSsiccLwOfXvilUbhuVhjHGO9RM7LKqhQSRy3tT1YMuVYbV9K3ucbTDcydgxPJJNM8sSjax5B3c04szOoH3AOe+fwqPbmQsGwMdOxpMEiQHOSSWHYDtWT4gYrYEfdBOSa0fn852BJBGAtRXwWW1YOodfTr+lTUXNFo0pPlmmzzoXXltutjhtuWCjr7V1/h+9+12qSZ+6uCv8AnvVWTw7BNMC6ngdFGMfWtfTbWGzgCRIiqK5aFKcJa7Hdia1OcbR3LcTb1zjGR3FIpG7y42Hy8FvSsrXJ7mGHNqrkn+6MkCrWlGY2kTTr+9K7mroU7y5TjdO0Oe5dYYfruJ68U2OPBQZye4qRT8rhxk4znOKjjOd7E4UDoOpqzO+hKVOzGQSTwR9alYlFJOB2HvUUse4IdwAAztzT0dGVQMgHrmqJYjxjy8ckDnn+VZFubr7YwdeM8dh1rcGWGAcL1z1zTShVmcOvHrSlC9io1OVNCBMKoXoeSakcgFSozzzmkUxhgcksfQ04uwIULjj2qjMqyyM8+1R8gGSfepoGIB3DII4FOKlhhQDxgmooohE0hMpJLcD+79KWqZTs1YLkt5bKhCvjAzUNukqKomId1XqOnSnTNgjduKr1IpqS72OOhGPrUt63K6WQqsWUkglvWueuNTaS9+zzIGQnbnuK6OMIuUQ/d7DmqzWkbTicRLnH05qKkZStZmlKcY35kNjjjVUUqFDHAUDilitUDjCqM5yRU6IoGCpyfxxTlXBO04+vrV2RDkyEIQ+HYsR0NPG5BjOTnv3pQTuxgZ71G7uzBucjpnpQ7IWrJJAFXgAHFUry1W5iKOvynvVlpPMDIQdp4BHehTtB35Pbik0mNNx1RgRaFb28jOoCg9citq1RAF2MGTHHuKnK5wpCn0pFRYlKhflUYGKmNNR2KqVZTXvMeo2McfKT3601n455A9ulJK+FBXGPQ00FiueACOlXcyHKBuBABUd6f8oAw2enPpUS8EnjA9aVjmPKDlu/pTQDZScsCw6cA1RZ23OMKqhsDnO4Y6+1VZ5hbarPNdQzSK6qsUkaFwBjlcDpzzXNanb30IaS2jmit2ctBCeqDjrnoDzxWVVuMbo1ox9pLlvY9HD4AHfHSkcZJOcD6ciq5Xa4O4ntjpTnddwzk89u1aXM7dh5bPOMCkcjgsANx4ApnLZOcKeKr3dv57Id/CHIA6Gk2+hSiupckJBqMyncoUnJOBUmWKsDnI4x61G3ysATlu4oYkSSPlAADnGPwpAVyRg4wMVG8gdsYCg/oKQOA2BnkfhS6jsLc3CWsLtITx0AHNNt7tJ4xtdd3p/9eud8TXbxkDblcE4J61X8PTyKUbBAbque3rWDrNT5Trjhb0uc6pgXkYEAAdR3zUbWiHDKAp9cCrKbRFubk4yaj85ARGGwx6Zrey6nMpPZFW+txeW/lhuAOR61y2oxSi3MMCncuQxXkH613KRqVIYbj3FVorVRLIfLHPG7uayqUec3o4j2focl4U0ycXHmyZ5HLNXdRLlQg4JH0pohEKAw4yODx1qeJfm3lQWHc1pRpKmrGWIxDry5hrMuWQcsOvFRuVI8rjJGTjinyOCGVGCnPOO1IpBcDGTjrWhiiZGGAVbC4xjFR+WTIzt93HQCnrkNnHAFHQtsweM1RNxrMB+8fjPFMcjaoVAVHJzTptnylzll5x2FVUu0mRirZULgEf0qW7blJNq6GyMx3hMAquAvqTQCyorOg4HzEdKb5ixAgAk8Ee/tTywf5WHy9cVCLfoLt83gnCHnA9KUfuxg5JbkY/lSBwp4yewFOjIOMud+OuOlUiWNkYuTwEjUHcCO1NjmDz7EZen3c0l2SsMggDMQvGK5lZ0F4jW7ESFlBBzketYzqcjN6VLnTOxQcAHk8kn2oTbK+UH7te9RDKsincVPLGpySkIwCPQetbrU5noOX7odzzyMU1QCzbh8hPAHHFEe5nJ24XsMUTRjehZiCPm46UwW49eG+VMACjcjNgjkelBZgScZwOxqGLcFOxvnZs5btRcLdR67EuPKTPA3e1ORAJS0YO7ufSlkC7SQMuB0pkbMQC7YI5IoF5inIJDHcD2x+tM8pW/1ajjvT5C+35RzTXbbgjJzwfekNAcKpPQ1VNygCsScFtoyKslgVDEHkevaq5GUJ2DGc4x0pN9iopdSOSU/aQQw55I71OpA3YJBPP0rAu9WSG4GFJUNhj3H0q7YXsd0pkVskdayjVi3a5rOjKMVJo0l3rGS4O4c8HrTDJhjkHnjHpS4clCp+UZyDTJCJHIB4HGOma1bMUkDuPLJCexAHNKdsfIyBjPTpSZJypyMc1BdFypUY+6ealuyuUldkX9oQ+ftB57npVtHYuPKwVB5rz26lnjvWUEhy3DHpXWaPOWhQY2kjnJ+9XPSrOTszrr4bkipI25AG6ngdqaGJVM5KgYA9KEySCGwxoGWJxjA46V1HCDsjMM8gcEZqOQtkCMgLjp1xTirZyduR14qvMGdGSJ9jkHD4zilcaMO7lgGsXMd9fzQBQuxI5CoxjnOO9XdO+yvAxtbhrmPdyzuXOePWmiy1AnL6knOOtupNWLeKS3ib7VOszZyGCBOPoKG9AjuXJ97/c+8f8KiXfGyBmxjg571YWQluFwuOKjCA/MwGfSk11RadtCf5igHXP5mmxsG3ct1wOKaXUDkZNOhfOOvTv2qkT0JCcnAyT6+9RSv5eSR06c9KldgCckkDgY/lVe4XzI2UrwRjPc0m9Bx31OW1LVZZJnNqP3a8U/TNUeaJnkLEKTwOmagv9EuTMy2zqA3UkdKuwWIs7FIEUFxyx9feuBc/M2z1G6XIkjE1K7lubtldwFTkE8g+2KraRqUkN3HGxzlyCCO3rUWpxxM21s+du3AjOQOlS6FpEt1deYWk2dNzdTWCcnLTc7LQjT12PRrQuVJJG0gYyKQjM4LAMo7k4qOIIoWJm5xj8KsyKAqqAPL75r1FqjwXoyb5VJUDjHJHU0D5HG1CUIyTn+lRLG3nblkO3ptzwKsoCDktnHbFWiHZEcp82NlMhUN6DpTsqE4kIx3zTjuGSCGBPQ8VRzN9qdXjO04yccfhQ2kOKuXdgAIyASeD60qBkY7QDHjimb8YZvlwMDApYp4pgVglUuh+bB609CbMlRiq7eeeMjr9aYW25jVsso59aTYS3ykcnOakZ1yy/KSOP8A9dPcnYpXEx+zsTGW3EYAPWqcNmsU8k7sxDDhCOAPStJowxByAKrXG5OjgZ4BIyRWbXVm0ZfZQzO1mYY659gKerqclGAXOKZcQu0LhThm5AqDTLU28C+Ydzk88VKbvaw7LlvcmdUSR5dpLjjPbFMsbhnlIf75OT3wBVoDI2j5U9xTAiqxdBgCnZhzJqzJFUGQ+rdT6U0WsKHzDs3dRnqTU0e8qx4GT6dKayhmLSJ90/Kepq7EXae5YOegAUBf1pwOGCk7mXj60zC4IYkgcnIpoIkbcuVJHp0qrkJE/RdwYZOSKjxIyKwGc8kGmOdygRleOpHemzu20BScE9qTfUEiRQRuDMSQePao0h8vJEm5ic/N2qZFwpIOSeWxSknvwuOvenYL2FMnlgLgb2PcUSKcZd8H2piEEAKrEetOwwZhQKxDJcASCIMu8nNKzHzCGQ4A4NRS2qvOJyo8xelSAMyZbOalX6lvl6DXOCSWznoOlQXAyvBYDrU0qksBt5z1pwUFcDA9QaTVwTscVrsMwlbK/I3IcDpSeG4p2uGkHyRj14zXWTwxyqUMeU9KWKCKJUKptXtXMsP7/Nc7Hi/3fI0Sxvx84xxx70z7p3EgnuRUvykc5GOMVBhTIcDPqK6ji3EkyFJQDdk8E1WtZpZ94mQRtnuOtWWyeiqCTwBShR1zgg96nqXzJKxh69axrZvII1L5z0rJ0y+Md2qnJiPr/DXXXSLIpRsYIxjFYsGhxwXZeNmOTnBFc1WnLnTiddGtHkcZm/EwMakj6ZqVCvzHgkVW2lU27grD2pVG1P7uT1BzXUmcLRYlPyngZ7c1W3DdtDc+1PY/JkkNnjIqMgNng8cnNN3EmkQt5iyMxcbB3NQJLM0j+YkXlZwjK2SR9OlZuqW09xdTQmORkn8tPNDfIkY+8D7/AONT6XCYYp/LiMMLSlooW6qMAfhk5NQ1YpSubIfDlVU8e3FNyXJO7jsfWhWLBivA9ahiOWZN3T0pFLUmV93QcDpmlDEN8gzjqTUTEqm1MZxnce1IjEqgkbc3c9Kd2Fi2G243kAdgKhaVBJsJJY9BilV8tjPGePUVF9nT7QZRnfjGc9KG30CNluTBiAOi89elJIgflhwQaY37whSOM9Ce1TFkRNxbGB+VPfcNtihb6ZCpL43sTn5u1Wliii+RAqtnJIHSgTwyQlkbOOWI4FYOpanI7SNafdjHzsDjmspSjBaG8YTquzZ0caoSCByOM+tSbQJwSoOTj6Vxeja1MbxUkYvk4PrXYoztgKBuz9406VWNRaCrUJUZWZKzKmPm2nPUjNSjb5m9gSxGBTUIDgPgL3z3+lJNu5KvtUc5rbzOa3QeEUyMcnPXGaEYMv3vlzxioY2wpYYZT3Azn1qyrgINoyM9T2pp3BqxFufbhx16cY/WoLO2hgDGFQu4ZY5q0GUdMtuOODkU2Rd+AjBccn3pNDUmtAeQRoCOEHApFIUnaOuBk0gVzkyYCjpg0gfBUvzk4AAzigB1xIEDYyXx1Udq5u7TUf7ViKjcuckk8Ad66OQ7cA5PGSR2phZduSvB68c1M4c/UulU9n0uIrFlBDby3btSO8gBVVG8dPSlkUoSyjanoO9RtJGhOGI3cHJ5zTuTa48ZR1JYBiMAelSsMZJG7JwPWoFbc2Rzz+NV767lgGQpLAEluwpOSSuylBydi8zhWI2560sEhcDBBAOG4rnNI1OW6unhkbJPzZA5966JQo3gnc3BKg9KmnNVFzIdWn7N8rJS/wA+0jAPNRMsjbWQk8jvxSzYLqVYbc4xngUPdJDbNI3Cj8K073ISfQQhweSFUHIxTkYMdqoBzyTWfaXsd5MAp5B4571onKoxbjb/ABUotS1Q5xcdGO3KGbZznv6UMzIFHDD1piZZeFzkdaYG2XCKUyx6H0p3JsSuVGSzfKewp7EFDhm24z70wsWPCD39qXJGQcEDnPanclikdCGxjikkYCL5zk+tIXXI+Ue2DTGIViUwe5zQNIWPagHX5uee9BYcfLzjqaieVl3F1wnUEmsy41aGJwnmAKMHPtUOajuaRpSnsjXGMZTo3XNNdlV0UDqeMVUhn+0RFocbM8A96sO20LgEsecDtT5r7EONnZjpGIyRzu7gUxTgkxnBHenYKclt1Q3EmzO0Zz1FD03Euw5iflCkHucVGWOct9wdxTWKL5fVSfQ05sHO3r+VIq45ZFUjJDc+maY8hHG7Yx7gUpHAYDPseKaUB5A2+1FhXFDZJXktjnmhphHjqT0x6Ghs5OCOeg9KZ0XAA3e1K7QEiuecDIPODSiUL94DH86ifhc9++RVATI84LB1dcgZ9KbnYcY3MrW5FGomW6LLtkiMGSdu3PzfjV/SCzRTOgf7OZiYS+QduB0z2znFVnknm1K5jF81vHGqkJsUk5GSRntUFldXKzxhrwXEbztByoAI253DHp0NG6I2Z0ysEB5zjtVRpH81gqfKOhz1qwVGc55H60hwp3HjPrUPU2WhS1O8NpaM78HsDXOjxDeR/KwHGDyMcH0rV8R2z3VmNh+ZfxrkBb6lqUsds6MkKkLnbz9c1y1pT5rI9HC06coXlbzPR9OuPOhSQkHIzU6hUkZ1OCx6VT063+zW8cakEIO9XJNxAKOoOcn6V1q9tTz5W5nbYnYjAORj3qKa3E8WyUnaR1zQwDjoMrzjsafuDoAwOCOarfRme2qKrxrb2jxjIAONx/nXEahPHFHKqk7y3UDt6mu9nBlVdpC84IIzxWBf+Go55mcMcN1Gelc1aEpL3TuwtWEW/aM5vw7A8moiQNls5Jx1P9K9HjR2TYfugctmszTNNSyjCBgWH8W3mtWPn5VUnHBINVQpcisyMXWVWV1sVpRObqIIcoO2P61fVg6lJUPJ2nvTSMbcEqMYGBRESiNtUk56ZrdR5Tlk72JsKkflxDbt6YFVftEYBMsoCrwRnAqyJGEPz4XPXmuR8S3EuXit0ztPROc1NWfJG5ph6XtZ8p01vNbgBIXBxyMGp2ClTkkE89K850nULj+2Ujkz8nJx6V38UjuQWAx2B7VNGt7RbGmJwzotajjvBPJfPr0FQW0LWyOTK0m5sgnt7VV1C8eFeGGPTNXoGXyw2CFUZq003bsZSi4xv3HqpwQM+2fWgsVkVWPzd8dKC2U3Bjzzzxmog2xS0uMngAVT0M1qOZmZs8kdgOlV4kVDgqS7E8dakOSvHGe1ARt4IOF7ipeupa0JC4HITp0A/rTJwrJswDuPJPP4U52CqORz0BP61FFH5a7ss4LZBzQ9rCXcrWNhbWs8rwDD8E+1aMJdw52ge9A2chVAY8nn+dCE5IUHIH1ojFR0Q5Tc9WOliDlVQgYIY44qjrVrLeW5jjcpgZHHWrryheGDdMk01HVsFshjxinJKScWEJSg1JHPaBp9zBf7pwAi84Ga6Vpg0m0qeeh7Uu/C4PT0oVd+JAcg8YxUQpqCsh1arqvmYnmhSNhJHQimSq7yoV4XqeKGAJHIDA5wD0qSNwo+c5HYitLX3M/Qk2Fm3KykVG8ipC3cZ+op4dRnYVCk547VDdxiW2dE4UjHFD0V0C1dmYUmuMLkqWG3OK2LeVXZWUAoe4PNedXwuYrxoCrZDYLY/lXbeHjss4xISD7+1cdCrKUnGR6OKoQhBSiWtYZvsMgiPzhelecXcriUxuGBJwc9vpXp9yUlXY4HPArAuvDsTSGTknPAzTxNKVRpxJwdeFJNTKHhm5kDmCRtyFsKRXWq3ODjgdTWNo+nLaOwCbVJxhjWuNoK7iVxWlCLjGzMMVKM53iAZwATjce1NLEsdwJY85p07AOvHGeAaADj5csfWtzlMHVNXFrKF2AnPOelXbLUIryMtGWVh1GKqa7ov2t/NSQo6jBGKk0qxNjb7T87E5J9a5o+0U3fY65eydNW3NTJPDdaczg/MW9qjDAnZnBPrSjBTAXnp0/Wt7nLYdkMpORjtk1FlSSARgHIFJnY21snofpUZjKklX2knOMdaGNLuSiTOdxz2GKi8o7myg3HvUF7dx2cReTsePelgvPtMKyxMdrc8io5lexfI0r9DF1hnllmVrW0kigZELyqSct6Y7c1a0pXxItxFbpLbsY1Ea4CrgHA+vWo7/8Af3dykVn5rbFjlZpdmc8jj1HrVjTI2gt2EkXluWJOZPMLcdSat7Gavc1FO1AAM89MUuGJI7ehqOIkd/xJqcEsOoI9TSLIJWGDGoBI6g9BT0WPaAFGcflTW2hcsBjn8qYLiBx8jjfjoDU311Ls7aExIYH5dwBxinNvVhgfLnJB7ipYc/dLZ4qSQ/LlgAevFWlchu2gzllHUAdhTguGBZvpmh2B6dQO9ReYQOuAP1oEkSHlhwM+tIAQcnqOgAqDznaQeWoxzkqamhkdl5Xp3Pc0J3G42FiA5Zg2egzyasoTtIjGPeo9m05aQYxwPU05W3LxkCqSsSxXbDApyT/eFSs+1Rsxn+KqkolbmI4wRy1TRk7NvGfrwaaeomtBCCwOR8p6g1yXiEtZaktwp+Ugj6iuxVOThqz9UsVvlCnAK9GrKrTco6bm+HqqnPXY5HSXkvNSEmFAViV+XBx7120aBYlXPPUnFUdO0uGyUqgLk9asuZ/Owsf7rHX/AAqKMHTj725piKqqy93ZCyxRThXaMSbT8uAOKlYhmKfNtH4VDKrAxhG8uNeo9T6VIzEkDGV7k8Vsc76CjaBkjAHrUcyhpFdgWK9PShiWY7hkdqagb5iAMD1pO7QLTUWNUBZycsPb+VOEmXPPIPIJ6VBPMkcil5dgAOFHGaS1aP52UbmY9M5pKWtirO1yaUOVbcAWbp2ApVbcw+b5l688UwtneFK7u5PQU0t833VA7t60/MW5L5u2fHU4zuxRazq0zBcnb1PTNQoJBvb5Rn7tOHyNI4Hznj2pXYaWsRz6pF5ixqcsO3pUwuFZxtwRjg+9cXqkt1a382E/dyAfMRmrcCz3VoJPP2hidqjoOeOa51WbbVjteGgop3OticM42lWcjk1KuVTBPOPwrltNv7i3uTb3SsMnbuIroo5EIVg2SePrW1OopanLVouDsZus6q1mhSQAOSeR6VU0/Ws3ISUnL/yqh4zjkMnnoNyDAYZ5xWPY3E97fRiOIpsO0ZPOBXJOrJVLHoU6EJUr2PS4ir/MQePU0/ITKjj096q20ZMAEg2sAOc9TUwYmXBBJIyD1rvT0PKa1K9zZW8hBkAMh6H1p9rEsUexRj0NI6b5h5qYCfdbNPz8/DbuOMUlFXuNydrNj3ALA5yV4wRzSpxnI4PemFuhHJzzT2kVF3feb0qlYh3I2QKGLEkdcConQTRAZ2jOfmNTbsxjP3s9+KYu1iFcZHXJpNJjuBI3KmfmHIA6U4HadoGM9M9TTHbBzg8dKSMMyZbAPehAOlO0425XPAHWocqXCHPtUhXbk9V60whN24E7un0pMFoDRncCCRj9RQu5nwDkdKryeaJeoaOpVLDG0DHv3pIb2JCcMQASe2f8aixvOWABx1NSGXHQEcU0pnLtgAHtVWJKl0iNv3xq6nqPWnRqVUCNQqgYx6VOQrLhsBelRShvKYRuFfGASMgfhUW1uXzO1jnrowDV7j7ddTRgKvlGLIBGOc4HWr+ntCbV2tppZlDEFpCSQcdBkdKY8OqbyDfQHH/TD/69WLfzoo2W5kWd89UXbx6U2Jb7F0tuXpnHbPapE+7n/wCtVaNRkv17Y9asfeHPBqUWyK5j8+OSMNgsuA9Zul6TJa3hleXdgYC1sqQeFPTrkU8k8FByec4pOEW1JlxqyinFbMfG4DYzgn170skjbhyNue9RE5ZRnjPYVMVDLkEnHStLtmVktyMjg5Od1RuDsZHAxS8liAQCPWkuYnaFwr4BB4qWWtzlLrV7hJpBaI/kRdSo/XNbmg6kb6No5Mhl9BjNcq9neRSywrFMyyHLY6Gum8P6dLEnn3LkyngLnhR6VyUXNyPQxEacafQ6CKZJASBkLxk9qa+G53kH2pYlJIJyc0EBGQNgsecY5ru1seXpfQcoG4gsQMdPSkXaqjAO3OOadluPlyPT0qVgCF3HI7cVRLIwFQZx1qMspcEtjjAXNSNym0sCw/GkEZLBjt49e3sKTv0GvMYud5CjDdzjrQN5kYqRgCkc/N852gYzikc5yA2F7nFJsaQ58ykZA4GcmqN7fpbZySS3AA7VYUSNIZA2ExwB0qORIJSQ6qwjOcelTK7WhcOVPUfvLRoWOAeaVnABBB3VBLLtC7s4zyMdKeQMluNoHXoaLiaOU8RXJiuSbgkpsJBGcn2FXfC8k0mngzlk3HIHUgVfukhnYCURhh0GM1I0ggVVUZ3DJVR0+tc8YWm5NnXOtemoWLLb2UbB0PRhSOxIBXAbpyKjMm6IdhnOB1xVdZVTCQjOck55xW7ZzJXLodhGuMsc/MfSoY5D5xjBwSN2SafEcggHHYE9DULPELghXDS9Pak2EVuh9zaJIHyd+RjHXmuPnn1TR1eGGJDAxP3hmu0cvsONoOM1RvbcTRZkXd2K1lVhzax0ZvQq8uk9UcjbX04m3uS7BNpzk4Nd1pRMsKMwIIANZdvpMCHK4PONrckVtQq0SAcADjA9velQhKLvIrFVYTVoobe2yXKFHVTkd+cVn2ej29pKZN3ze1a5ZZMqeFx16c0yQMCGVxtxxxxWzgm+axzxqyiuW5KuQgPmEAH7vrSqxGQrhvU9warMJDjYB5Y7jqalt3EoPlkAHsRyKq92Q1oOLfPhsuG6AcUy7lNtFujQkgdKmZQDywD+opJBlRnp70WdhJpNFDT9QS6aTAOVOOaugfvC4HAGMEfrUK28cbnai5bqccVZCZQgnHpSinazHUcW7x2Ar8pDVHIXztwduPvCnBsjDHFRyH5gGOVx2PSqbISH4ySTwelMYkklPujsRSj5zgckUSAhCQceuO9FhdRhYkZXIHQUICVO4c96gVyXKZIxzkjip1J29cA96lO5bVkNXAx0JP8AnNRoJPMbOSPTFPYbcMG68cUITyCTTEJI7GPI4A5psVxuhLN29qkZTgjOfqagKsqkRg8np2pO6GrWAyAqNwwPXvUHmlo3MSqHwQC2cZqU+YVQdezcVDNGzwyIpIJGM1LbKSRiyanOrbXvNNU+hLD9KvafMZ4neSSGXDY3QEkdOlYH9hXMF1dSbI5WfZJGxI/hPK49629KWQRSt5XkRySFo48g7QQM9PfNEdVqgkkpWi9DStWBVThunGKtBS2BgEDk1QtZ9oAb7xqfeSRyMA9Kq+gNakokCsRypPTP86esjM2On41i63qyWZRcKZWPBHXFP0PUDeA4Xkd/eo9oubkNfYy5PaW0Nw4xkHPHHNSAkKMcAcbRVTY7OwZvkNSmQIr5OdtaGNug2W8hhnWI4EsucZGasIocfN90cEioQsU22QqN2PTpU0T8cZx05oXmDt0BQo4JUluQDSqjA5yNvp3odEPzbhux1NNhUKxLuG7Y7U9hXuWY/l5J+X86HyT/AHn9ahe4xMiIuXf24Aqb5iACeepxVJohpoAT8pbI56dKfM6nlc8dKrsVJYlvm4zzSRtJnGeOxHWhuw7X1JFbEQYqdx7d6VW2klh83YGo1djgbSKem5QSWyT364ouDGMx3fMwIpApyxf/AFfYClfClQ+evNNDiRSxbCtwB0xSY7jAxAAjIEeMDFQSBiG8sbmPPPSrJdQihenQcVCc5PRc9qTKTsNUHjcAW6ke9RXErMXQA7hznrk0Sbl3Ek5fge1Q+cgm2k4YDPNS9ikr6mcivDcPPdOSM/Kv8qtw3CTpuXBOecdhVfUYpZ7fbbSEMM1V0exaziCtJvkPLMemaxV4yslobtxlDmb1NOMnYQmQgOeepFSxA/NukBLHHPb2qiZJfM2AgjqzE/yq3Co53DI7etXF6mU0SyvsQA9R0wO9YqWl5/aSyvIoiLZwev0rZX96qsVKjvnk0D9420ICAePelOHMx06jpp26k+/KhehAxn0p5RFyzKS3TioURSxKoQepyKnaT5lzklvatU+5jtsNVVjJwpJ+vWnSltoJzx2z1pTyRg/Ooxx0pjSlVO4HngYpbFbjkdETJDHPGMVKHSNdxX7o7d6ggIZfMQknvu4NBTgmUEk8DHehNpA0mTB1z8hwvXFZN9qqw3YVCDt5O3j8K1fLCoVI4IwDXMazoNzNdCWzkxu5Kt0FZ1pTS902w8ablab0Ons7yK7iWRCSD69qdLKIgowWDH1zVHRLZrO2WN1G8DB960znjZj0/wDrVrBtxTe5hUUVJqOxCZSJ8HATsRTBc7ZgnzDdkgnpT7j92CWUEDpz0rGvtUBkC2ah3J2haiU+Xdl06bqbI2OCwyv+NLvLE7lAPTg1y0WtS2935N4CNx6YwRXTphwpXPIDcd6IVFPYdSk6dr9R8Zw2SxGB2pGbeDtzg80FiV2AHPsKazfLtJAJ71oYjMk/Kq4IPUjg1LtKR7mJyPTtTAzOpRdwC9TThwFGT6Y9aQmJhdvOPcelD87RjA7jHanEBs9CvTI7UwkySFgcEdOetAhxXgYA9qYzZb72SOopjPk4+YfSlAzlsjI9eDQNIr3AbaMEg5pOfu4wDwT3pxBKEk5OeOajMaPCVbJyCDgkH86Vrl30MuWQWmpTSzQzSq6KI3RC+0d1x255pumRmKKYGNoY3kLRxN1QYHbtzziq98oa/kjW3vJGjRctHPtUDHHfrUWm3UKNsMN1H5khUGV93zAcjOeOKT20Ety5YXE0vMqFWBwp9a0CrCUEMc4wc9qjDbQN4yM8Y5pZiSRjgDt3qNkat3d7Gdq+kpqEiMWKyKeDVzSLaO0hxGSxPGT61Kh3DK7uD0qzGvPIAOKFCPNzIp1ZcvI9i3E/IJIB6896VzucjjJqv5i4OecDn0FSRthfvfL19DWl+hj5j0MiEjHy+tWQQRyegqpGXV8KSVzkg/0qyZABwRtxnkU0hNksbFhjjrSBY1LEAgk/nUXmB8DGTjgg1m6jqyWs6LgkqNzc9KJTUVdlQhKbsjZjJIyoGc9CKdIwXAZjuJ5ANUrO/FxBFLGASffkCrQkQnAwzdeneqTT2IlFxeo+YrjATBNVwjMmHfJznKjHFPkVfMRmBLhenam5IOSB9BQwW2hLnIIVs47Z6n0pn/LMPJhcc4zmo2dlBUrgdm96bGQse0OXJPXrk0rhsSiVTjIP+NULO4nkmnEybEDYQdOKspjzNxfpxxSSHaGwMj19aTu9Sk0tAE4fAQjhuWpjyAEkgf41Fjag4C9+aq+Y3msS4K46dAKTkNRuOkWZpfMaYCPOAo7U2RPlJjwfVj3qG8vEt4VJ6cnk8YptrfRXduDFgDOOtZpxvY1tLl5raEvmOBgD8u9DcKAvPYEcZqJmaIMS/wCXWs/U9WaCJJVGDnqeMUnJRWo4wc3ZGkMJKAF5bnpUzSIo3ZOAcHJxXN6HrjXs80WGLLyGI6VvRkSBlOW9OetEJqavEKtN05WkSiXJLAcDpz2qaNmD8c5HAA61BvKrs2bhnGB2p9vJulbHVTg5q0zNrS5bjk2IR0HY0qMMgucDoKiD/vRkcHqTShtr7Nmd3JJ9aq5JbVh0UgkUyQ4fg/XPaoz9zC5BGOc0RuWyWGT0x1zQ2CXUfIink559D0rnbjxOILwwtjCtg5Oa3lbAGVxzXMa14c+23/2iFvLYnLL2PvWNZzt7h04b2d2qp1EdyJI8oVbjJ/HvUyMSoZwA/QlegqnplsLa2RE+fbgc8HFWi20MyqQOpFbRbtqYTSvaOxIMBi6Elcc+lPDqR5g/nTIlGwFQMHkCnSqeMfd9KaIdjP16QizdI3AJU49q5KK4W50mSKGSOLUIjmLdxuPp/wDXqz4muykhjLYGetYGnoLy5IxuHX61wVal6h6+HoKNK7fma813daj5Ed1bL5oALSLnAPeux092FtEMHGMYPBFUNMsjAwZzuGOgHT6VqoWG0KNo9a6aUWtWcNeope7HYmXlhszn2pJ/3alsZHcmnxEKoOCc9CaCdzHOSDXRa6OPqV4LpJFYREEfxZFTnaU47jBINRyhVOFG0j26U5XVVbcw2gdvWktNGKXdDVDIm1myBnnHWooIdoChhtBz9KdIeeOfWmszKowBnuaTGhX+YE9CD2pgYDbvUhT3zSGTJCg4J9O9RyShcj5tvY9qVykhZmUKeBu6epqqTsGFPX9akc8HBwScg9RTJMKFC45H5UmNKxh6o/l3UnkSyebIAZI1h8wcdD2wajt4Y5vJmW5eTZI0jhl2lpMY59MelXLlLuK7lltFidJgC6uxGCBjOfSq9sCn2hpHQytJmQIOFOBx+WKG9AWrNNCcDkYPPPan8ZzgY96pxSp5gG4Z71YEvBDFcfXtUJ3NGrMfLL5ByFLIeuDU8RLxrJgr7E1CGVgCMYHQ0ofltpOM9x1PtTWjEx00rh02KCv8XPNXEcMRg4+tVY8cnaC1KJVVuhOT0WqWmpO+hbZyGz17DFORz3/x4qo2Pv73I/ug1LGyhySxyR09ad9RWJx8q5AIIPA9BWTqGmi8uRJK5AxtO3v7VfMshfaFPJ4JOc1IyYAxz6mlKKmrMqE5U3dFfToVsv3SoAgAwQetaYAIycDuPWqKKqbyuWI65PSnxyEZZm6+tOOmhNRuTuWmdwF8vOO5/wAKY2/zNxK7cZx6GoUeRnDFhjqBU7EEE7gT9aq9ydhNxY/Njbik3Acbdqimsy7fkYH0FQs3GSpZiOx4oYLUlkk24EQXA6nPOKhNwsh+QjA4JPrSt83yBB7nNVyEj6YxnCjFS73KSQ6QD5mc5Ynio1jAZiSCWPIxnFEhKugDZLDk+lN859jM4CheKWlyktLnDeN7qdLp4YgzIw4KVpeEY5E0qJrgFXJJOeDW7NDFMQzxgj1xyaahAfylwCvNc8aVp87Z2TxHNSVNLYlnIWMBV5J71R1G2S6twkyA56c1ZuWOcrjjqx9KapAwGyw6+taSV9Dni3GzMux0+HT438lCGfq2c1tWgXOd+D15qFAHUlVCemR0+tSRh9jKCDilCPLsOcnPVjpJG3EREnB5Aq4ifu1fHPrVVEkOcAYBqxlxhcgcZ6VZD7D4WEiNsbIz9KdCjmUMpyoGMH+dRxyHqU2rnOasIUfAGD3FNK4m7BkIQr5VumPWh0WM70JJBzQijaPm3Behxk0Nlmwg49fSn0JT1J4mDr3J4I4pGBViVGSeKbEcfe4PYVKQPlOcg/rTSuhXsyJPklAUcEc4qwhBOSTjvntUDZEnKbT0DYoCgFS75J69s0IfoTNKI1KnOz+9SpypIyQehzUMm7OFAcZ6H0p4BC4Q8DrmmK2hk69pq3sW35WYc81h6bpDwXR+cqw6HGeK7DAyMA++acIIlGUxyaydGMpcxvHEyhDkERMIB6D71IXJlKqcjvnvUzZ2kEjHpRwmcjkDg9q2sc3NbcaOW2Ddt68dM05QAT1wOlRTb1GQfm9KTzWC/dORyTjpS2E7vUkfDZ3AewqNGDZCjGKVwj4aT5ucg+hqEyMA+w7D6n+dDAeXww4zuHP9KZKkhBIGOcdKcv8Aq8liT7U1XbywGOT9e9BSYx26HAJHBHTFRFiwYkZA79jUTzkzmID7v8R6Uy5UzDG47SfSsy0u5MZhsVtu49CKguZGWEtHGWcDIXOM/jTY9xJXptxgk9aRpBGpLsAuMkt6UXuDWpmyX1+2Nmn4PvMP8KbYCZvtBmjSJpJS+3O7AwB1/Coxe75fNitLp4j0IXAYeuDU0d4j7XhUrglWBGCp9MUrvqFlfQfAowNycnkGpQnz7m69uO1VHztCI2DjIzU0Tlo/n+8OMg1K7F3e5dXGAD8o61JhT8qc9waqrIcjJGPfvUqspC4OR04qkQTmbap8w9OpqS1ZWQSZ4Jz1qs+CCrDP4Ui3CxYj2MTngetNOz1HbTQ0HPzcY5HSkibLDcoDcj1qB2HYHnpn1oV9rkb1J9M8iquTbSxYIEZyD09etMkufM2hdwHqMVC82F3OwKDPJrCbXFWW4OwlYsfvCMLz/WolNI1p0nPZHTq6FQWJLN2HenOQnynJJ71iaPqpvs7hgL39a1tpLjPPeqjJSV0RODpy5WShip3bevv3pzyFME+n0xTVbGQoJP6UhLOuWwuTwPSqIHRvvBGNozziqeragtlEWDZYjCrjp71M0ZUHcQee1YfiPT7i7ZTAMKByTWdSUlHTc2oxi5pSeguk6xJd3Xls7KoBJ/2q1oiQGeQg85Arm9E0eSGd5rqT5jwoHArpYwqAK2No7mppczXvF4nkU/cHbWKbmI4GcH0qCRlcEEZUDJzwKmYgBiWJPt3qteKZ4doYoG6960ehgnd2Yj7WfLEcDIwKr71Xc6hix49SadGqqQoYYAwc9TTygDHnBPalYd7ELOH4C5CrjPekEkYYjkMBgDGKbLIFJGenT0zUQVVm8zIL479alspeZLDI5Lbgd2e3pUN1qsFuQFYn+8R0z6U3U52jtJFi+90HPSuOFyztJuOwRgbhuznnk49OlZzm17sTqoUVNc0tjtbnUWWFZEYf3j/9amWeuCWIPMdjE5Izya5G2uzIZUt3YxIcZIxkZ7VELzDE4VIt2BI7ZycfoKydSVzoWHhy6npySCZFaM4TqSRWbc6u8IfyIy0adZAOP/1VFospk0yIsOCOMelY+qLd6bff6PGJLd/4T+v51tOT5UzlpU1zuL1Z1On3/wBqtBMgwwOCVNXFuGklKSRFcDO71rE8NRlbQONp384Hb2rcQ8ZbGO3fitYNuKbOepyxk0iTaSVYEYHPPpU1uRuIXgHpn1qpFvDMS6lQflxwfxp0jJtOAyev+NWnYza6FqUt03cZwVNMGwN0ypPSmK5CLh9zdyacrK52kDjn3p7iWhLGX2ttI5OQT6U3pKF6nHam7TkHfgHsajlb925QttH6GgFqywAOVGTzyfSmvuV9wYYHYiuftbq/i1Mxyc25zgk8mt4yHYCfu4544qYzUkXUpODWojM+8NkHI6npTzKy/KQDxwRUMYZXJbkHoBU3ynBA+b3qkQx6MAhBPPrUXzZKgjbnOM96kA+T5jzVeXcSVT5cHqaZBNIeRySo6CoWKnPcj24pzMQv8NQRspJXeGcdaTYJEhLMhVQfopxj3qKQMqBuN7cEdcUpfbnafc+lZ19qMcJAfkex5z6VEpJK7NIQlN2RO20MBkADv60km4soQ8D73vWfb6lFOxztDHjaeuatNIQqHjPpUqSa0LcXF6jmUKH7N0z71BMqSQukvPmAqfXFKZScfMNw7f1qOTc6uHXdng4460XEUit9bxjbLA6JgAtGc46c4ohiMaSM7l5ZX3s2MDOMDA/Cqgs7eAOk8vzbjtzMwJHuM1PFBHEuyEsFJzyxbmiT6Cj3Ay8Anqp6VOsqtHkZAPcCqYkAOMZyPyqZcMnOcjpWd7GpObjylGRnHHSrXnAx4z16VQjkUjhskcEYp25mZWXqByDVXaE/M1VkJQY57c04SLnJI3A9/WoUKxoCVyT2x0quURmJOTz2q9jNGgk4L4B5z1qNSvmnBXfjnPpUAKggjgj1pzSqASwAA6mi99x2Keu+a0CiJyhBzlRw1cTK10C0KCVmkY/L2r0CTbKARlCvUD0pRBDuD8HB5461jOm5u6OujifZxs1cz/DFrPZWbG4AL9QBzXSRkcMRy38NU4MLkIcAn6VPFuBwMMfbtW1NcqsctWbnJyZMZedowPw6CnAdhx6k1EUDujtgEUu4iTC42jqSc1XqZ27E4dcbeTjgio5GySTzjsajBw5deD1zTFPOfveme1O4JC/KCztyT2NOyO+MAZqu8oyyKwz1+lIZF8xUY4PYk/rU3Q7EwO7J9+tVp3RhtYbVJwCe9SuNzYyQo6VVkbPMijg4HFNgl3FkzuOAMEdahkY+cDuPAxSoSzu3y7emM9KidlyJBzjgelToytdiO4VJHGMgg7sA0hJUfIo5IH4UwcsxB/ePgn0pfN2ttOM9sd6l6DRneJSEtcI3zc4Gf1rhore4u528qOSSMrtDj5Tn3J6ivQL2FLofvVGQc4PanWltDEm+NACfWsXFylc7aeIVOny21MjRdFa20/8A0gkM2Advamy+Gkluy6lvI/2jmt6SVlQiNQSTjmpYjgFW6N1x6elP2cdiPrFRu9yzZlYYEWMBgByRVk/Mh3LnsM81QRfIt2EBzwduaSyklZFE/wDrTk5I/KtE+hg1e8jTtY/ITahVQORUkjb8EPyOoHeqaTJkh/kI9O49atR7Ixlccgd+1WuxDve5MhAyrYXnINLuY5z07Gq4OHCsTtHIJ/lUoZc5AIYHkU0SyVCQ4AO4jt61l6lqz2V4I1KluuPbNaicnOD9fSqmpabb36YuNu8fdOcVNRScfd3NKUoRl760LdjdrdW6TAnbjnJ6GpEcqrNLgY6/SqtjbC0gWKMEKDz71YnB8vCjIPGDzkVSva73Jly81lsRFVlkWYDjOAR0IqaAzFnR8FB0pIidipwPbHT2qXeQCFAyPaml1JlLoPGAcDr0pC5KsqHBGM0O2FzkZ6jFRgeYwJI3eoNVchdyUNtJBfJ689qjd22EFySO/rQdrZYHp1HrUEpBO3f7/SkwSCGfen7xCGHHFQxxpBI0sQwz8nvSuXLZ7Y7CmPIQ/wA3yjtkVL8ytehNIwMZAHzGuQ1u/NhqS+dCjwSEEs3b3FdMJUfPze+Ky9Ts0vIXDxhh05HSs6qclobYeShL3tjlL7UXGqQyb03scEIf4e36V2FvIJVRwPkx3rlIPDTRzb1cdcgV1FqjQxbDtwByeorKmpXdzfEzptJQJ2LA7hzn2ptwWe3kWI7HK4VvfHWogyhgAxJbpxxTbyZ1t5PKbLKhI+vat7nG0ZLNZhI45LF96j5t0O4k+ue9TaerwxyMsbRxM2Y0Y8qP854qFWligjubSaS5GP3qsc7vXHoR6UlhdmX7S4csgl+X24HHtTZKJBPtbKqelEU29c9MngVGpyoVVyep9Kex+Q7cDvisrGt0SAqgLN3NSC8VWKsw3Nziq07o0QVs4AznPWuNF9df2rKk0bsxYeVxkfWplPk2NqNJVb67Ho8MxkjBx1HepIyGbd06/Q1n2SsIl8xtpPUDsateYVLcg+1aX0MWkmWcOWDOvHbimzeWCAWG0+lRCQgA4Iz05qOCRmLb0XG7jnrQ2NItxuW5yy9zUyOqMGY4B7VTt58s4ZcBTj1xTp0aWHKPgk8HpxRfsFtbMvxO2SWACg8c81OshLYU4H061RTdGoyCzAc5NPWZhjacE+nUVd7ENXLbNkkH7p4C0TccKfqPwqHftbnOM9fesbUdaVLloySwQckdqUpKK1Kp05Tdom+CWGMjaOmKSRiy4QLuHQHpWTot/FdQkK2c5JJPSr7TIpXnA7D1pqSauhTg4S5X0AwDYQThifmIqrf3sVrC7sPuDG73qaViQG6Zqpe2cdxAyFshz83pmpls0ioNXXMM0vVPt0J8pcFeDk9qtsQQQxG4c/Q1mx/ZtLtWESEAnr1JPrWfda8m8RquCeuOtRz8qtLc1dJzbdNaGwoCA7T8rfw+tKOF9PQVDDKWRCSAAM4/WlB3MW/gA5Jq0zBisNoAUkHv3zVWOQebwwJAwO+KrvfRXF55aHBAPy5p+AHypwenSk2nsVyuOjHOzFm8vBOMDPFTWwk8pBKy71+8QOtMTLE4XjH+ealjUxy4DA8Y+lK2tw5rqxYXYI2CkAZ6k96fGI+DkHPc1Wf5pRx8mM4pUG0u2GJOO/H4UxFxGIU9OO1RxS8H5doBxk1Gsq5Y980TAugG7C5z0ouCJjEJVB+oIPep4FWOBUHKjoSelVQ3yqCSVznirAlCjkdsk01bcTb2LQO4EDB9M9qepyAASW4PPasS/wBQNrcw8ZhY4z71opK8gDYAz0z6UKabsNwaSl3NFZBkZbB9Oxo4JJByR2P+NVQdxI6ehI6U/c2A+/cV4wKu5BZLBnBPXGMg01mkeQqwBjxw2e/pUaMQSGAUeuKWORevH0z3oAkU7lZBhSeuacjYABbpwBVeMEAiT5sHOacU3urbSCBxg9aYtyYkANtBJ7AdqjzhiWG3vmmhtrFg/P55pHmjxlgMngHrQBJcOrqD82BzmoTL1JHuKr30spjCxfKpxzimq5/iJBPepb1BKyJRK7HAUjv1qCSUKcyNxnAB9aUuMDJH9aguGUJwA2KGNDvN3N8rBT79cU4gFchj15xWdKWaTcnGAOvepHkI+UHBIpJ9wfkWX4QhXwT+OKi+dlKn8aqvc+WypyxPccU8ybl6nmkmnoOzRLuCbQhyO+e1RSMAzEdB2qMy7MKTxUFzLmGcQ53MpA9elFhEMt8p3mJWdT3RDtB+o60qNlQ67CX5yOhNUQ4MEoVZjn/VlBwBjjBHTHeks5NodnfIL9Qe+Bkj2zmhoOZi287IoPXGPxqy8gYFduAfeiipWxT3QsKAhY2yQQeSadDDGjDCgkd8UUUkVd3Lo4jJHUUE7gjEc4HSiimwHOxDrg1K0ayRjI6c/jRRQAwtsbIHX04qWCViDk5zxRRSRoloXQx8vHr1NIi5Xlj1oorQxRWvi6WcilyeCQemK8x1LWZImliSJczAAuSSR9KKK56256eCSaZ2fg5T/ZySZ+Zzg10JQOylsEjnOKKK1p/CjjxP8RjgdwOemM4qN3beoBwD1oorQwK93GJURH53HFUZ7C3hwyIC+7GTzRRWckjWMmlZEnKrySR0ArO165eGxO3oTj8KKKUtgppe0RxGl30p1e2yeZGwTmu+Y7mHoo6etFFZ0djfGfEiwg3HGT0xVa9vWgc4UMQMZJoorWWxz0knLUu2spljVmAyVqWFmJ+U7c/pRRTRMhC5eYpwByD70+NyYQOmfSiiktw6D921SKlTlc+owRRRVIl7DQquxDqrJ6EdKt7QF2qSBmiinETF5weeBjHtUsLl1APpRRT6iGiZgyIeQafcIqMjKCDu9aKKGNbkysQC55IpiymSIseCvPFFFUQKzfrVaVQisF/iyaKKl7FDCM4yc4qGYYicEkhfWiik9hrcZbv5gJYDIFK43IB0oopLYHuV1i2KzBj61Xkk/wBkZFFFMTFUDnIBI7kdj2oDbUJHXNFFAmVz824kmhVxt5zyaKKRSKkttE8shKYznIBIB+oFQNGpJIGAOgHSiigR/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules with scale are typically present in guttate psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Guttate psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous erythematous, scaly papules are present in this patient with guttate psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35384=[""].join("\n");
var outline_f34_35_35384=null;
var title_f34_35_35385="Treatment of chronic graft-versus-host disease";
var content_f34_35_35385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of chronic graft-versus-host disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/35/35385/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35385/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/35/35385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35385/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/35/35385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35385/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/35/35385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft-versus-host disease (GVHD) occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GVHD has been classically divided into acute and chronic disease based upon the time of onset:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute GVHD &mdash; disease presenting within the first 100 days of hematopoietic cell transplantation (HCT)",
"     </li>",
"     <li>",
"      Chronic GVHD &mdash; onset of disease after the first 100 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, this division at day 100 post-HCT is artificial and there has been a shift towards defining acute and chronic GVHD based upon the clinical manifestations of these diseases, rather than the arbitrary cut-off of a particular date post-transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/1\">",
"     1",
"    </a>",
"    ]. For unclear cases, the NIH consensus diagnostic criteria for GVHD includes an overlap syndrome in which diagnostic or distinctive features of chronic GVHD and acute GVHD appear together. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A continuum of clinical findings may be observed in patients with acute and chronic GVHD, as both disorders commonly affect similar organs, principally the skin, liver, and gastrointestinal tract. However, the target organs affected by and the clinical and histologic features associated with chronic GVHD may differ from those observed with acute disease. As an example, autoimmune phenomena, such as autoantibody formation, are more common with chronic disease. In addition, clinical aspects of chronic GVHD may also mimic features frequently observed with systemic lupus erythematosus, systemic sclerosis, sicca syndrome, eosinophilic fasciitis, rheumatoid arthritis, and primary biliary sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=see_link&amp;anchor=H6225514#H6225514\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\", section on 'Autoantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic GVHD is the single major factor determining long-term outcome and quality of life following HCT. Because of the profound immunosuppression observed with this disorder, recurrent infections occur in almost all affected patients. These complications account for most of the morbidity and mortality associated with chronic GVHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25529?source=see_link&amp;anchor=H5#H5\">",
"     \"Quality of life following hematopoietic cell transplantation\", section on 'Chronic graft-versus-host disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the treatment of chronic GVHD. The diagnosis of chronic GVHD and the prevention and treatment of acute GVHD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major approaches to the prophylaxis of acute GVHD following hematopoietic cell transplantation: pharmacologic therapy and T cell depletion. Although T cell depletion (but not pharmacologic therapy) may help decrease the incidence and severity of chronic GVHD, chronic disease frequently develops, resulting in significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple different regimens have been used in an attempt to prevent the development of chronic GVHD; none appears to be effective at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42041?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24792?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    as preventive therapy based upon its efficacy in patients with established chronic GVHD (see below). At 80 days post-transplantation, 59 patients were randomly assigned to treatment with thalidomide (200 mg twice daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/9\">",
"     9",
"    </a>",
"    ]. The study was terminated early because the first interim analysis revealed a higher mortality and incidence of chronic GVHD among the group receiving thalidomide. The reasons for this seemingly paradoxical observation are unclear, although the thalidomide might have interfered with normal regulatory mechanisms.",
"   </p>",
"   <p>",
"    In another study, thymus tissue implants, thymic endothelial cells or thymic hormones (thymosin fraction five and thymopentin) were administered to recipients of HLA-matched sibling HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/10\">",
"     10",
"    </a>",
"    ]. No difference in the incidence of chronic GVHD was observed in patients receiving thymic tissue or thymic hormones compared with concurrent or historic controls.",
"   </p>",
"   <p>",
"    Many studies have examined the efficacy of glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and intravenous immune globulin (either alone or in combination) in preventing both acute and chronic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .) In a randomized study, for example, the prophylactic efficacy of cyclosporine alone versus cyclosporine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    was evaluated in 122 patients in whom HCT was performed from a HLA-identical sibling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/11\">",
"     11",
"    </a>",
"    ]. A significantly increased incidence of chronic GVHD was observed in patients receiving combination therapy versus cyclosporine alone (44 versus 21 percent), suggesting that the addition of methylprednisolone to cyclosporine therapy may enhance the probability of developing chronic GVHD. At a median follow-up of 6.1 years, there was also the suggestion that more patients receiving the combination developed other complications, such as aseptic necrosis of the bone and chronic pulmonary disease, and have required immunosuppressive therapy for a longer duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To test the ability of prolonged use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in preventing chronic GVHD, patients who had received allogeneic HCT and had acute GVHD or histologic evidence of subclinical GVHD were randomly assigned to receive either six or 24 months of oral cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/13\">",
"     13",
"    </a>",
"    ]. Clinical extensive chronic GVHD developed in 39 and 51 percent of those in the six- and 24-month treatment groups, respectively (p = 0.25).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STANDARDIZED RESPONSE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before reviewing the literature on therapy, it is important to note that a major obstacle to progress in chronic GVHD is the lack of standardized criteria for quantitative measurement of therapeutic response in clinical trials. A collaborative discussion of the community of hematopoietic cell transplant (HCT) physicians has led to the National Institutes of Health (NIH) Consensus Criteria for Clinical Trials in Chronic Graft-versus-Host Disease (GVHD), which established for the first time comprehensive diagnostic, staging, and response criteria for chronic GVHD (cGVHD). This document was developed to address specific objectives for response criteria to be used in future chronic GVHD-related clinical trials.",
"   </p>",
"   <p>",
"    The proposed measures are practical for use both by transplantation and non-transplantation medical providers, adaptable for use in adults and children, and focused on the most important chronic GVHD manifestations. The measures should also give preference to quantitative measures; capture information regarding signs, symptoms, and function separately from one another; and use validated scales whenever possible to demonstrate improved patient outcomes. Moreover, these measurements need to meet requirements for regulatory approval of novel agents.",
"   </p>",
"   <p>",
"    Based on these criteria, a proposed set of measures to be considered for use in clinical trials, and forms for data collection have been provided, and are available on the ASBMT website at:",
"    <a class=\"external\" href=\"file://www.asbmt.org/displaycommon.cfm?an=1&amp;subarticlenbr=29\">",
"     file://www.asbmt.org/",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Measures should be made at three-month intervals and whenever major changes are made in treatment. Provisional definitions of complete response, partial response, and progression are proposed for each organ system and for overall outcomes. While the proposed response criteria are based on current expert consensus opinion and are intended to improve consistency in the conduct and reporting of chronic GVHD trials, the usefulness of these criteria remains to be demonstrated in practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of immunosuppressive medications as prophylaxis against",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the treatment of acute GVHD affects the choice of therapy of chronic GVHD. Prophylaxis against acute GVHD consists of the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . We currently recommend a regimen in which methotrexate is last given on day 11 after the transplant and cyclosporine is tapered after day 90 if the patient is doing well (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, a number of exceptions to this general course:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In mismatched related sibling or matched unrelated donor transplants,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      may need to be continued for much longer than 90 days, sometimes even years.",
"     </li>",
"     <li>",
"      A slower taper may also be preferable in older patients to prevent chronic GVHD.",
"     </li>",
"     <li>",
"      Some patients with chronic GVHD have unresolved acute GVHD, which is being treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other immunosuppressive agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, the patient who develops chronic GVHD may or may not already be taking an immunosuppressive agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with limited uncomplicated chronic GVHD, as defined above, can usually be effectively treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone. By comparison, patients with extensive disease, particularly those with high risk features, usually require the addition of another immunosuppressive agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Determination of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of chronic GVHD is determined in part by the severity of the disease. Chronic GVHD is graded as either limited or extensive based upon the clinical severity and target organs affected. Limited disease is characterized by localized skin involvement alone or evidence of hepatic dysfunction. Extensive disease presents either with generalized skin involvement, or with localized skin involvement or hepatic dysfunction plus at least one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver histology showing chronic progressive hepatitis, bridging necrosis, or cirrhosis",
"     </li>",
"     <li>",
"      Involvement of the eye (Schirmer's test with less than 5 mm wetting) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18794?source=see_link\">",
"       \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Involvement of minor salivary glands or oral mucosa (as demonstrated on labial or mucosal biopsy specimen)",
"     </li>",
"     <li>",
"      Involvement of any other target organ",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of combinations of features have been used to define patients at high risk in different studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One or more of the following: chronic GVHD that has evolved from acute GVHD; lichenoid skin changes; and serum bilirubin concentration greater than 1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      At least two of the following: chronic GVHD that has evolved from acute GVHD; hepatic dysfunction; and lichenoid skin or mucous membrane changes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Extensive chronic GVHD with persistent thrombocytopenia (platelet count less than",
"      <span class=\"nowrap\">",
"       100,000/microL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternate-day",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be effective in the treatment of limited chronic GVHD and in those with extensive disease but without risk factors associated with a poor long-term prognosis (high-risk disease). As an example, the effectiveness of prednisone alone versus prednisone plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    was evaluated in a study of 179 asymptomatic patients with early stage extensive chronic GVHD, defined by the presence of positive skin and oral biopsies in patient without clinical signs or symptoms of the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients were randomly assigned to therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day) plus either placebo or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). Although recurrent malignancy-related mortality was similar in the two groups, actuarial survival at five years was higher in patients treated with prednisone alone (61 versus 47 percent for combined therapy, p = 0.0001). However, prednisone alone was less effective among those with thrombocytopenia, resulting in a five-year survival of only 26 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prednisone plus cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the dismal long-term survival of patients with chronic GVHD and high risk features (eg, thrombocytopenia) who are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone prompted the evaluation of more aggressive medical regimens. One such study evaluated the effectiveness of prednisone (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily alternating every other day with prednisone), and one double-strength TMP-SMX tablet twice daily in 61 patients with high risk chronic GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Forty patients received such a regimen as primary therapy for chronic GVHD associated with thrombocytopenia, while the remaining patients received this combination as salvage therapy after having failed the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    regimen delineated in the previous study. At four years, actuarial survival was 51 and 67 percent for those administered prednisone plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    as primary and salvage therapy, respectively, suggesting improved survival using the combined regimen (versus prednisone alone, see above) for this high-risk group. Deaths resulted from interstitial pneumonia, relapse of the original disease, GVHD, infection, organ failure, and hemorrhage.",
"   </p>",
"   <p>",
"    A second study randomly assigned patients with newly diagnosed clinical extensive chronic GVHD and platelet counts",
"    <span class=\"nowrap\">",
"     &gt;100,000/&micro;L",
"    </span>",
"    to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (starting dose 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/21\">",
"     21",
"    </a>",
"    ]. While treatment with the two-drug combination reduced some of the risks associated with steroids (eg, avascular necrosis), there were no significant differences between the two treatment arms in terms of overall mortality, transplantation-related mortality, recurrent malignancy, or discontinuation of all immunosuppressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    , an agent previously used for nausea but withdrawn because of the induction of profound teratogenicity, has significant immunosuppressive properties. In murine models of acute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic GVHD, substantial benefit has been observed with thalidomide compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical studies suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    is effective in humans:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A preliminary study evaluated the effectiveness of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      in 23 patients with chronic GVHD refractory to conventional therapy and in 21 patients with high risk chronic GVHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/18\">",
"       18",
"      </a>",
"      ]. Benefits with thalidomide included an overall response rate of 64 percent and a survival rate of 76 percent among the patients receiving salvage therapy and 48 percent among those with high risk GVHD.",
"     </li>",
"     <li>",
"      A phase I-II trial of 80 patients with refractory GVHD found a 20 percent response rate to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/24\">",
"       24",
"      </a>",
"      ]. Patients with previously severe acute GVHD had no response. Although therapy was well tolerated, sedation, constipation and rashes occurred, occasionally requiring discontinuation of the drug. Neutropenia was also dose limiting in several patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Differences in the overall response rates may be related to the characteristics of enrolled patients, such as the presence or absence of high-risk features, or whether chronic GVHD had developed de novo or occurred despite the administration of immunosuppressive medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Psoralen ultraviolet irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoralen ultraviolet irradiation (PUVA) treatment has also been used in the treatment of chronic GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/25-33\">",
"     25-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one technique, patients receive a dose of the UV sensitizer 8- methoxypsoralen, followed by UV irradiation of the skin.",
"     </li>",
"     <li>",
"      A second technique (extracorporeal photopheresis) consists of re-infusion of ultraviolet-irradiated autologous peripheral lymphocytes that have been collected by apheresis and incubated with 8-methoxypsoralen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With either technique, immunosuppression results from a decrease in the number and function of circulating lymphocytes due primarily to the inhibition of DNA transcription and mitosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6666?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\", section on 'Extracorporeal photochemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional postulated mechanisms of immunosuppression following PUVA include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/34-39\">",
"     34-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A decrease in T cell proliferation, mitogen response, and natural killer (NK) cell activity",
"     </li>",
"     <li>",
"      A modulation of MHC-alloreactive cytotoxic T-cell precursors",
"     </li>",
"     <li>",
"      Activation of suppressor pathways by ultraviolet resistant antigen presenting cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increasing donor regulatory T cells",
"     </li>",
"     <li>",
"      Alteration of cytokine production, specifically IL-1 and IL-2",
"     </li>",
"     <li>",
"      Decreasing the numbers of circulating dendritic cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these observations were made either in vitro, in animal models, or in psoriasis patients, and the results in patients after HCT may be different.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study, for example, found that approximately 30 percent of patients administered PUVA therapy achieved a complete remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An early report in 49 patients with moderate or severe chronic GVHD noted that the percentages of immature",
"      <span class=\"nowrap\">",
"       CD19+/CD21-",
"      </span>",
"      B-cells prior to extracorporeal photopheresis were significantly lower in patients achieving CR when compared with nonresponders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis of 25 patients with chronic GVHD (80 percent extensive) who underwent extracorporeal photopheresis reported that the patients whose GVHD responded had higher baseline circulating myeloid dendritic cells (mDC) and plasmacytic dendritic cell precursors (CD4+ T cells) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/40\">",
"       40",
"      </a>",
"      ]. The best cutoff values to predict response were mDC of 3.7",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (79 percent sensitivity, 82 percent specificity) and CD4+ T cell count of 104",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (71 percent sensitivity and 82 percent specificity).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some, but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/31\">",
"     31",
"    </a>",
"    ], the efficacy of PUVA seemed to be limited to the skin complications of chronic GVHD, such as a steroid-sparing effect on skin lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/42\">",
"     42",
"    </a>",
"    ]. This modality may therefore be most effective if used earlier in the course of the disease when GVHD is limited to the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA), a relatively nontoxic hydrophilic bile acid with a striking choleretic effect, is that chronic GVHD affecting the liver shares many features with primary biliary cirrhosis, a disorder known to respond to this agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43526?source=see_link\">",
"     \"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis\"",
"    </a>",
"    .) One study evaluated the effectiveness of 6 to 12 weeks of UDCA in 12 patients with refractory chronic GVHD of the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/43\">",
"     43",
"    </a>",
"    ]. Compared with baseline values, treatment resulted in a 33, 32, and 37 percent decrease in the serum concentrations of bilirubin (p&lt;0.005), alkaline phosphatase (p&lt;0.038), and AST (p&lt;0.007), respectively. Drug discontinuation quickly resulted in a rise in the serum levels of all three markers. Long-term efficacy of this treatment has not been determined.",
"   </p>",
"   <p>",
"    The mechanism of action of UDCA in chronic GVHD is unclear. One possibility is that the agent simply replaces the more hydrophobic detergent and toxic bile acids. A more intriguing mode of action may be altered expression of HLA class I antigens on hepatocytes, thereby diminishing the immune attack [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H304241\">",
"    <span class=\"h2\">",
"     Interleukin-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-2 (IL-2) is a T cell derived cytokine that plays a central role in immune responses. IL-2 is also important for the development and function of regulatory T cells (Tregs). Interest in the use of IL-2 in the management of GVHD was initially based upon mouse studies that suggested that Treg cells could control GVHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of graft-versus-host disease\", section on 'Regulatory T cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a phase I dose escalation study, 28 patients with glucocorticoid refractory chronic GVHD were treated with eight weeks of daily low-dose subcutaneous IL-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/45\">",
"     45",
"    </a>",
"    ]. At enrollment, patients were on a median of three concurrent agents for the management of GVHD. They had a median of three areas of GVHD involvement. The maximum tolerated dose of IL-2 was 1x10",
"    <sup>",
"     6",
"    </sup>",
"    international",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Higher doses produced persistent constitutional symptoms (eg, fever, malaise, and arthralgia). Severe (grade",
"    <span class=\"nowrap\">",
"     3/4/5)",
"    </span>",
"    toxicities included thrombotic microangiopathy (two patients), infection (three patients), and myocardial infarction (two patients). None of the patients experienced a relapse of the underlying malignancy. Of the 23 patients who could be evaluated for response, 12 had a partial response and 11 had stable disease. Prolonged responses were seen in a subset of patients who chose to continue IL-2 for an extended period, many of whom were able to taper glucocorticoid dose.",
"   </p>",
"   <p>",
"    This study suggests that IL-2 administration is safe and may produce responses in chronic refractory GVHD. We await further study of this agent prior to incorporating it into routine care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Novel agents and modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer agents have continued to be introduced, including immunosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , rapamycin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, for both prophylaxis and therapy of chronic GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In initial studies,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      has been used as salvage therapy with some success [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A double-blind randomized trial to determine whether the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil improves the efficacy of initial systemic therapy of chronic GVHD was closed because an interim analysis indicated a low probability of a positive result [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two studies performed in patients with refractory sclerotic chronic GVHD, response rates to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      were seen in 7 of 14 patients and in 15 of 19 patients, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. Another retrospective study of imatinib reported improvement in 12 of 39 patients with steroid-refractory sclerotic chronic GVHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/53\">",
"       53",
"      </a>",
"      ]. This agent has also had some effectiveness in patients with chronic GVHD involving the lungs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Newer immunosuppressive agents are currently being investigated. Currently, there are no clear guidelines concerning their role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reports on the successful use of the anti-CD20 monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in patients with refractory chronic GVHD suggest the potential use of agents directed at B-cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/55-59\">",
"       55-59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/9/40086?source=see_link\">",
"       Pentostatin",
"      </a>",
"      (initial dose: 4",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      IV every two weeks for 12 doses, continued as long as benefit was documented) was given to heavily pretreated (median of 4 prior regimens) patients with chronic GVHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/60\">",
"       60",
"      </a>",
"      ]. An objective response was seen in 32 of the 58 patients (55 percent), with a one-year overall survival of 78 percent. Similar response rates were noted in a phase II trial of this agent in 51 children with corticosteroid-refractory chronic GVHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two agents of particular interest that are being evaluated in ongoing clinical trials are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and rapamycin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/48\">",
"     48",
"    </a>",
"    ]. Additional study is required to properly understand how these drugs may be optimally used in patients with this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Limited chronic GVHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with limited chronic GVHD and without any significant morbidity may not need any specific systemic therapy. As examples, patients with limited skin involvement may only require the administration of topical steroids (such as a fluorinated topical steroid), those with chronic GVHD involving the eye may respond to topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    eyedrops, and those with localized disease of the mouth (eg, xerostomia) may improve with agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    , gargled oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , or use of a non-absorbable steroid mouthwash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=see_link&amp;anchor=H27#H27\">",
"     \"Oral toxicity associated with chemotherapy\", section on 'Xerostomia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26826?source=see_link\">",
"     \"Treatment of dry eyes in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36762?source=see_link\">",
"     \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Extensive chronic GVHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic approach to the patient with extensive chronic disease varies based upon the clinical presentation. Patients with rapidly progressive chronic GVHD should receive high dose corticosteroids, usually initiated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 60 mg per day. This is also commonly administered in combination with the reinitiation of therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In patients with more subtle or indolent disease, lower doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone may be sufficient. In this setting, prednisone at a dose of 20 to 30 mg per day may be adequate to control symptoms with responses usually observed within two to four weeks.",
"   </p>",
"   <p>",
"    Other agents may be used either in those who fail to improve with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , or as a steroid-sparing agent in patients who improve with initial therapy. These include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or clofazimine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      is usually begun at 400 mg administered in two divided daily doses. The target dose of thalidomide is between 800 and 1200 mg daily.",
"     </li>",
"     <li>",
"      Clofazimine is usually initiated at 300 mg per day; if a response is observed after several months, it is decreased to 100 mg daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic manipulations may also be used, particularly among those with skin involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PUVA therapy, which may be used in patients with chronic GVHD and extensive skin involvement, is usually begun at 25 percent of the normal dose; those with chronic GVHD and extensive skin involvement may be very sensitive to burning with this modality (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Psoralen ultraviolet irradiation'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Extracorporeal photopheresis may also be used. This is commonly done if the manipulations previously mentioned have failed to control the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/66-71\">",
"       66-71",
"      </a>",
"      ]. Earlier use may result in significantly better results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with limited chronic GVHD have a favorable prognosis even without therapy, while those who have extensive GVHD, particularly with multiorgan involvement, have poor long-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Several patient-, transplant-, and disease-related prognostic factors have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/17,19,75-77\">",
"     17,19,75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study analyzed data from 5343 patients with chronic GVHD included in the Center for International Blood and Marrow Transplant Research database [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/77\">",
"     77",
"    </a>",
"    ]. A chronic GVHD risk score was developed using 10 variables measured at the time of chronic GVHD diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age of recipient at transplantation (&lt;29 years = 0 points; 30 to 59 years = 1 point; &gt;60 years = 2 points)",
"     </li>",
"     <li>",
"      Prior acute GVHD (none = 0 points; present = 1 point)",
"     </li>",
"     <li>",
"      Time from transplant to development of chronic GVHD (&gt;5 months = 0 points; &lt;5 months = 1 point)",
"     </li>",
"     <li>",
"      Serum bilirubin at diagnosis of chronic GVHD (&lt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      = 0 points; &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      = 2 points)",
"     </li>",
"     <li>",
"      Karnofsky performance score (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"       table 1",
"      </a>",
"      ) (&gt;80 = 0 points; &lt;80 = 1 point)",
"     </li>",
"     <li>",
"      Platelet count (&gt;100 x",
"      <span class=\"nowrap\">",
"       109/L",
"      </span>",
"      = 0 points; &lt;100 x",
"      <span class=\"nowrap\">",
"       109/L",
"      </span>",
"      = 1 point)",
"     </li>",
"     <li>",
"      Type of donor (HLA-identical",
"      <span class=\"nowrap\">",
"       sibling/well-matched",
"      </span>",
"      or partially matched unrelated donor = 0 points; other = 1 point)",
"     </li>",
"     <li>",
"      Disease status at transplant (early = 0 points; intermediate = 1 point; advanced = 2 points)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Donor/recipient",
"      </span>",
"      sex mismatch",
"      <span class=\"nowrap\">",
"       (female/male",
"      </span>",
"      = 1 point; others = 0 points)",
"     </li>",
"     <li>",
"      GVHD prophylaxis (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      combination = 0 points; other = 1 point)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this study, early disease included patients undergoing transplant in first remission of acute leukemia, first chronic phase of chronic myelogenous leukemia (CML), or for myelodysplastic syndromes (MDS) with refractory anemia or refractory anemia with ring sideroblasts. Intermediate disease included those with second or later complete remission for acute leukemia, second or later chronic phase or accelerated phase for CML. Advanced disease included patients in relapse or primary induction failure for acute leukemia or blast crisis for CML or MDS with refractory anemia with excess blasts or excess blasts in transformation. Using these variables, patients could be divided into six risk groups (RG) based upon overall risk score with associated rates of overall survival (OS) and non-relapse mortality (NRM) at five years:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      RG1 &mdash; 0 to 2 points; 91 percent OS; 5 percent NRM",
"     </li>",
"     <li>",
"      RG2 &mdash; 3 to 6 points; 67 percent OS; 20 percent NRM",
"     </li>",
"     <li>",
"      RG3 &mdash; 7 to 8 points; 51 percent OS; 33 percent NRM",
"     </li>",
"     <li>",
"      RG4 &mdash; 9 to 10 points; 40 percent OS; 43 percent NRM",
"     </li>",
"     <li>",
"      RG5 &mdash; 11 points; 21 percent OS; 63 percent NRM",
"     </li>",
"     <li>",
"      RG6 &mdash; &gt;12 points; 4 percent OS; 67 percent NRM",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While requiring validation in another patient cohort, this score is attractive because it incorporates several known risk factors and is relatively easy to apply clinically. Knowledge of these clinical characteristics associated with a poor outcome may help the clinician identify those patients in whom more aggressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supportive treatment regimens may be most appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35385/abstract/8,16,78,79\">",
"     8,16,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3113104\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic graft-versus-host disease (GVHD) is the single major factor determining long-term outcome and quality of life following allogeneic hematopoietic cell transplantation.",
"     </li>",
"     <li>",
"      Unlike acute GVHD, there is no known effective regimen to prevent the development of chronic GVHD. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of chronic GVHD may be complicated by the current administration of immunosuppressive agents for active prophylaxis against",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment of acute GVHD. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of chronic GVHD is determined in part by the severity of the disease. Chronic GVHD is graded as either limited or extensive based upon the clinical severity and target organs affected. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Determination of risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited chronic GVHD &mdash; Patients with limited chronic GVHD and without any significant morbidity may not require systemic therapy, but may respond to the localized treatment of symptoms. As examples, patients with limited skin involvement may only require the administration of topical steroids, those with chronic GVHD involving the eye may respond to topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      eyedrops, and those with localized disease of the mouth may improve with agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      , gargled oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , or use of a non-absorbable steroid mouthwash. Patients with limited chronic GVHD that does not respond to local measures or who are not candidates for localized therapy are candidates for systemic treatment with alternate-day",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Limited chronic GVHD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extensive GVHD &mdash; The therapeutic approach to the patient with extensive chronic disease varies based upon the clinical presentation (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Extensive chronic GVHD'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with rapidly progressive chronic GVHD should receive high dose corticosteroids, usually initiated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 60 mg per day. This is also commonly administered in combination with the reinitiation of therapeutic doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prednisone plus cyclosporine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with more subtle or indolent disease, lower doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      alone may be sufficient. In this setting, prednisone at a dose of 20 to 30 mg per day may be adequate to control symptoms with responses usually observed within two to four weeks. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prednisone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who fail to improve with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , may benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or clofazimine. These agents may also be useful in patients who are unable to tolerate high dose steroids. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Thalidomide'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with limited chronic GVHD have a favorable prognosis even without therapy, while those who have extensive GVHD, particularly those with multiorgan involvement, have poor long-term outcomes. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/1\">",
"      Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/2\">",
"      Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4 Suppl 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/3\">",
"      Siadak M, Sullivan KM. The management of chronic graft-versus-host disease. Blood Rev 1994; 8:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/4\">",
"      Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/5\">",
"      Soci&eacute; G, Schmoor C, Bethge WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011; 117:6375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/6\">",
"      Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005; 105:4200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/7\">",
"      Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005; 106:3308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/8\">",
"      Fraser CJ, Scott Baker K. The management and outcome of chronic graft-versus-host disease. Br J Haematol 2007; 138:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/9\">",
"      Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996; 2:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/10\">",
"      Witherspoon RP, Sullivan KM, Lum LG, et al. Use of thymic grafts or thymic factors to augment immunologic recovery after bone marrow transplantation: brief report with 2 to 12 years' follow-up. Bone Marrow Transplant 1988; 3:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/11\">",
"      Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997; 89:3880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/12\">",
"      Deeg HJ, Flowers ME, Leisenring W, et al. Cyclosporine (CSP)or CSP plus methylprednisolone for graft-versus-host disease prophylaxis in patients with high-risk lymphohemopoietic malignancies: long-term follow-up of a randomized trial. Blood 2000; 96:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/13\">",
"      Kansu E, Gooley T, Flowers ME, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001; 98:3868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/14\">",
"      Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12:252.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.asbmt.org/ (Accessed on April 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/16\">",
"      Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004; 125:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/17\">",
"      Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/18\">",
"      Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/19\">",
"      Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/20\">",
"      Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988; 72:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/21\">",
"      Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002; 100:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/22\">",
"      Vogelsang GB, Wells MC, Santos GW, et al. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model. Transplant Proc 1988; 20:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/23\">",
"      Heney D, Bailey CC, Lewis IJ. Thalidomide in the treatment of graft-versus-host disease. Biomed Pharmacother 1990; 44:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/24\">",
"      Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86:3604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/25\">",
"      Hymes SR, Morison WL, Farmer ER, et al. Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction. J Am Acad Dermatol 1985; 12:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/26\">",
"      Atkinson K, Weller P, Ryman W, Biggs J. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986; 1:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/27\">",
"      Deeg HJ. Ultraviolet irradiation in transplantation biology. Manipulation of immunity and immunogenicity. Transplantation 1988; 45:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/28\">",
"      Eppinger T, Ehninger G, Steinert M, et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/29\">",
"      Kripke ML. Immunological unresponsiveness induced by ultraviolet radiation. Immunol Rev 1984; 80:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/30\">",
"      Kapoor N, Pelligrini AE, Copelan EA, et al. Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: preliminary experience in standard treatment resistant patients. Semin Hematol 1992; 29:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/31\">",
"      Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107:3074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/32\">",
"      Marshall SR. Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006; 3:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/33\">",
"      Knobler R, Barr ML, Couriel DR, et al. Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol 2009; 61:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/34\">",
"      Bredberg A, Forsgren A. Effects of in vitro PUVA on human leukocyte function. Br J Dermatol 1984; 111:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/35\">",
"      Granstein RD, Lowy A, Greene MI. Epidermal antigen-presenting cells in activation of suppression: identification of a new functional type of ultraviolet radiation-resistant epidermal cell. J Immunol 1984; 132:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/36\">",
"      Okamoto H, Horio T, Maeda M. Alteration of lymphocyte functions by 8-methoxypsoralen and long-wave ultraviolet radiation. II. The effect of in vivo PUVA on IL-2 production. J Invest Dermatol 1987; 89:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/37\">",
"      van Prooijen HC, Aarts-Riemens MI, Grijzenhout MA, van Weelden H. Ultraviolet irradiation modulates MHC-alloreactive cytotoxic T-cell precursors involved in the onset of graft-versus-host disease. Br J Haematol 1992; 81:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/38\">",
"      Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/39\">",
"      Bastien JP, Krosl G, Therien C, et al. Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease. Blood 2010; 116:4859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/40\">",
"      Akhtari M, Giver CR, Ali Z, et al. Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Transfusion 2010; 50:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/41\">",
"      Kuzmina Z, Greinix HT, Knobler R, et al. Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Blood 2009; 114:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/42\">",
"      Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008; 112:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/43\">",
"      Fried RH, Murakami CS, Fisher LD, et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992; 116:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/44\">",
"      Hillaire S, Boucher E, Calmus Y, et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994; 107:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/45\">",
"      Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/46\">",
"      Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/47\">",
"      Basara N, Blau WI, R&ouml;mer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/48\">",
"      Couriel DR, Saliba R, Escal&oacute;n MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/49\">",
"      Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/50\">",
"      Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009; 113:5074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/51\">",
"      Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/52\">",
"      Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009; 114:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/53\">",
"      de Masson A, Bouaziz JD, Peffault de Latour R, et al. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood 2012; 120:5089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/54\">",
"      Stadler M, Ahlborn R, Kamal H, et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood 2009; 114:3718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/55\">",
"      Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000; 133:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/56\">",
"      Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004; 104:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/57\">",
"      Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/58\">",
"      Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 2010; 51:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/59\">",
"      Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 2010; 95:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/60\">",
"      Jacobsohn DA, Chen AR, Zahurak M, et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 2007; 25:4255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/61\">",
"      Jacobsohn DA, Gilman AL, Rademaker A, et al. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. Blood 2009; 114:4354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/62\">",
"      Singhal S, Powles R, Treleaven J, et al. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymphoma 1997; 24:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/63\">",
"      Sari I, Altuntas F, Kocyigit I, et al. The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol 2007; 82:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/64\">",
"      Wang Y, Ogawa Y, Dogru M, et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant 2008; 41:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/65\">",
"      Joseph RW, Couriel DR, Komanduri KV. Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. J Support Oncol 2008; 6:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/66\">",
"      Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/67\">",
"      Alcindor T, Gorgun G, Miller KB, et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001; 98:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/68\">",
"      Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002; 6:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/69\">",
"      Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/70\">",
"      Seaton ED, Szydlo RM, Kanfer E, et al. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003; 102:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/71\">",
"      Rubegni P, Cuccia A, Sbano P, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol 2005; 130:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/72\">",
"      Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/73\">",
"      Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004; 104:3501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/74\">",
"      Ozawa S, Nakaseko C, Nishimura M, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol 2007; 137:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/75\">",
"      Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/76\">",
"      Pavletic SZ, Smith LM, Bishop MR, et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol 2005; 78:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/77\">",
"      Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011; 117:6714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/78\">",
"      Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35385/abstract/79\">",
"      Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12:375.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3550 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-D141E0F7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35385=[""].join("\n");
var outline_f34_35_35385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3113104\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STANDARDIZED RESPONSE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Determination of risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prednisone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prednisone plus cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Psoralen ultraviolet irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H304241\">",
"      Interleukin-2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Novel agents and modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Limited chronic GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Extensive chronic GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nonpharmacologic therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3113104\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3550\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3550|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42041?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25529?source=related_link\">",
"      Quality of life following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6666?source=related_link\">",
"      Treatment of acute graft-versus-host disease: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26826?source=related_link\">",
"      Treatment of dry eyes in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36762?source=related_link\">",
"      Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43526?source=related_link\">",
"      Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_35_35386="Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST";
var content_f34_35_35386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/35/35386/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35386/contributors\">",
"     George D Demetri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35386/contributors\">",
"     Jeffrey Morgan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35386/contributors\">",
"     Chandrajit P Raut, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/35/35386/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35386/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35386/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35386/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/35/35386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/35/35386/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/35/35386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract typically present as subepithelial neoplasms, and they are divided broadly into two groups. The most common group consists of neoplasms that are collectively referred to as gastrointestinal stromal tumors (GISTs). They are most often located in the stomach and proximal small intestine, but can occur in any portion of the alimentary tract including occasionally in the omentum, mesentery, and peritoneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A far less common group of mesenchymal GI tract neoplasms is comprised of a spectrum of tumors that are identical to those that might arise in the soft tissues throughout the rest of the body. These include lipomas, liposarcomas, leiomyomas, true leiomyosarcomas, desmoid tumors, schwannomas, and peripheral nerve sheath tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, classification, molecular pathogenesis, diagnostic workup of localized GISTs will be reviewed here. Treatment for GISTs, and GI tract leiomyomas and leiomyosarcomas are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34938?source=see_link\">",
"     \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=see_link\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite being the most common nonepithelial benign neoplasm involving the GI tract, mesenchymal tumors are thought to constitute only 1 percent of primary GI cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, their true frequency is unknown. Epidemiologic data such as that from National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program are difficult to interpret since the early definition of so-called \"malignant GIST\" was derived from criteria published in 1990, at a time before GIST was molecularly characterized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experience from epidemiologic studies and active GIST therapeutic trials suggest that the annual incidence of GIST in the United States is at least 4000 to 6000 new cases (roughly 7 to 20 cases per million population per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The most reliable international epidemiologic data are derived from population-based studies that reexamined histologically and immunohistochemically all cases of potential GIST diagnosed between 1983 and 2000 within one province of Sweden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/10\">",
"     10",
"    </a>",
"    ], between 1990 and 2003 in all of Iceland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/11\">",
"     11",
"    </a>",
"    ], between 1995 and 2003 in the Netherlands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/12\">",
"     12",
"    </a>",
"    ], and between 1998 and 2004 in Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/13\">",
"     13",
"    </a>",
"    ]. In the Swedish study, 288 of the 1460 cases examined were felt to represent GISTs, for an annual incidence of 14.5 per million population. The Icelandic study reported an incidence of 11 per million population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More recent data suggest that the frequency of incidentally detected subcentimeter gastric GIST lesions may be much higher than expected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In a Japanese study of 100 whole stomachs resected from patients with gastric cancer that were step-sectioned at 5 mm intervals and examined by light microscopy and immunohistochemistry for KIT (CD117), CD34, and desmin expression, there were 50 microscopic GISTS (all of which were positive for KIT and CD34 expression, and negative for desmin) in the stomachs of 35 individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/14\">",
"     14",
"    </a>",
"    ]. Ninety percent were located in the upper stomach. An additional 28 stomach specimens had microscopic leiomyomas, defined by expression of desmin.",
"   </p>",
"   <p>",
"    The authors suggested that given the relatively low annual incidence of clinical GISTs, only a few microscopic tumors may grow into a clinically relevant size with malignant potential. Further study is needed to confirm these observations and to clarify the genetic events responsible for the transformation of microscopic GIST lesions into clinically relevant GISTs.",
"   </p>",
"   <p>",
"    GISTs occur predominantly in middle-aged and older individuals, and rarely in those under the age of 40. In an analysis of SEER registry data, the mean age at diagnosis was 63 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/7\">",
"     7",
"    </a>",
"    ]; it was 66 to 69 years in two European population-based series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Familial GIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of GISTs appear to be sporadic, several kindreds with heritable mutations in the KIT gene have been identified. These families have a predisposition to multiple gastric and small bowel GISTs, and in some cases, skin hyperpigmentation, dysphagia, or GI autonomic nerve tumors such as paragangliomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/16-24\">",
"     16-24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Molecular pathogenesis of GIST and KIT mutations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Phenotypic and molecular features appear to be indistinguishable in familial and sporadic cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In several kindreds with familial GIST, resected tumors have been accompanied by diffuse interstitial cells of Cahal (ICC) hyperplasia in the adjacent gut wall (Auerbach's plexus), which are thought to represent the precursor lesion to GIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/16,18-20,25\">",
"     16,18-20,25",
"    </a>",
"    ]. Sporadic ICC hyperplasia has also been described that may represent a precursor lesion to sporadic GIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/15\">",
"     15",
"    </a>",
"    ]. Sporadic diffuse ICC hyperplasia must be distinguished from syndromic ICC hyperplasia associated with hereditary GIST syndromes",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/26\">",
"     26",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"   </p>",
"   <p>",
"    Individuals with neurofibromatosis type I (NF1) also have a high incidence of GISTs. In the setting of NF1, GISTs are frequently in the small intestine (more than 70 percent) and multiple. Unlike GISTs that arise outside of the setting of NF1, only a few cases have been reported to carry somatic mutations in the KIT or PDGFRA genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. KIT is often expressed in tumors that are wild-type for KIT and PDGFRA, but the mechanism of overexpression is not clear. Mutations in the a gene that encodes for a subunit of the succinate dehydrogenase (SDH) enzyme (see below) have not been found in GISTs that arise in the setting of NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Molecular pathogenesis of GIST and KIT mutations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1013925\">",
"    <span class=\"h2\">",
"     Pediatric GIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;GISTs are rare in children and they tend to arise within defined syndromes, including the Carney triad and Carney-Stratakis syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast to adults, 85 percent of pediatric GISTs lack mutations in KIT or PDGFRA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Classification and molecular pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    On the other hand, approximately 12 percent of pediatric GISTs have germline mutations in a gene that encodes for a subunit of the succinate dehydrogenase (SDH) enzyme, and all have loss of function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/29\">",
"     29",
"    </a>",
"    ]. The coexistence of GISTs and paragangliomas in children with inherited germline SDH mutations in the absence of KIT or PDGFRA mutations is referred to as the Carney-Stratakis syndrome to distinguish it from the Carney triad (GIST, paraganglioma, and pulmonary chondroma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Interestingly, SDH mutations have not been reported in the Carney triad [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38121?source=see_link&amp;anchor=H7#H7\">",
"     \"Pheochromocytoma in children\", section on 'Non-familial syndromes'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1013670\">",
"     'SDH subunit mutations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    GISTs occurring in children also have distinct clinical and pathologic features. In addition to a female predilection, which is not seen in adults, chronic GI bleeding is the most common presentation, multifocal gastric tumors and lymph node metastases are more common than in adults, and the histopathology is more likely to be epithelioid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Furthermore, despite multiple disease recurrences and metastatic disease, pediatric GIST appears to have a more indolent disease course than adult GIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spindle cell and epithelioid tumors arising from the",
"    <span class=\"nowrap\">",
"     stromal/mesenchymal",
"    </span>",
"    components of the GI tract have undergone a striking evolution in the way they are perceived and classified over the last 30 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/37\">",
"     37",
"    </a>",
"    ]. Based upon their histology, GISTs were originally considered to derive from smooth muscle. However, they rarely showed clear-cut features of complete muscle differentiation (as did usual leiomyomas), and in many cases, their immunophenotypic profile differed from that of leiomyomas arising from other sites (eg, uterus or soft tissues). Some stromal tumors were found to have clear ultrastructural evidence of autonomic neural differentiation. Although initially designated plexosarcomas, these lesions became better known as gastrointestinal autonomic nerve tumors or GANTs (",
"    <a class=\"graphic graphic_table graphicRef64941 \" href=\"mobipreview.htm?17/31/17915\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    By the early 1990s, it became apparent that there were inconsistencies and ambiguities in the heterogeneous collection of tumors classified under the morphologic and immunophenotypic rubric which then defined \"GIST\". Some of the tumors classified as GIST were truly myogenic, while others were neural, some showed bidirectional differentiation, and others seemed to have a \"null\" phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/38\">",
"     38",
"    </a>",
"    ]. Up to two-thirds of GISTs were CD34 immunopositive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/39\">",
"     39",
"    </a>",
"    ], which was initially promulgated as a reproducible marker to identify these tumors. However, CD34 was neither selective nor specific for GIST.",
"   </p>",
"   <p>",
"    A significant breakthrough was achieved with the identification of the near-universal expression of the CD117 antigen by GISTs, in contrast to leiomyomas, true leiomyosarcomas, and other spindle-cell tumors of the GI tract, which were typically CD117-negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/1,40\">",
"     1,40",
"    </a>",
"    ]. The CD117 antigen is part of the KIT transmembrane receptor tyrosine kinase (RTK) that is the product of the KIT (also denoted c-kit) protooncogene. In more than 80 percent of GIST cases, a mutation in the KIT gene leads to a structural variant of the KIT protein which is abnormally activated and enables oncogenic signaling in the cell.",
"   </p>",
"   <p>",
"    Although the majority of GISTs (&ge;90 percent) are positive for KIT expression, some are not. A partial explanation was provided by the finding of activating mutations in another RTK, the platelet-derived growth factor receptor alpha (PDGFRA) in some KIT-negative GISTs.",
"   </p>",
"   <p>",
"    The current view is that the overwhelming majority of mesenchymal tumors arising in the GI tract fall into the GIST category, and are identified by KIT expression; as a group, these tumors are more specifically defined by the presence of activating mutations in the KIT gene or PDGFRA. In contrast, the true smooth muscle neoplasms (leiomyomas, leiomyosarcomas) and Schwann cell neoplasms (Schwannomas) of the GI tract lack KIT gene mutations, and they fail to express significant levels of KIT protein. Tumors that were previously classified as GANTs share molecular genetic identity with GISTs (ie, they are also KIT-positive), and thus, GANT probably does not warrant further designation as a specific and separate entity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/37,41\">",
"     37,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The biologic behavior of GIST is variable. The majority were previously thought to be benign due to their characteristically bland histopathologic features. However, it is becoming increasingly clear that with long follow-up, virtually all GISTs have the potential for malignant behavior, even those 2 cm or less with bland histologic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, it is not appropriate to define any GIST as \"benign\" per se [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/8,42,43\">",
"     8,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distinction between GIST and other non-GIST spindle cell GI tract neoplasms is a clinically important one because the uncontrolled oncogenic signaling through KIT or a mutant PDGFRA isoforms can be specifically targeted therapeutically with orally active tyrosine kinase inhibitors (TKIs) such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate (known as Gleevec&reg; in the United States, Glivec&reg; in the rest of the world) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    malate (known as Sutent worldwide). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis of GIST and KIT mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, around 95 percent of GISTs arising in adults overexpress KIT. Approximately 80 percent of GISTs have KIT gene mutations that lead to constitutive activation of the KIT receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/2,40,44-48\">",
"     2,40,44-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In normal cells, KIT receptor tyrosine kinase activity is regulated by binding of the endogenous ligand for the receptor (known as KIT ligand or stem cell factor, SCF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/16\">",
"     16",
"    </a>",
"    ]. Most KIT gene mutations (approximately 75 percent) in GISTs affect exon 11 (which codes for the intracellular juxtamembrane domain) and result in spontaneous (ligand-independent) receptor dimerization and receptor activation. However, in some cases, a mutation is present in exon 9, 13, or 17, with a different structural biological mechanism that results in uncontrolled KIT signaling.",
"   </p>",
"   <p>",
"    These \"gain of function\" mutations in KIT are observed in both sporadic and hereditary cases, and the KIT protooncogene has been postulated to play an important role in tumorigenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/2,17,18,40,44-48\">",
"     2,17,18,40,44-48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Familial GIST'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The relationship between KIT gene mutations and KIT protein (CD117) expression in GISTs is not entirely straightforward. Uncontrolled KIT activation may be present even in the absence of KIT mutations, especially in pediatric GISTs and GISTs that arise in the setting of NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/19-22,49\">",
"     19-22,49",
"    </a>",
"    ]. These tumors typically stain for KIT but are \"wild-type\" (ie, no detectable mutations in KIT), and they have a poor response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/22\">",
"     22",
"    </a>",
"    ]. The mechanism of KIT overexpression in cases without an identifiable mutation in KIT is unclear. (See",
"    <a class=\"local\" href=\"#H1013925\">",
"     'Pediatric GIST'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Immunohistochemically KIT-negative GISTs account for 4 to 5 percent of cases. In such patients, and in those with an unclear diagnosis, mutational analysis is necessary to confirm the diagnosis of a GIST:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      KIT gene mutations have been detected in some GISTs that fail to express KIT protein, suggesting that transcriptional silencing has occurred via a different mechanism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, many KIT-negative GISTs have activating mutations in a different RTK, PDGFRA (see",
"      <a class=\"local\" href=\"#H6\">",
"       'PDGFR alpha mutations'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Approximately 10 percent of adult GISTs lack mutations in either the KIT gene or PDGFRA. They are often localized to the stomach, multicentric in origin and can have an indolent clinical course [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/28,34\">",
"       28,34",
"      </a>",
"      ]. In the metastatic setting,",
"      <span class=\"nowrap\">",
"       KIT/PDGFRA",
"      </span>",
"      wild-type GISTs are more resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and more sensitive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      than are GISTs with a mutant kinase. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link&amp;anchor=H9#H9\">",
"       \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Influence of mutations on response to therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Some of these cases have mutations in genes that encode subunits of the enzyme succinate dehydrogenase (SDH). Approximately 85 percent of the GISTs that arise in children are",
"      <span class=\"nowrap\">",
"       KIT/PDGFRA",
"      </span>",
"      wild-type and are often associated with germline mutations in an SDH subunit gene and a cancer syndrome. (See",
"      <a class=\"local\" href=\"#H1013670\">",
"       'SDH subunit mutations'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H3\">",
"       'Familial GIST'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     PDGFR alpha mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of GISTs lacking KIT mutations have activating mutations in the related RTK, PDGFRA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/5,23,24,50\">",
"     5,23,24,50",
"    </a>",
"    ]. In one series, such mutations were detected in 14 of 40 KIT mutation-negative GIST lesions, and the activation of downstream signaling intermediates, and cytogenetic changes associated with tumor progression in these tumors were indistinguishable from those with KIT gene mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/23\">",
"     23",
"    </a>",
"    ]. A more recent analysis of 1105 GISTs detected PDGFRA mutations in 7.2 percent of tumors, although the samples were enriched by a large number of KIT-negative cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/25\">",
"     25",
"    </a>",
"    ]. KIT-negative tumors are more likely to have PDGFRA mutations.",
"   </p>",
"   <p>",
"    As noted previously, the TK inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    have demonstrable antitumor efficacy in tumors that lack KIT gene mutations, but are characterized by alterations in the PDGFRA pathway (including GIST, desmoid tumors, and dermatofibrosarcoma protuberans). However, not all activating mutations in PDGFRA are biologically equivalent. Some PDGFRA mutations are characterized by relative insensitivity to imatinib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], although others confer sensitivity to this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/5,25\">",
"     5,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of this variability, and because molecular analysis for the specific type of PDGFRA mutation is typically not carried out on these tumors, patients with advanced tumors that appear histologically compatible with a diagnosis of GIST should not be denied a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , even if they are KIT- and PDGFR-negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1013670\">",
"    <span class=\"h2\">",
"     SDH subunit mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inactivation of the succinate dehydrogenase (SDH) complex seems to be an event shared by sporadic and syndromic GISTs that lack mutations in",
"    <span class=\"nowrap\">",
"     KIT/PDGFRA.",
"    </span>",
"    Somatic and germline mutations in the genes encoding for the B, C, and D subunits of the (SDH) enzyme have been described in children with sporadic GISTs that are wild-type for KIT and PDGFRA and those arising in the setting of the inherited Carney-Stratakis syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1013925\">",
"     'Pediatric GIST'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    More recently, somatic and germline loss of function mutations in SDH subunits have also been described in adults with sporadic, KIT and PDGFRA-wild-type GISTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/51\">",
"     51",
"    </a>",
"    ]. While these data suggest that SDHA might function as a tumor suppressor gene, a larger number of",
"    <span class=\"nowrap\">",
"     KIT/PDGFRA",
"    </span>",
"    wild-type GISTs needs to be evaluated for SDHA mutations before definitive conclusions about the role of this gene in the development of sporadic GISTs can be drawn. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cellular origin of GISTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;KIT or PDGFR immunoreactivity is thought to define a group of tumors showing differentiation toward (or derived from, see below) the interstitial cells of Cajal (ICC). These cells, also sometimes referred to as the GI pacemaker cells, form the interface between the autonomic innervation of the bowel wall and the smooth muscle itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/37\">",
"     37",
"    </a>",
"    ]. They have immunophenotypic and ultrastructural features of both smooth muscle and neuronal differentiation and serve to regulate peristalsis. Because GISTs, like the ICCs, express KIT, and two-thirds also express CD34 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/39\">",
"     39",
"    </a>",
"    ], a link between the two has been proposed.",
"   </p>",
"   <p>",
"    It is postulated that GISTs originate from CD34-positive stem cells within the wall of the gut and differentiate toward the pacemaker cell phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Despite the attractiveness of the hypothesis of GIST tumors arising from ICCs within the gut wall, it is still open to question. Primary GISTs arising outside of the GI tract in the omentum and mesentery have been described, and they are phenotypically identical to true GIST lesions of GI tract origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/18,53\">",
"     18,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of a subepithelial tumor arising in the GI tract is broad and can include GIST, leiomyosarcoma, leiomyoma, malignant melanoma, schwannoma, malignant peripheral nerve sheath tumor, fibromatosis (desmoid tumor), inflammatory myofibroblastic tumor, or even metaplastic (\"sarcomatoid\") carcinoma. By light microscopy alone, the distinction among GISTs and other tumors in the differential diagnosis (particularly leiomyomas, true leiomyosarcomas, and GI tract schwannomas) can be difficult because the histologic findings seen on hematoxylin and eosin-stained sections do not reliably or specifically relate to the immunophenotype or the molecular genetics of the lesions.",
"   </p>",
"   <p>",
"    The distinction is usually based upon immunohistochemical and molecular analytic techniques, although there is some overlap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/18\">",
"     18",
"    </a>",
"    ]. As noted above, a key distinguishing point is the near-universal expression of KIT by GISTs. Approximately 95 percent of GISTs are KIT-positive, while 60 to 70 percent are positive for CD34, 30 to 40 percent are positive for smooth muscle actin, 5 percent for S-100 protein, and 1 to 2 percent are positive for desmin or keratin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/1,8,40\">",
"     1,8,40",
"    </a>",
"    ]. The comparative immunohistochemical profile for GIST, leiomyosarcoma, leiomyomas, and schwannomas are depicted in the table (",
"    <a class=\"graphic graphic_table graphicRef79128 \" href=\"mobipreview.htm?32/22/33131\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     GIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cellular morphology of GISTs ranges from predominantly spindle-shaped to epithelioid in character. Histologically, the appearance of these tumors usually falls into one of three relatively uniform categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spindle cell type &mdash; 70 percent",
"     </li>",
"     <li>",
"      Epithelioid type &mdash; 20 percent",
"     </li>",
"     <li>",
"      Mixed type &mdash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    KIT-negative GISTs, which may harbor PDGFRA mutations, are more often of the epithelioid type, and they present more commonly in the omentum and mesentery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GISTs of the spindle cell type are composed of relatively uniform eosinophilic cells arranged in short fascicles or whorls (",
"    <a class=\"graphic graphic_picture graphicRef61000 \" href=\"mobipreview.htm?3/11/3256\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/37\">",
"     37",
"    </a>",
"    ]. Compared to usual leiomyomas (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Leiomyomas'",
"    </a>",
"    below), the eosinophilic cytoplasm is more pale and often has a fibrillary appearance. The nuclei tend to be uniform, and there may be juxtanuclear cytoplasmic vacuoles and nuclear palisading. Stromal collagen is minimal in most cases, and stromal hemorrhage is a common feature. Marked cytologic pleomorphism is rare and should raise the possibility of an alternative diagnosis.",
"   </p>",
"   <p>",
"    Epithelioid GISTs are composed of rounded cells with variably eosinophilic or clear cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef61000 \" href=\"mobipreview.htm?3/11/3256\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/39\">",
"     39",
"    </a>",
"    ]. They tend to have round to oval nuclei with vesicular chromatin, and the architecture may be nested, leading to confusion with an epithelial or melanocytic neoplasm.",
"   </p>",
"   <p>",
"    Some GISTs of either epithelioid or spindle cell type morphology, particularly those associated with the small bowel, contain stromal \"skeinoid\" fibers, which are hyaline brightly eosinophilic structures composed of nodular tangles of collagen fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GISTs of the mixed type may have areas of abrupt transition between spindle and epithelioid areas or complex intermingling of both cell types throughout.",
"   </p>",
"   <p>",
"    Among patients with GIST, some data suggest that histologic type may impact prognosis. In a report of 48 patients, the five-year recurrence-free survival rate was significantly higher among patients with spindle cell as compared to epithelioid or mixed histology (49 versus 23 percent respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/57\">",
"     57",
"    </a>",
"    ]. However, others report a prognostic influence of the degree of cellularity but not histologic type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/4,50\">",
"     4,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic or usual GI tract leiomyoma has a similar morphologic appearance to leiomyomas in other organs. In the gut, they are usually small and well circumscribed. The tumors typically arise from the muscularis propria; growth may be intraluminal, extraluminal, or a combination with a dumb-bell shape. Leiomyomas can range in size from less than 0.5 cm (microleiomyomas) to as large as 30 cm.",
"   </p>",
"   <p>",
"    Microscopically, leiomyomas are formed of fascicles of benign-appearing spindle cells without nuclear atypia; mitoses are sparse or absent, and necrosis virtually never occurs (",
"    <a class=\"graphic graphic_picture graphicRef61429 graphicRef74175 \" href=\"mobipreview.htm?30/49/31513\">",
"     picture 2A-B",
"    </a>",
"    ). The nucleus is centrally located and oval but may be displaced to one side by distinct vacuoles suggesting signet-ring cells. These vacuoles do not contain fat or mucosubstances, which differentiates them from liposarcomas and carcinomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Leiomyosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cells of a true leiomyosarcoma are characteristically elongated, with an abundance of cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef51522 \" href=\"mobipreview.htm?18/61/19412\">",
"     picture 3",
"    </a>",
"    ). Multinucleated giant cells are common. Most are histologically high grade, and by immunohistochemistry, they express smooth muscle actin, desmin, or both (",
"    <a class=\"graphic graphic_table graphicRef79128 \" href=\"mobipreview.htm?32/22/33131\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epithelioid changes, in which the cells become rounded or polygonal cells with a clear perinuclear space lacking smooth muscle myofibrils, may occur in an otherwise typical leiomyosarcoma. When the epithelioid component predominates, the term leiomyoblastoma has been applied historically, although it is now recognized that these lesions are in fact GISTs. This is one reason the clinical behavior of the so-called \"leiomyoblastomas\" was reported to range from malignant (epithelioid leiomyosarcoma) to benign (epithelioid leiomyoma) in the era before GIST was defined by molecular genetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSTIC DETERMINANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, the clinical behavior of GISTs is highly variable. Criteria for identifying those tumors most likely to display malignant behavior (recur",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastasize) have been sought, analyzed, and disputed for years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor characteristics on CT or endoscopic ultrasound (EUS) may not only suggest the diagnosis of a GIST but may also, to some extent, correlate with recurrence risk. Tumors that are larger than 5 cm, lobulated, enhance heterogeneously, and have mesenteric fat infiltration, ulceration, regional lymphadenopathy, or an exophytic growth pattern on CT are more likely to metastasize [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/60-64\">",
"     60-64",
"    </a>",
"    ]. In contrast, GISTs with less metastatic potential tend to enhance in a homogeneous pattern and often show an endoluminal growth pattern. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Endoscopic ultrasonography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    From a histologic standpoint, as a group, GISTs tend to have bland morphologic features, although this morphology does not predict benign behavior. With prolonged follow-up, it appears that almost any GIST presenting with clinical symptoms or signs leading to treatment has the potential to behave in a malignant fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/65\">",
"     65",
"    </a>",
"    ]. It is now widely accepted that the terms \"benign\" or \"malignant\" should not be applied to GIST, since these terms are not clinically useful for patient management. Since all GISTs are now regarded as potentially malignant, consensus classifications focus on stratifying lesions (clinicopathobiologic risk categorization) according to the relative risk of recurrence and metastasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/8,42,43\">",
"     8,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tumor size, mitotic rate, and location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor size and mitotic rate formed the foundation for the NIH 2002 consensus approach to GIST risk stratification, as illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef56996 \" href=\"mobipreview.htm?3/25/3484\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/8,37,57,66\">",
"     8,37,57,66",
"    </a>",
"    ]. As noted above, one of the tenets of this risk stratification schema is that virtually all GISTs (especially those larger than 1 cm) have malignant potential, a concept supported by three large retrospective studies from the Armed Forces Institute of Pathology (AFIP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/2,67,68\">",
"     2,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AFIP series represent the largest published experience with GISTs diagnosed and treated in the modern era for which long-term clinical follow-up is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/42\">",
"     42",
"    </a>",
"    ]. They also served to validate and expand the 2002 consensus criteria, confirming the results of earlier studies indicating that anatomic location affects the risk of disease recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/69\">",
"     69",
"    </a>",
"    ]. In general, intestinal GISTs are more aggressive than are gastric tumors.",
"   </p>",
"   <p>",
"    The differences in outcome between gastric and small bowel GISTs can be illustrated by the published experience of AFIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 1765 cases of gastric GIST, tumor-related mortality was 17 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/67\">",
"       67",
"      </a>",
"      ]. Only 2 to 3 percent of tumors smaller than 10 cm and with fewer than 5",
"      <span class=\"nowrap\">",
"       mitoses/50",
"      </span>",
"      high-power fields (hpf) metastasized, while 86 percent of tumors &gt;10 cm with &gt;5",
"      <span class=\"nowrap\">",
"       mitoses/50",
"      </span>",
"      hpf metastasized. Intermediate tumors &gt;10 cm with a low mitotic rate and those &lt;5 cm with a high mitotic rate had relatively low metastatic potential (11 and 15 percent, respectively).",
"     </li>",
"     <li>",
"      In a series of 906 patients with a small bowel GIST, tumor-related mortality was 39 percent, more than twice that seen in the gastric tumor series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/68\">",
"       68",
"      </a>",
"      ]. As with gastric GISTs, fewer than 3 percent of the small bowel GISTs &lt;5 cm and with &le;5",
"      <span class=\"nowrap\">",
"       mitoses/50",
"      </span>",
"      hpf metastasized, while distant spread was observed in 86 percent of tumors &gt;10 cm and with &gt;5",
"      <span class=\"nowrap\">",
"       mitoses/50",
"      </span>",
"      hpf. However, in contrast to the intermediate-risk gastric tumors, small bowel tumors &gt;10 cm with a low mitotic rate, and those &le;5 cm with mitoses &gt;5",
"      <span class=\"nowrap\">",
"       mitoses/50",
"      </span>",
"      hpf had a high metastatic rate (&gt;50 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies indicate that all GISTs larger than 2 cm have some finite risk of recurrence, while gastric GISTs that are 2 cm or less in size with a low mitotic rate can be regarded as having an exceedingly low recurrence risk. However, until long-term data on the natural history of GISTs &lt;2 cm in size from all sites are known, it is misleading to regard any as being truly \"benign\".",
"   </p>",
"   <p>",
"    A modification of the NIH consensus criteria has been proposed by Huang to better distinguish the highly lethal subset of tumors (",
"    <a class=\"graphic graphic_table graphicRef53231 \" href=\"mobipreview.htm?39/42/40620\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/43\">",
"     43",
"    </a>",
"    ]. In a series of 289 patients, the cumulative five-year disease-specific survival rates for GISTs classified as risk level I through IV were 100, 96, 67, and 25 percent, respectively. However, this modification does not take disease site into account.",
"   </p>",
"   <p>",
"    As an alternative to the risk-classification systems that stratify patients into discrete categories, others have quantified the risk of disease recurrence after complete resection as a continuous variable though the use of a",
"    <a class=\"external\" href=\"file://www.mskcc.org/cancer-care/adult/gastrointestinal-neuroendocrine-tumors/prediction-tools\">",
"     GIST tumor nomogram",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The implications of risk stratification schema such as these on selecting patients for adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=see_link&amp;anchor=H3#H3\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Estimation of recurrence risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     TNM staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Largely based upon data from the AFIP series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], a TNM (tumor-node-metastasis) staging system for GIST was developed by the American Joint Committee on Cancer (AJCC) and International Union Against Cancer (UICC), and published in the 2010 7th edition of the cancer staging manual (",
"    <a class=\"graphic graphic_table graphicRef51606 \" href=\"mobipreview.htm?8/35/8766\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/71\">",
"     71",
"    </a>",
"    ]. Although the T and N designations are similar for all disease sites, there are separate stage groupings for",
"    <span class=\"nowrap\">",
"     gastric/omental",
"    </span>",
"    and small",
"    <span class=\"nowrap\">",
"     bowel/esophageal/colorectal/mesenteric",
"    </span>",
"    primaries. Rates of disease progression for gastric and small bowel GISTs, stratified by stage at diagnosis, are presented in the tables (",
"    <a class=\"graphic graphic_table graphicRef78594 \" href=\"mobipreview.htm?10/1/10268\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54480 \" href=\"mobipreview.htm?10/14/10476\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an alternative to the risk-classification systems that stratify patients into discrete categories, others have quantified the risk of disease recurrence after complete resection as a continuous variable though the use of a",
"    <a class=\"external\" href=\"file://www.mskcc.org/cancer-care/adult/gastrointestinal-neuroendocrine-tumors/prediction-tools\">",
"     GIST tumor nomogram",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/70\">",
"     70",
"    </a>",
"    ]. The implications of risk stratification schema such as this on selecting patients for adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=see_link&amp;anchor=H3#H3\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Estimation of recurrence risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14297093\">",
"    <span class=\"h2\">",
"     Tumor rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not included in the TNM staging system, tumor rupture (either at surgery or spontaneously) is an independent risk factor that negatively impacts disease-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. A separate modification of the NIH consensus criteria for risk stratification has been proposed that incorporates both site and tumor rupture as prognostic variables (",
"    <a class=\"graphic graphic_table graphicRef85938 \" href=\"mobipreview.htm?13/13/13532\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Significance of tumor genotype and kinase mutation status",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, about 80 percent of GISTs have a mutation in the KIT gene; most affect exon 11 and less commonly exon 9, 13, or 17. The older literature postulated that patients with KIT mutations had a worse prognosis than those with wild-type KIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/46,47,50,57,75,76\">",
"     46,47,50,57,75,76",
"    </a>",
"    ]. However, it is not clear whether the presence or absence of KIT gene mutations per se is an important negative prognostic factor. However, specific types of KIT mutations are associated with an aggressive phenotype, including those that affect exon 9 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/57,75,77,78\">",
"     57,75,77,78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Molecular pathogenesis of GIST and KIT mutations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The specific type of exon 11 deletion may also have prognostic significance, although the data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/46,50,57,79,80\">",
"     46,50,57,79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    also correlates with the underlying kinase genotype. Patients with exon 11 mutations are more likely to respond to imatinib than are those with other mutations (eg, in exon 9) or who lack mutations altogether. This issue is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link&amp;anchor=H9#H9\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Influence of mutations on response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Gene expression analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emerging data suggest that clinical behavior might be predicted by gene expression analysis. In one report, 32 fresh-frozen surgical samples of untreated stomach and small bowel GISTs were analyzed using oligonucleotide microarrays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/81\">",
"     81",
"    </a>",
"    ]. Gene expression analysis consistently separated the groups according to tumor site, the frequency of metastases and clinical outcome. Of the genes that were differentially expressed, CD26 (T-cell activation antigen) was strongly associated with poorer survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     K-ras mutations and leiomyosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of the K-ras oncogene are seen frequently in leiomyosarcoma, and they may be associated with a worse prognosis. In a study of 51 patients with leiomyosarcoma, mutations of K-ras were present in 14 percent and associated with significantly worse median survival (25 versus 42 months for wild-type K-ras) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some mesenchymal tumors of the GI tract are asymptomatic and discovered incidentally during an endoscopic or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    study or on a CT done for another purpose. More often, they are associated with nonspecific symptoms (ie, early satiety, bloating) unless they ulcerate, bleed, or grow large enough to cause pain or obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of patients with leiomyomas and leiomyosarcoma (without separation of the GISTs within these subtypes), there were three major presentations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/83\">",
"     83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overt GI bleeding &mdash; 40 percent",
"     </li>",
"     <li>",
"      Abdominal mass &mdash; 40 percent",
"     </li>",
"     <li>",
"      Abdominal pain &mdash; 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two-thirds of patients had overt or occult GI bleeding. Fewer (25 to 40 percent) presented with intestinal obstruction, possibly because the tumor served as a lead point for intussusception. Intestinal perforation can occur uncommonly. Rare patients have been described who present with severe hypoglycemia due to paraneoplastic tumor production of insulin like growth factor II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GISTs occur throughout the GI tract from the esophagus to the anus. Within the GI tract, GISTs are most common in the stomach (40 to 60 percent) and",
"    <span class=\"nowrap\">",
"     jejunum/ilium",
"    </span>",
"    (25 to 30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/7,66,69,85\">",
"     7,66,69,85",
"    </a>",
"    ]. Duodenum (5 percent), colorectum (5 to 15 percent), and esophagus (&le;1 percent) are less common sites. Tumors lacking any association with the bowel wall have been referred to as extragastrointestinal stromal tumors (EGISTs), and occur in the retroperitoneum, mesentery and omentum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/4,85,86\">",
"     4,85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with multifocal disease are usually classified as advanced stage, although some (particularly those with rare hereditary conditions) are affected by multiple primaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Familial GIST'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    GISTs frequently metastasize to liver and peritoneum and rarely to regional lymph nodes. They uncommonly metastasize to the lungs, the most common site of metastasis for most soft tissue sarcomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical manifestations specific to anatomic location are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34938?source=see_link\">",
"     \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC WORK-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of a gastrointestinal mesenchymal tumor may be suggested by a finding of a subepithelial mass on EGD or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    study, or as a result of CT or ultrasound that was performed incidentally or because of abdominal pain, mass, or other symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     CT and MRI scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced CT is the imaging method of choice to characterize an abdominal mass, evaluate its extent, and the presence or absence of metastatic disease. Oral as well as IV contrast should be administered to define the bowel margins.",
"   </p>",
"   <p>",
"    Although MRI has a comparable diagnostic yield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/32\">",
"     32",
"    </a>",
"    ] and lacks radiation exposure, CT is a preferred initial imaging study for screening and staging, except, perhaps in a patient who cannot receive intravenous contrast. CT is better at global evaluation of the abdomen, especially the hollow viscera, than is MRI.&nbsp;MRI may be preferred for GISTs at specific sites, such as rectum or liver. For these fixed structures, MRI may provide needed better anatomic definition, especially in evaluating for surgery.&nbsp;Issues related to radiation exposure from medical imaging are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The usual CT appearance of a GIST is that of a solid smoothly contoured mass that enhances brightly with IV contrast. Very large tumors (&gt;15 cm) may appear more complex due to necrosis, hemorrhage, or degenerating components. It may be difficult to identify the origin of a large mass because of exophytic growth.",
"   </p>",
"   <p>",
"    On CT, leiomyomas may appear as a smoothly contoured hypodense lesion immediately adjacent to the gut lumen. True leiomyosarcomas are typically large masses that have varying degrees of internal necrosis with heterogeneous contrast enhancement. Dystrophic calcification may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematogenous metastases from GIST most commonly involve the liver, omentum, and peritoneal cavity. In contrast, metastases from leiomyosarcoma most often involve the lung.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Upper endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy may be useful to further characterize the lesion if a gastric mass is identified. Both GIST and leiomyomas may appear as a submucosal mass with smooth margins, a normal overlying mucosa, and bulging into the gastric lumen (",
"    <a class=\"graphic graphic_picture graphicRef52275 \" href=\"mobipreview.htm?9/22/9570\">",
"     picture 4",
"    </a>",
"    ). Central ulceration is occasionally seen.",
"   </p>",
"   <p>",
"    Endoscopic biopsies using standard techniques usually do not obtain sufficient tissue for a definite diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/89\">",
"     89",
"    </a>",
"    ]. Endoscopic ultrasound (EUS)-guided fine-needle biopsy forceps also may not yield enough tissue, but might exclude other lesions that arise submucosally (see below). Snare biopsies (in which a polypectomy snare is used to remove a large piece of tissue) can result in perforation and generally should be avoided except in carefully selected cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Endoscopic ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS is the most accurate method for distinguishing leiomyomas from other submucosal lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Leiomyomas arise from the fourth hypoechoic layer (the muscularis propria), distinguishing them from more superficial lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53060 \" href=\"mobipreview.htm?41/2/42017\">",
"     image 1",
"    </a>",
"    ). Specific sonographic features may also distinguish a leiomyoma from other submucosal lesions, such as a lipoma or esophagogastric varices, and from other neoplasms such as lymphomas, carcinoids, cysts, pancreatic rests, and polyps. In one series, EUS correctly diagnosed 48 of 50 submucosal mass lesions confirmed by pathology or angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1242?source=see_link&amp;anchor=H12#H12\">",
"     \"Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract\", section on 'Gastrointestinal stromal tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EUS also may be helpful for distinguishing a leiomyoma from a leiomyosarcoma. Tumors that disrupt the normal tissue planes, contain cystic spaces, and are associated with enlarged lymph nodes are more likely to be malignant. Benign tumors are more likely to have regular margins, a tumor size &le;30 mm, and a homogeneous echo pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/92\">",
"     92",
"    </a>",
"    ]. In one report, the combined presence of two out of three EUS features (irregular extraluminal margins, cystic spaces, and lymph nodes with a malignant pattern) had a positive predictive value of 100 percent for a malignant or borderline GIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/92\">",
"     92",
"    </a>",
"    ]. However, sonographic characteristics alone are usually insufficient proof that a tumor is benign. Serial examinations may be helpful in such cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     EUS-guided fine-needle aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined use of cytologic analysis and immunohistochemistry for KIT mutations may permit the diagnosis of some of these lesions by EUS-guided fine-needle aspiration (FNA). In a study of 65 patients undergoing EUS-FNA for an upper gastrointestinal tract submucosal lesion, among the 28 lesions with a definitive pathologic diagnosis, the sensitivity of EUS-FNA for diagnosis of GIST was 82 percent and the specificity was 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3561?source=see_link&amp;anchor=H109379258#H109379258\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\", section on 'Mucosal and submucosal lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Necessity of preoperative biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative diagnosis of a GIST requires a high degree of suspicion and familiarity with its radiologic appearance. Preoperative biopsy is not generally recommended for a resectable lesion in which there is a high suspicion for GIST, and the patient is otherwise operable. However, a biopsy is preferred to confirm the diagnosis if metastatic disease is suspected or if preoperative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is considered prior to attempted resection in a patient who has a large locally advanced lesion thought to represent a GIST. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=see_link\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a biopsy is undertaken, EUS-guided biopsy is preferred over a percutaneous biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/94\">",
"     94",
"    </a>",
"    ]. Image-guided percutaneous biopsy carries the theoretical risk of rupture of the tumor capsule with peritoneal spread of disease. However, percutaneous biopsy of a lesion suspicious for GIST may be indicated in a patient with clearly unresectable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     PET scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET scanning using fluorodeoxyglucose (FDG-PET) is highly sensitive for detecting tumors with a high glucose metabolism, including GIST but is not specific for making a diagnosis. It has not replaced CT as the initial imaging modality of choice in patients suspected of having a GI tract mesenchymal tumor.",
"   </p>",
"   <p>",
"    The reported sensitivity of PET for GIST (including metastatic lesions) is 86 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. PET can be useful for detecting an unknown primary site or resolving ambiguities from CT (eg, when the CT findings are inconclusive or inconsistent with the clinical findings) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While a baseline PET may be indicated for patients in whom PET will be used to monitor the response to therapy with a tyrosine kinase inhibitor, nearly all the data obtained by PET scan imaging can be found in a good quality traditional IV contrasted CT scan, with superior anatomic definition. A clinical scenario where baseline and follow-up PET scan might prove useful is a borderline resectable GIST (or a potentially resectable tumor that requires extensive organ disruption) in which there is a narrow window for moving to alternative therapy (eg, resection or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ) if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/35/35386/abstract/94,98\">",
"     94,98",
"    </a>",
"    ]. An FDG-PET response, which is characterized by a marked decrease in the glycolytic metabolism of GISTs, can be seen as early as 24 hours after treatment is initiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link&amp;anchor=H3#H3\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Assessing response to therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=see_link&amp;anchor=H8#H8\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Neoadjuvant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15771459\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mesenchymal neoplasms affecting the gastrointestinal (GI) tract are collectively referred to as gastrointestinal stromal tumors (GISTs). (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GISTs that arise in adults are characterized by the near-universal expression of the CD117 antigen, in contrast to other spindle-cell tumors of the GI tract (ie, leiomyomas, leiomyosarcomas), which are typically CD117-negative. The CD117 antigen is part of the KIT transmembrane receptor tyrosine kinase that is the product of the KIT (also denoted c-kit) protooncogene. In more than 80 percent of GIST cases, a mutation in the KIT gene leads to an abnormally activated KIT protein and enables oncogenic signaling in the cell. A subset of GISTs lacking KIT mutations have activating mutations in the related receptor tyrosine kinase, platelet-derived growth factor receptor alpha (PDGFRA). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Molecular pathogenesis of GIST and KIT mutations'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A subset of GIST that are wild-type for both KIT and PDGFRA have mutations in a subunit of the enzyme succinate dehydrogenase (SDH). (See",
"      <a class=\"local\" href=\"#H1013670\">",
"       'SDH subunit mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GISTs occur predominantly in middle-aged and older individuals, and rarely in those under the age of 40. Although the majority of GISTs are sporadic, several kindreds with heritable mutations in the KIT gene have been identified. These families have a predisposition to multiple gastric and small bowel GISTs, and in some cases, skin hyperpigmentation, dysphagia, or GI autonomic nerve tumors such as paragangliomas. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Familial GIST'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GISTs are rare in children and often arise as a component of a defined syndrome (Carney-Stratakis syndrome, Carney triad, Neurofibromatosis type 1). In contrast to adults, 85 percent of GISTs arising in children are wild-type for KIT and PDGFRA. (See",
"      <a class=\"local\" href=\"#H1013925\">",
"       'Pediatric GIST'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical behavior of GISTs is highly variable; the main prognostic determinants are tumor size, mitotic rate, and tumor location. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Tumor size, mitotic rate, and location'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some GISTs are asymptomatic and discovered incidentally. More often, they are associated with nonspecific symptoms (ie, early satiety, bloating) unless they ulcerate, bleed, or grow large enough to cause pain or obstruction. While GISTs are most often located in the stomach and proximal small intestine, they can occur in any portion of the alimentary tract including occasionally in the omentum, mesentery, and peritoneum. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contrast-enhanced CT is a preferred initial imaging study for screening and staging, except perhaps in a patient who cannot receive IV contrast. MRI may be preferred for GISTs at specific sites, such as rectum or liver, where it provides better anatomic definition, especially in evaluating for surgery. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'CT and MRI scanning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative biopsy is not generally recommended for a resectable lesion in which there is a high suspicion for GIST and the patient is otherwise operable. However, a biopsy is preferred to confirm the diagnosis if metastatic disease is suspected or if preoperative",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      is considered prior to attempted resection in a patient who has a large locally advanced lesion thought to represent a GIST. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Necessity of preoperative biopsy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The combined use of cytologic analysis, immunohistochemistry, and reverse transcriptase polymerase chain reaction (RT-PCR) for KIT mutations may permit the preoperative diagnosis of some GISTs by endoscopic ultrasound-guided fine-needle aspiration (FNA). Tissue rather than cytologic study may be required for a definitive diagnosis. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Endoscopic ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PET scanning using fluorodeoxyglucose (FDG-PET) is highly sensitive for detecting tumors with a high glucose metabolism, including GIST, but is not specific for making a diagnosis. While a baseline PET may be indicated for patients in whom PET will be used to monitor the response to therapy with a tyrosine kinase inhibitor, nearly all the data obtained by PET scan imaging can be found in a good quality traditional IV contrasted CT scan, with superior anatomic definition. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'PET scan'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/1\">",
"      Rubin BP, Fletcher JA, Fletcher CD. Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors. Int J Surg Pathol 2000; 8:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/2\">",
"      Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/3\">",
"      Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/4\">",
"      Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/5\">",
"      Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28:889.",
"     </a>",
"    </li>",
"    <li>",
"     Atlas of Tumor Pathology: Tumors of the esophagus and stomach. Electronic fascicle v2.0b, Armed Forces Institute of Pathology, Washington DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/7\">",
"      Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/8\">",
"      Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33:459.",
"     </a>",
"    </li>",
"    <li>",
"     US population data from the US Census bureau, 2008 www.census.gov/popest/states/NST-ann-est.html (Accessed on March 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/10\">",
"      Nilsson B, B&uuml;mming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005; 103:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/11\">",
"      Tryggvason G, G&iacute;slason HG, Magn&uacute;sson MK, J&oacute;nasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/12\">",
"      Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005; 41:2868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/13\">",
"      Tzen CY, Wang JH, Huang YJ, et al. Incidence of gastrointestinal stromal tumor: a retrospective study based on immunohistochemical and mutational analyses. Dig Dis Sci 2007; 52:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/14\">",
"      Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006; 37:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/15\">",
"      Agaimy A, W&uuml;nsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007; 31:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/16\">",
"      Broudy VC. Stem cell factor and hematopoiesis. Blood 1997; 90:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/17\">",
"      Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/18\">",
"      Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001; 54:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/19\">",
"      Th&eacute;ou-Anton N, Tabone S, Brouty-Boy&eacute; D, et al. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer 2006; 94:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/20\">",
"      Janeway KA, Liegl B, Harlow A, et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 2007; 67:9084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/21\">",
"      Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/22\">",
"      Mussi C, Schildhaus HU, Gronchi A, et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008; 14:4550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/23\">",
"      Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/24\">",
"      Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/25\">",
"      Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23:5357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/26\">",
"      Agaimy A, M&auml;rkl B, Arnholdt H, et al. Sporadic segmental Interstitial cell of cajal hyperplasia (microscopic GIST) with unusual diffuse longitudinal growth replacing the muscularis propria: differential diagnosis to hereditary GIST syndromes. Int J Clin Exp Pathol 2010; 3:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/27\">",
"      Wang JH, Lasota J, Miettinen M. Succinate Dehydrogenase Subunit B (SDHB) Is Expressed in Neurofibromatosis 1-Associated Gastrointestinal Stromal Tumors (Gists): Implications for the SDHB Expression Based Classification of Gists. J Cancer 2011; 2:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/28\">",
"      Pappo AS, Janeway KA. Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/29\">",
"      Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011; 108:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/30\">",
"      Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med 2009; 266:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/31\">",
"      Matyakhina L, Bei TA, McWhinney SR, et al. Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab 2007; 92:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/32\">",
"      Scarpa M, Bertin M, Ruffolo C, et al. A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol 2008; 98:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/33\">",
"      Janeway KA, Pappo A. Treatment guidelines for gastrointestinal stromal tumors in children and young adults. J Pediatr Hematol Oncol 2012; 34 Suppl 2:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/34\">",
"      Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 2005; 29:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/35\">",
"      Agaram NP, Laquaglia MP, Ustun B, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008; 14:3204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/36\">",
"      Call J, Walentas CD, Eickhoff JC, Scherzer N. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. BMC Cancer 2012; 12:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/37\">",
"      Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002; 10:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/38\">",
"      Newman PL, Wadden C, Fletcher CD. Gastrointestinal stromal tumours: correlation of immunophenotype with clinicopathological features. J Pathol 1991; 164:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/39\">",
"      Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000; 13:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/40\">",
"      Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/41\">",
"      Lee JR, Joshi V, Griffin JW Jr, et al. Gastrointestinal autonomic nerve tumor: immunohistochemical and molecular identity with gastrointestinal stromal tumor. Am J Surg Pathol 2001; 25:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/42\">",
"      Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/43\">",
"      Huang HY, Li CF, Huang WW, et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 2007; 141:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/44\">",
"      Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/45\">",
"      Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61:8118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/46\">",
"      Emile JF, Th&eacute;ou N, Tabone S, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004; 2:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/47\">",
"      Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/48\">",
"      Andersson J, Sj&ouml;gren H, Meis-Kindblom JM, et al. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002; 160:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/49\">",
"      Yamamoto H, Tobo T, Nakamori M, et al. Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q. J Cancer Res Clin Oncol 2009; 135:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/50\">",
"      Mart&iacute;n J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005; 23:6190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/51\">",
"      Pantaleo MA, Astolfi A, Indio V, et al. SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst 2011; 103:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/52\">",
"      Sakurai S, Fukasawa T, Chong JM, et al. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal. Jpn J Cancer Res 1999; 90:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/53\">",
"      Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumors: a study of 27 cases. Arch Pathol Lab Med 2000; 124:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/54\">",
"      Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/55\">",
"      Min KW. Small intestinal stromal tumors with skeinoid fibers. Clinicopathological, immunohistochemical, and ultrastructural investigations. Am J Surg Pathol 1992; 16:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/56\">",
"      Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003; 27:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/57\">",
"      Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20:3898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/58\">",
"      Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/59\">",
"      Lee JS, Nascimento AG, Farnell MB, et al. Epithelioid gastric stromal tumors (leiomyoblastomas): a study of fifty-five cases. Surgery 1995; 118:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/60\">",
"      Chun HJ, Byun JY, Chun KA, et al. Gastrointestinal leiomyoma and leiomyosarcoma: CT differentiation. J Comput Assist Tomogr 1998; 22:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/61\">",
"      Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 2003; 23:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/62\">",
"      Ghanem N, Altehoefer C, Furtw&auml;ngler A, et al. Computed tomography in gastrointestinal stromal tumors. Eur Radiol 2003; 13:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/63\">",
"      Burkill GJ, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003; 226:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/64\">",
"      Hatch GF 3rd, Wertheimer-Hatch L, Hatch KF, et al. Tumors of the esophagus. World J Surg 2000; 24:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/65\">",
"      Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003; 90:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/66\">",
"      DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/67\">",
"      Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/68\">",
"      Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/69\">",
"      Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/70\">",
"      Gold JS, G&ouml;nen M, Guti&eacute;rrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10:1045.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer. American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/72\">",
"      Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 2007; 14:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/73\">",
"      Hohenberger P, Ronellenfitsch U, Oladeji O, et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010; 97:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/74\">",
"      Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/75\">",
"      Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59:4297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/76\">",
"      Kim TW, Lee H, Kang YK, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004; 10:3076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/77\">",
"      Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003; 9:3329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/78\">",
"      Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003; 106:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/79\">",
"      Bachet JB, Hostein I, Le Cesne A, et al. Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br J Cancer 2009; 101:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/80\">",
"      Wozniak A, Rutkowski P, Piskorz A, et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 2012; 23:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/81\">",
"      Yamaguchi U, Nakayama R, Honda K, et al. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 2008; 26:4100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/82\">",
"      Hill MA, Gong C, Casey TJ, et al. Detection of K-ras mutations in resected primary leiomyosarcoma. Cancer Epidemiol Biomarkers Prev 1997; 6:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/83\">",
"      Chou FF, Eng HL, Sheen-Chen SM. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. Surgery 1996; 119:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/84\">",
"      Pink D, Schoeler D, Lindner T, et al. Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases. J Clin Oncol 2005; 23:6809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/85\">",
"      Liegl B, Hornick JL, Lazar AJ. Contemporary pathology of gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/86\">",
"      Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/87\">",
"      Gasparotto D, Rossi S, Bearzi I, et al. Multiple primary sporadic gastrointestinal stromal tumors in the adult: an underestimated entity. Clin Cancer Res 2008; 14:5715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/88\">",
"      Lee SH, Ha HK, Byun JY, et al. Radiological features of leiomyomatous tumors of the colon and rectum. J Comput Assist Tomogr 2000; 24:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/89\">",
"      Tio TL, Tytgat GN, den Hartog Jager FC. Endoscopic ultrasonography for the evaluation of smooth muscle tumors in the upper gastrointestinal tract: an experience with 42 cases. Gastrointest Endosc 1990; 36:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/90\">",
"      Yasuda K, Cho E, Nakajima M, Kawai K. Diagnosis of submucosal lesions of the upper gastrointestinal tract by endoscopic ultrasonography. Gastrointest Endosc 1990; 36:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/91\">",
"      Boyce GA, Sivak MV Jr, R&ouml;sch T, et al. Evaluation of submucosal upper gastrointestinal tract lesions by endoscopic ultrasound. Gastrointest Endosc 1991; 37:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/92\">",
"      Palazzo L, Landi B, Cellier C, et al. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut 2000; 46:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/93\">",
"      Watson RR, Binmoeller KF, Hamerski CM, et al. Yield and performance characteristics of endoscopic ultrasound-guided fine needle aspiration for diagnosing upper GI tract stromal tumors. Dig Dis Sci 2011; 56:1757.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/95\">",
"      Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/96\">",
"      Kamiyama Y, Aihara R, Nakabayashi T, et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005; 29:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/97\">",
"      Demetri GD, Benjamin RS, Blanke CD, et al. NCCN task force report: optimal management of patients with gastrointestinal stromal tumor (GIST)- Update of NCCN Clinical Practice Guidelines. J Natl Comp Cancer Net 2007; 5(2 suppl):S-1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/35/35386/abstract/98\">",
"      Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist 2008; 13 Suppl 2:8.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7745 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35386=[""].join("\n");
var outline_f34_35_35386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15771459\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Familial GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1013925\">",
"      Pediatric GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION AND MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Molecular pathogenesis of GIST and KIT mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PDGFR alpha mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1013670\">",
"      SDH subunit mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cellular origin of GISTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - GIST",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Leiomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSTIC DETERMINANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tumor size, mitotic rate, and location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - TNM staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14297093\">",
"      Tumor rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Significance of tumor genotype and kinase mutation status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Gene expression analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      K-ras mutations and leiomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSTIC WORK-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CT and MRI scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Upper endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Endoscopic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - EUS-guided fine-needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Necessity of preoperative biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PET scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15771459\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7745\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7745|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/2/42017\" title=\"diagnostic image 1\">",
"      Small bowel leiomyoma CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7745|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/11/3256\" title=\"picture 1\">",
"      Gastrointestinal stromal tumor CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/39/32372\" title=\"picture 2A\">",
"      Rectal leiomyoma Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/45/40661\" title=\"picture 2B\">",
"      Jejunal leiomyoma Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/61/19412\" title=\"picture 3\">",
"      Small bowel leiomyosarc Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/22/9570\" title=\"picture 4\">",
"      Gastrointestinal stromal tumor CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7745|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/31/17915\" title=\"table 1\">",
"      Neural tumors GI tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/22/33131\" title=\"table 2\">",
"      Immunohistochemistry of GISTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/25/3484\" title=\"table 3\">",
"      Risk aggressive behavior GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/42/40620\" title=\"table 4\">",
"      GIST progn criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/35/8766\" title=\"table 5\">",
"      TNM staging GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/1/10268\" title=\"table 6\">",
"      Dis prog gastric GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/14/10476\" title=\"table 7\">",
"      Dis prog small int GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/13/13532\" title=\"table 8\">",
"      Mod NIH risk strat for GIST incl rupture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=related_link\">",
"      Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1242?source=related_link\">",
"      Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34938?source=related_link\">",
"      Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38121?source=related_link\">",
"      Pheochromocytoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_35_35387="Use of steroids and antibiotic in PPROM";
var content_f34_35_35387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Corticosteroid and antibiotic management of PPROM in the absence of labor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Week of gestation when PPROM occurs",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Plan",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Corticosteroids*",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24 to 32 weeks",
"       </td>",
"       <td>",
"        Expectant management if no evidence of chorioamnionitis or fetal compromise",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes&bull; and GBS prophylaxis at delivery if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;32 but less than 34 weeks",
"       </td>",
"       <td>",
"        Deliver immediately if fetal lung maturity can be documented or there is evidence of an intraamniotic infection clinically or on amniocentesis; otherwise deliver at 34 weeks",
"       </td>",
"       <td>",
"        Yes, if there is evidence of fetal lung immaturity or fetal lung status is unknown",
"       </td>",
"       <td>",
"        Yes, if expectant management&bull; and GBS prophylaxis at delivery if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;34 weeks",
"       </td>",
"       <td>",
"        Deliver",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GBS prophylaxis begun on admission and continued until delivery",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A single course of corticosteroids is given. If contractions begin and there are no contraindications to tocolysis, tocolytics can be given for 48 hours during which time a course of corticosteroids is also administered.",
"     <br>",
"      &bull; Broad spectrum, see text for possible regimens. GBS prophylaxis is given at delivery if indicated because of positive or unknown GBS culture results.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35387=[""].join("\n");
var outline_f34_35_35387=null;
var title_f34_35_35388="Sclerotherapy prevent rebleed";
var content_f34_35_35388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of trials of sclerotherapy for prevention of recurrent variceal hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Design",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up duration, months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rebleeding*, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rebleeding*, number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deaths*, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MacDougall",
"       </td>",
"       <td>",
"        No Rx vs EST&bull;",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        75 vs 43",
"       </td>",
"       <td>",
"        100 vs 54",
"       </td>",
"       <td>",
"        38 vs 21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Terblanche",
"       </td>",
"       <td>",
"        No Rx vs EST &Delta;",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        77 vs 58",
"       </td>",
"       <td>",
"        73 vs 43",
"       </td>",
"       <td>",
"        63 vs 62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Westaby",
"       </td>",
"       <td>",
"        No Rx vs EST",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        80 vs 55",
"       </td>",
"       <td>",
"        125 vs 66",
"       </td>",
"       <td>",
"        53 vs 32&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Korula",
"       </td>",
"       <td>",
"        No Rx vs EST&bull;",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        84 vs 49",
"       </td>",
"       <td>",
"        98 vs 48",
"       </td>",
"       <td>",
"        33 vs 33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soderlund and Ihre",
"       </td>",
"       <td>",
"        No Rx vs EST&bull;",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        64 vs 58",
"       </td>",
"       <td>",
"        99 vs 50",
"       </td>",
"       <td>",
"        70 vs 62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Copenhagen Sclerotherapy Project",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        No Rx vs EST",
"       </td>",
"       <td>",
"        ?&sect;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        54 vs 48",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        138 vs 64",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        78 vs 65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9-52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burroughs",
"       </td>",
"       <td>",
"        No Rx vs EST&Delta;",
"       </td>",
"       <td>",
"        ?&yen;",
"       </td>",
"       <td>",
"        59 vs 55",
"       </td>",
"       <td>",
"        183 vs 130",
"       </td>",
"       <td>",
"        54 vs 47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gregory",
"       </td>",
"       <td>",
"        No Rx vs EST",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        60 vs 52",
"       </td>",
"       <td>",
"        180 vs 116",
"       </td>",
"       <td>",
"        56 vs 63",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Controls versus sclerotherapy",
"     <br>",
"      &bull; Rebleeding in controls treated by shunt, vasopressin, Linton tubes",
"      <br>",
"       &Delta; Acute episodes of bleeding in controls were treated with EST also.",
"       <br>",
"        &loz; Deaths due to variceal hemorrhage markedly reduced (25 vs 5, p&lt;0.001).",
"        <br>",
"         &sect; Duration of follow-up not well defined (range provided). In this study survival advantage was noted only after 40 days.",
"         <br>",
"          &yen; Not well defined, duration of study provided.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35388=[""].join("\n");
var outline_f34_35_35388=null;
var title_f34_35_35389="ACST use of medical treatments";
var content_f34_35_35389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Use of medical treatments in the Asymptomatic Carotid Surgery Trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 227px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The use of lipid lowering drugs rose dramatically over the 10-year course of patient enrollment, from 17 percent in earlier randomization (1993 to 1996) to 58 percent in later randomization (2000 to 2003). Patient numbers reflect year of randomization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363:1491. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35389=[""].join("\n");
var outline_f34_35_35389=null;
var title_f34_35_35390="Withdraw theophylline in asthma";
var content_f34_35_35390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The effect of abrupt withdrawal of theophylline in five children with glucocorticoid-dependent asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 231px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left panel represents the average daily scores for symptoms of asthma and the number of extra respiratory treatments (RT) with bronchodilator. The right panel shows the average daily dose of prednisone required to treat the patient during theophylline (T) and placebo (P) treatment periods.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Brenner, M, Berkowitz, R, Marshall, N, Strunk, RC, Clin Allergy 1988; 18:143.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35390=[""].join("\n");
var outline_f34_35_35390=null;
var title_f34_35_35391="Healthcare facilities with recalled methylprednisolone";
var content_f34_35_35391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Healthcare facilities that received lots* of methylprednisolone acetate (PF) recalled from New England Compounding Center on September 26, 2012",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Healthcare facilty",
"       </td>",
"       <td class=\"subtitle1\">",
"        Phone number",
"       </td>",
"       <td class=\"subtitle1\">",
"        City",
"       </td>",
"       <td class=\"subtitle1\">",
"        State",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cypress Surgery Center",
"       </td>",
"       <td>",
"        559-740-4094",
"       </td>",
"       <td>",
"        Visalia",
"       </td>",
"       <td>",
"        CA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encino Outpatient Surgicenter",
"       </td>",
"       <td>",
"        818-986-1037",
"       </td>",
"       <td>",
"        Encino",
"       </td>",
"       <td>",
"        CA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ukiah Valley Medical Center",
"       </td>",
"       <td>",
"        707-463-7345",
"       </td>",
"       <td>",
"        Ukiah",
"       </td>",
"       <td>",
"        CA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Universal Pain Management",
"       </td>",
"       <td>",
"        661-267-6876",
"        <br/>",
"        x166",
"       </td>",
"       <td>",
"        Palmdale",
"       </td>",
"       <td>",
"        CA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interventional Spine And Sports Medicine",
"       </td>",
"       <td>",
"        203-598-7246",
"       </td>",
"       <td>",
"        Middlebury",
"       </td>",
"       <td>",
"        CT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Florida Pain Clinic",
"       </td>",
"       <td>",
"        352-237-5906",
"       </td>",
"       <td>",
"        Ocala",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interventional Rehab Center",
"       </td>",
"       <td>",
"        850-484-8800",
"       </td>",
"       <td>",
"        Pensacola",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marion Pain Management Center",
"       </td>",
"       <td>",
"        352-622-1845",
"       </td>",
"       <td>",
"        Ocala",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        North County Surgicenter",
"       </td>",
"       <td>",
"        561-626-6446",
"       </td>",
"       <td>",
"        Palm Beach Gardens",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orlando Center For Outpatient Surgery",
"       </td>",
"       <td>",
"        407-426-8331",
"       </td>",
"       <td>",
"        Orlando",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain Consultants Of West Florida",
"       </td>",
"       <td>",
"        850-494-0000",
"       </td>",
"       <td>",
"        Pensacola",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgery Center Of Ocala",
"       </td>",
"       <td>",
"        352-237-5906",
"       </td>",
"       <td>",
"        Ocala",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical Park Center",
"       </td>",
"       <td>",
"        305-271-9100",
"        <br/>",
"        x226",
"       </td>",
"       <td>",
"        Miami",
"       </td>",
"       <td>",
"        FL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forsyth Street Ambulatory Surgery Center",
"       </td>",
"       <td>",
"        478-749-1610",
"       </td>",
"       <td>",
"        Macon",
"       </td>",
"       <td>",
"        GA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain Specialists Of Idaho",
"       </td>",
"       <td>",
"        208-522-7246",
"       </td>",
"       <td>",
"        Idaho Falls",
"       </td>",
"       <td>",
"        ID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Walter Knox Memorial Hospital",
"       </td>",
"       <td>",
"        208-365-3561",
"        <br/>",
"        x3342",
"       </td>",
"       <td>",
"        Emmett",
"       </td>",
"       <td>",
"        ID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        APAC Centers For Pain Management",
"       </td>",
"       <td>",
"        708-483-7007",
"       </td>",
"       <td>",
"        Westchester",
"       </td>",
"       <td>",
"        IL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        APAC Centers For Pain Management",
"       </td>",
"       <td>",
"        773-935-2760",
"       </td>",
"       <td>",
"        Chicago",
"       </td>",
"       <td>",
"        IL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thorek Memorial Hospital",
"       </td>",
"       <td>",
"        773-975-6734",
"       </td>",
"       <td>",
"        Chicago",
"       </td>",
"       <td>",
"        IL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambulatory Care Center, LLC",
"       </td>",
"       <td>",
"        812-475-1800",
"       </td>",
"       <td>",
"        Evansville",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fort Wayne Physical Medicine",
"       </td>",
"       <td>",
"        260-436-9337",
"       </td>",
"       <td>",
"        Fort Wayne",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OSMC Outpatient Surgery Center",
"       </td>",
"       <td>",
"        574-266-4173",
"       </td>",
"       <td>",
"        Elkhart",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Bend Clinic",
"       </td>",
"       <td>",
"        574-237-9372",
"       </td>",
"       <td>",
"        South Bend",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Union Hospital",
"       </td>",
"       <td>",
"        812-238-4964",
"       </td>",
"       <td>",
"        Terre Haute",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wellspring",
"       </td>",
"       <td>",
"        812-376-0700",
"       </td>",
"       <td>",
"        Columbus",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baltimore Pain Management",
"       </td>",
"       <td>",
"        410-682-5040",
"       </td>",
"       <td>",
"        Baltimore",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Berlin Interventional Pain Management",
"       </td>",
"       <td>",
"        410-641-3759",
"       </td>",
"       <td>",
"        Berlin",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Box Hill Surgery Center",
"       </td>",
"       <td>",
"        410-877-8141",
"       </td>",
"       <td>",
"        Abingdon",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Greenspring Surgery Center",
"       </td>",
"       <td>",
"        410-653-0077",
"       </td>",
"       <td>",
"        Baltimore",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Harford County ASC, LLC",
"       </td>",
"       <td>",
"        410-538-7000",
"       </td>",
"       <td>",
"        Edgewood",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain Medicine Specialists",
"       </td>",
"       <td>",
"        410-825-6945",
"       </td>",
"       <td>",
"        Towson",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgcenter Of Bel Air",
"       </td>",
"       <td>",
"        410-638-5523",
"       </td>",
"       <td>",
"        Bel Air",
"       </td>",
"       <td>",
"        MD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Michigan Neurosurgical Institute",
"       </td>",
"       <td>",
"        810-606-7112",
"       </td>",
"       <td>",
"        Grand Blanc",
"       </td>",
"       <td>",
"        MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Michigan Pain Specialists",
"       </td>",
"       <td>",
"        734-995-7246",
"       </td>",
"       <td>",
"        Brighton",
"       </td>",
"       <td>",
"        MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuromuscular &amp; Rehabilitation",
"       </td>",
"       <td>",
"        231-935-0860",
"       </td>",
"       <td>",
"        Traverse City",
"       </td>",
"       <td>",
"        MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Southeast Michigan Surgical Hospital",
"       </td>",
"       <td>",
"        586-427-1000",
"       </td>",
"       <td>",
"        Warren",
"       </td>",
"       <td>",
"        MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maps-Edina Medical Pain Clinic",
"       </td>",
"       <td>",
"        763-537-6000",
"       </td>",
"       <td>",
"        Minneapolis",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maps-Medical Advanced Pain",
"       </td>",
"       <td>",
"        763-537-6000",
"       </td>",
"       <td>",
"        Fridley",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical Advanced Pain Specialists",
"       </td>",
"       <td>",
"        763-537-6000",
"        <br/>",
"        x238",
"       </td>",
"       <td>",
"        Shakopee",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical Advanced Pain Specialists",
"       </td>",
"       <td>",
"        763-537-6000",
"       </td>",
"       <td>",
"        Maple Grove",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minnesota Surgery Center",
"       </td>",
"       <td>",
"        763-767-7139",
"       </td>",
"       <td>",
"        Edina",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minnesota Surgery Center",
"       </td>",
"       <td>",
"        763-537-6000",
"       </td>",
"       <td>",
"        Maple Grove",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High Point Surgery",
"       </td>",
"       <td>",
"        336-878-6048",
"       </td>",
"       <td>",
"        High Point",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        North Carolina Orthopaedic Clinic",
"       </td>",
"       <td>",
"        919-403-5148",
"       </td>",
"       <td>",
"        Durham",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgery Center of Wilson",
"       </td>",
"       <td>",
"        252-237-5649",
"       </td>",
"       <td>",
"        Wilson",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dr. O'Connell's Pain Care Center",
"       </td>",
"       <td>",
"        603-335-5070",
"       </td>",
"       <td>",
"        Merrimack",
"       </td>",
"       <td>",
"        NH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dr. O'Connell's Pain Care Centers, Inc.",
"       </td>",
"       <td>",
"        603-692-3166",
"       </td>",
"       <td>",
"        Somersworth",
"       </td>",
"       <td>",
"        NH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central Jersey Orthopedics Specialists PC",
"       </td>",
"       <td>",
"        908-561-2122",
"       </td>",
"       <td>",
"        South Plainfield",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edison Surgical Center",
"       </td>",
"       <td>",
"        732-452-0123",
"       </td>",
"       <td>",
"        Edison",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IF Pain Associates/Isaiah Florence",
"       </td>",
"       <td>",
"        201-287-1100",
"       </td>",
"       <td>",
"        Teaneck",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premier Orthopedics Surg. Associates, LLC",
"       </td>",
"       <td>",
"        856-690-1750",
"       </td>",
"       <td>",
"        Vineland",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comprehensive Pain Management",
"       </td>",
"       <td>",
"        973-796-5216",
"       </td>",
"       <td>",
"        Sparta",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Jersey Health Care",
"       </td>",
"       <td>",
"        856-363-1558",
"       </td>",
"       <td>",
"        Elmer",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Jersey Healthcare",
"       </td>",
"       <td>",
"        856-641-7557",
"       </td>",
"       <td>",
"        Vineland",
"       </td>",
"       <td>",
"        NJ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sahara Surgery Center",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        702-362-7874",
"       </td>",
"       <td>",
"        Las Vegas",
"       </td>",
"       <td>",
"        NV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Butani, Sunil H, Physician PC",
"       </td>",
"       <td>",
"        516-747-5042",
"       </td>",
"       <td>",
"        Mineola",
"       </td>",
"       <td>",
"        NY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obosa Medical Services",
"       </td>",
"       <td>",
"        914-530-2323",
"       </td>",
"       <td>",
"        Mount Vernon",
"       </td>",
"       <td>",
"        NY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rochester Brain And Spine",
"       </td>",
"       <td>",
"        585-334-5560",
"       </td>",
"       <td>",
"        Rochester",
"       </td>",
"       <td>",
"        NY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BKC Pain Specialists, LLC",
"       </td>",
"       <td>",
"        740-387-7246",
"       </td>",
"       <td>",
"        Marion",
"       </td>",
"       <td>",
"        OH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cincinnati Pain Management",
"       </td>",
"       <td>",
"        513-891-0022",
"       </td>",
"       <td>",
"        Cincinnati",
"       </td>",
"       <td>",
"        OH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marion Pain Clinic",
"       </td>",
"       <td>",
"        740-375-0200",
"       </td>",
"       <td>",
"        Marion",
"       </td>",
"       <td>",
"        OH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ortho-Spine Rehabilitation Center, Inc.",
"       </td>",
"       <td>",
"        614-793-8817",
"       </td>",
"       <td>",
"        Dublin",
"       </td>",
"       <td>",
"        OH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allegheny Pain Management",
"       </td>",
"       <td>",
"        814-940-2000",
"       </td>",
"       <td>",
"        Altoona",
"       </td>",
"       <td>",
"        PA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Hills Pain &amp; Rehab Associates",
"       </td>",
"       <td>",
"        412-469-7722",
"       </td>",
"       <td>",
"        Jefferson Hills",
"       </td>",
"       <td>",
"        PA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New England Anesthesiology (NEA)",
"       </td>",
"       <td>",
"        401-490-7530",
"       </td>",
"       <td>",
"        Warwick",
"       </td>",
"       <td>",
"        RI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ocean State Pain Management",
"       </td>",
"       <td>",
"        401-766-7700",
"       </td>",
"       <td>",
"        Woonsocket",
"       </td>",
"       <td>",
"        RI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ocean State Pain Management",
"       </td>",
"       <td>",
"        401-884-6070",
"       </td>",
"       <td>",
"        East Greenwich",
"       </td>",
"       <td>",
"        RI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intervene MD",
"       </td>",
"       <td>",
"        843-216-4844",
"       </td>",
"       <td>",
"        Mount Pleasant",
"       </td>",
"       <td>",
"        SC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCA Pain Care Center",
"       </td>",
"       <td>",
"        865-835-5196",
"       </td>",
"       <td>",
"        Oak Ridge",
"       </td>",
"       <td>",
"        TN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specialty Surgery Center",
"       </td>",
"       <td>",
"        931-484-2500",
"        <br/>",
"        x125",
"       </td>",
"       <td>",
"        Crossville",
"       </td>",
"       <td>",
"        TN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        St. Thomas Outpatient Neurosurgical",
"       </td>",
"       <td>",
"        615-341-3425",
"       </td>",
"       <td>",
"        Nashville",
"       </td>",
"       <td>",
"        TN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dallas Back Pain Management",
"       </td>",
"       <td>",
"        214-445-5077",
"       </td>",
"       <td>",
"        Dallas",
"       </td>",
"       <td>",
"        TX",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Harris Methodist Southlake Center",
"       </td>",
"       <td>",
"        817-748-8778",
"       </td>",
"       <td>",
"        Southlake",
"       </td>",
"       <td>",
"        TX",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insight Imaging-Roanoke",
"       </td>",
"       <td>",
"        540-581-0882",
"       </td>",
"       <td>",
"        Roanoke",
"       </td>",
"       <td>",
"        VA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New River Valley Surgery Center",
"       </td>",
"       <td>",
"        540-639-5888",
"       </td>",
"       <td>",
"        Christiansburg",
"       </td>",
"       <td>",
"        VA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PARS Interventional Pain",
"       </td>",
"       <td>",
"        304-865-7277",
"       </td>",
"       <td>",
"        Parkersburg",
"       </td>",
"       <td>",
"        WV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PF: preservative-free.",
"     <br/>",
"     * Lot #05212012@68, BUD 11/17/2012; Lot #06292012@26, BUD 12/26/2012; Lot #08102012@51, BUD 2/6/2013.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     All vials of methylprednisolone acetate that were sent to Nevada were recalled prior to use.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Healthcare-associated Infections (HAIs): Map of Healthcare Facilities which Received Three Lots of Methylprednisolone Acetate (PF) Recalled from New England Compounding Center on September 26, 2012. Available at:",
"     <a href=\"file://www.cdc.gov/hai/outbreaks/meningitis-facilities-map.html\" target=\"_blank\">",
"      file://www.cdc.gov/hai/outbreaks/meningitis-facilities-map.html",
"     </a>",
"     (Accessed October 11, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_35_35391=[""].join("\n");
var outline_f34_35_35391=null;
